<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="30891c38-5d64-7df7-e063-6394a90ae762"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ATAZANAVIR CAPSULES safely and effectively. See full prescribing information for ATAZANAVIR CAPSULES.
 <br/>
ATAZANAVIR capsules, for oral use
 <br/>
Initial U.S. Approval: 2003
</title>
   <effectiveTime value="20250317"/>
   <setId root="8a0c609f-e296-4925-a35c-e93a04467655"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="826774775"/>
            <name>Camber Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="676162024"/>
                        <name>Hetero Labs Limited Unit III</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="31722-653" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="31722-654" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="31722-655" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="30896854-fa7e-b772-e063-6394a90a423f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250317"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="31722-653" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Atazanavir
</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atazanavir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="MB5IUD6JUA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="150"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4MT4VIE29P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATAZANAVIR SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="QZU4H47A3S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATAZANAVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="31722-653-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220207"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="31722-653-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220207"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="31722-653-31" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220207"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212278" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220207"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>light green opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">H;A6</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="31722-654" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Atazanavir
</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atazanavir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="MB5IUD6JUA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4MT4VIE29P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATAZANAVIR SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="QZU4H47A3S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATAZANAVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="31722-654-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220207"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="31722-654-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220207"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="31722-654-31" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220207"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212278" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220207"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>light green opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">H;A7</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="31722-655" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Atazanavir
</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atazanavir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="MB5IUD6JUA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4MT4VIE29P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATAZANAVIR SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="QZU4H47A3S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATAZANAVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="31722-655-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220207"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="31722-655-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220207"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="31722-655-31" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220207"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212278" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220207"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="orange" xsi:type="CE">
                              <originalText>opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="24" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">H;A8</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="rcm">
               <id root="30891c38-5d65-7df7-e063-6394a90ae762"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Contraindications (
 
    <linkHtml href="#Section_4">4</linkHtml>)                                                 12/2024

   </paragraph>
                        <br/>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="30891c38-5d66-7df7-e063-6394a90ae762"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <effectiveTime value="20250206"/>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="30891c38-5d67-7df7-e063-6394a90ae762"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <br/>
                  <paragraph>Atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. 
  <br/>  Limitations of Use: 
  <br/>  • Atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#Section_8.4">8.4</linkHtml>)]
 
  </content>.  
  <br/>  • Use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions
 
  <content styleCode="italics">[see Microbiology (
  
   <linkHtml href="#Section_12.4">12.4</linkHtml>)]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>Atazanavir capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. (
 
    <linkHtml href="#Section_1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="30891c38-5d68-7df7-e063-6394a90ae762"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">• Pretreatment testing:</content>Renal laboratory testing should be performed in all patients prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules. Hepatic testing should be performed in patients with underlying liver disease prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules. (
 
    <linkHtml href="#Section_2.2">2.2</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Treatment-naive adults:</content>Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food or atazanavir 400 mg once daily with food. (
 
    <linkHtml href="#Section_2.3">2.3</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Treatment-experienced adults:</content>Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food. (
 
    <linkHtml href="#Section_2.3">2.3</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Pediatric patients:</content>Atazanavir capsule dosage is based on body weight not to exceed the adult dose and must be taken with food. (
 
    <linkHtml href="#Section_2.4">2.4</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Pregnancy:</content>Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food, with dosing modifications for some concomitant medications. (
 
    <linkHtml href="#Section_2.5">2.6</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Dosing modifications:</content>may be required for concomitant therapy (
 
    <linkHtml href="#Section_2.3">2.3</linkHtml>,
 
    <linkHtml href="#Section_2.4">2.4</linkHtml>,
 
    <linkHtml href="#Section_2.5">2.6</linkHtml>), renal impairment (
 
    <linkHtml href="#Section_2.6">2.7</linkHtml>), and hepatic impairment. (
 
    <linkHtml href="#Section_2.7">2.8</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="30891c38-5d69-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Overview</title>
                     <text>
                        <br/>
                        <paragraph>• Atazanavir capsules must be taken with food. 
  <br/>  • Do not open the capsules. 
  <br/>  • The recommended oral dosage of atazanavir capsules depends on the treatment history of the patient and the use of other coadministered drugs. When coadministered with H
 
  <sub>2</sub>-receptor antagonists or proton-pump inhibitors, dose separation may be required
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#Section_2.3">2.3</linkHtml>,
  
   <linkHtml href="#Section_2.4">2.4</linkHtml>, and
  
   <linkHtml href="#Section_2.5">2.6</linkHtml>) and Drug Interactions (
  
   <linkHtml href="#Section_7">7</linkHtml>)]
 
  </content>. 
  <br/>  • Atazanavir capsules without ritonavir are not recommended for treatment-experienced adult or pediatric patients with prior virologic failure
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#Section_14">14</linkHtml>)]
 
  </content>. 
  <br/>  • Efficacy and safety of atazanavir capsules with ritonavir when ritonavir is administered in doses greater than 100 mg once daily have not been established. The use of higher ritonavir doses may alter the safety profile of atazanavir (cardiac effects, hyperbilirubinemia) and, therefore, is not recommended. Prescribers should consult the complete prescribing information for ritonavir when using ritonavir.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="30891c38-5d6a-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Testing Prior to Initiation and During Treatment with Atazanavir Capsules</title>
                     <text>
                        <br/>
                        <paragraph>Renal laboratory testing should be performed in all patients prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules. Renal laboratory testing should include serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.5">5.5</linkHtml>,
  
   <linkHtml href="#Section_5.6">5.6</linkHtml>)]
 
  </content>. 
  <br/>  Hepatic laboratory testing should be performed in patients with underlying liver disease prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.3">5.4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="30891c38-5d6b-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage of Atazanavir Capsules in Adult Patients</title>
                     <text>
                        <br/>
                        <paragraph>Table 1 displays the recommended dosage of atazanavir capsules in treatment-naive and treatment-experienced adults. Table 1 also displays recommended dosage of atazanavir capsules and ritonavir when given concomitantly with other antiretroviral drugs and H
 
  <sub>2</sub>-receptor antagonists (H2RA). Ritonavir is required with several atazanavir capsule dosage regimens (see the ritonavir complete prescribing information about the safe and effective use of ritonavir). The use of atazanavir capsules in treatment-experienced adult patients without ritonavir is not recommended.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Recommended Atazanavir Capsules  and Ritonavir Dosage in Adults
  
   <sup>a</sup>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="490.1715">
                           <col width="57.6990910324244%"/>
                           <col width="21.1504544837878%"/>
                           <col width="21.1504544837878%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir Capsules </content>
                                    <content styleCode="bold">Once Daily</content>
                                    <br/>
                                    <content styleCode="bold">Dosage</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Ritonavir</content>
                                    <br/>
                                    <content styleCode="bold">Once Daily</content>
                                    <br/>
                                    <content styleCode="bold">Dosage</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Treatment-Naive Adult Patients</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">recommended regimen 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">unable to tolerate ritonavir 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">N/A 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">in combination with efavirenz 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Treatment-Experienced Adult Patients</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">recommended regimen 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">in combination with both H2RA and tenofovir DF 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup> See
 
  <content styleCode="italics">Drug Interactions (
  
   <linkHtml href="#Section_7">7</linkHtml>)
 
  </content>for instructions concerning coadministration of acid-reducing medications (eg, H2RA or proton pump inhibitors [PPIs]), and other antiretroviral drugs (eg, efavirenz, tenofovir DF, and didanosine).

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="30891c38-5d6c-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage of Atazanavir Capsules in Pediatric Patients</title>
                     <text>
                        <br/>
                        <paragraph>The recommended daily dosage of atazanavir capsules and ritonavir in pediatric patients (6 years of age to less than 18 years of age) is based on body weight (see Table 2). 
  <br/>
                           <content styleCode="bold">Table 2: Recommended Dosage of Atazanavir Capsules and Ritonavir in Pediatric  Patients (6 to less than 18 years of age)
  
   <sup>a,b</sup>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="566.58">
                           <col width="33.3920187793427%"/>
                           <col width="36.6431924882629%"/>
                           <col width="29.9647887323944%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Body weight
    
     <sup/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">Atazanavir Capsules Daily Dosage
    
     <sup/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">Ritonavir Daily Dosage
    
     <sup/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Treatment-Naive and Treatment-Experienced
     
      <sup>c</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Less than 15 kg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">Capsules not recommended 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">N/A 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">At least 15 kg to less than 35 kg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">At least 35 kg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Treatment-Naive, at least 13 years old and cannot tolerate ritonavir</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="top">At least 40 kg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">N/A 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>Administer atazanavir capsules and ritonavir simultaneously with food. 

 </paragraph>
                        <br/>
                        <paragraph>
                           <sup>b</sup>The same recommendations regarding the timing and maximum doses of concomitant PPIs and H2RAs in adults also apply to pediatric patients. See
 
  <content styleCode="italics">Drug Interactions (
  
   <linkHtml href="#Section_7">7</linkHtml>)
 
  </content>for instructions concerning coadministration of acid-reducing medications (eg, H2RA or PPIs), and other antiretroviral drugs (eg, efavirenz, tenofovir DF, and didanosine).  
  <br/>
                           <sup>c</sup>In treatment-experienced patients, atazanavir capsules must be administered with ritonavir.  
  <br/>  When transitioning between formulations, a change in dose may be needed. Consult the dosing table for the specific formulation.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="30891c38-5d6d-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Adjustments in Pregnant Patients</title>
                     <text>
                        <br/>
                        <paragraph>Table 4 includes the recommended dosage of atazanavir capsules and ritonavir in treatment-naive and treatment-experienced pregnant patients. In these patients, atazanavir capsules must be administered with ritonavir. There are no dosage adjustments for postpartum patients (see Table 1 for the recommended atazanavir capsules dosage in adults)
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#Section_8.1">8.1</linkHtml>)]
 
  </content>. 
  <br/>
                           <content styleCode="bold">Table 4: Recommended Dosage of Atazanavir Capsules and Ritonavir in Pregnant Patients
  
   <sup>a</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="718.2">
                           <col width="32.7777777777778%"/>
                           <col width="32.7777777777778%"/>
                           <col width="34.4444444444444%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir Capsules</content>
                                    <br/>
                                    <content styleCode="bold">Once Daily</content>
                                    <br/>
                                    <content styleCode="bold">Dosage</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Ritonavir</content>
                                    <br/>
                                    <content styleCode="bold">Once Daily</content>
                                    <br/>
                                    <content styleCode="bold">Dosage</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Treatment-Naive and Treatment-Experienced</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Recommended Regimen 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Treatment-Experienced During the Second or Third Trimester When Coadministered with either H2RA 
     
      <sup/>or Tenofovir DF
     
      <sup>b</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">In combination with
    
     <content styleCode="bold">
                                       <content styleCode="underline">EITHER</content>
                                    </content>H2RA
    
     <content styleCode="bold">
                                       <content styleCode="underline">OR</content>
                                    </content>tenofovir DF 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  400 mg 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  100 mg 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a</sup>
                           <content styleCode="italics">See Drug Interactions (7)</content>for instructions concerning coadministration of acid-reducing medications (eg, H2RA or PPIs), and other antiretroviral drugs (eg, efavirenz, tenofovir DF, and didanosine).  
  <br/>
                           <sup>b</sup>Atazanavir capsules are not recommended for treatment-experienced pregnant patients during the second and third trimester taking atazanavir capsules with 
 
  <content styleCode="bold">
                              <content styleCode="underline">BOTH</content>
                           </content>tenofovir DF and H2RA.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.6">
                     <id root="30891c38-5d6e-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Dosage in Patients with Renal Impairment</title>
                     <text>
                        <br/>
                        <paragraph>For patients with renal impairment, including those with severe renal impairment who are not managed with hemodialysis, no dose adjustment is required for atazanavir capsules. Treatment-naive patients with end-stage renal disease managed with hemodialysis should receive atazanavir capsules 300 mg with ritonavir 100 mg.
 
  <content styleCode="underline">Atazanavir capsules are not recommended in treatment-experienced patients with HIV-1 who have end-stage renal disease managed with hemodialysis </content>
                           <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#Section_8.7">8.7</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.7">
                     <id root="30891c38-5d6f-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.8 Dosage Adjustments in Patients with Hepatic Impairment</title>
                     <text>
                        <br/>
                        <paragraph>Table 5 displays the recommended atazanavir capsule dosage in treatment-naive patients with hepatic impairment. The use of atazanavir capsules in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended. The coadministration of atazanavir capsules with ritonavir in patients with any degree of hepatic impairment is not recommended. 
  <br/>
                           <content styleCode="bold">Table 5: Recommended Dosage of Atazanavir Capsules in Treatment-Naïve Adults with Hepatic Impairment</content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle"> </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">Atazanavir capsules 
      <br/>  Once Daily Dosage 
     </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Mild hepatic impairment (Child-Pugh Class A)  </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>  400 mg
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Moderate hepatic impairment (Child-Pugh Class B) </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>  300 mg
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Severe hepatic impairment (Child-Pugh Class C) </td>
                                 <td align="center" styleCode="Rrule" valign="middle"> Atazanavir capsules with or without ritonavir is not 
     <br/>  recommended 
     <br/>   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="30891c38-5d70-7df7-e063-6394a90ae762"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>   
 
  <content styleCode="italics"> Atazanavir Capsules:</content>  
  <br/>  • 150 mg capsule with off white to pale yellow colored granular powder filled in size 1 hard gelatin capsules with green opaque cap imprinted with "H" in black color and light green opaque body imprinted with "A6" in black color. 
  <br/>  • 200 mg capsule with off white to pale yellow colored granular powder filled in size 0 hard gelatin capsules with green opaque cap imprinted with "H" in black color and light green opaque body imprinted with "A7'' in black color.  
  <br/>  • 300 mg capsule with off white to pale yellow colored granular powder filled in size 00 hard gelatin capsules with orange opaque cap imprinted with "H" in black color and green opaque body imprinted with "A8" in black color.

 </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>• Capsules: 150 mg, 200 mg, 300 mg. (
 
    <linkHtml href="#Section_3">3,</linkHtml>
                           <linkHtml href="#Section_17">16</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="30891c38-5d71-7df7-e063-6394a90ae762"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <br/>
                  <paragraph>Atazanavir capsules are contraindicated: 
  <br/>  • in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens- Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.2">5.2</linkHtml>)]
 
  </content>. 
  <br/>  • when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening events (see Table 6). 
  <br/>  • when coadministered with drugs that strong inducers of CYP3A due to the potential for loss of therapeutic effect and development of resistance. 
  <br/>  Coadministration is contraindicated with, but not limited to, the following drugs listed in Table 6: 
  <br/>
                     <content styleCode="bold">Table 6: Drugs Contraindicated with Atazanavir (Information in the table applies to atazanavir with or without ritonavir, unless otherwise indicated)</content>
                  </paragraph>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="603">
                     <col width="48.2587064676617%"/>
                     <col width="51.7412935323383%"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Drug Class</content>
                              <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">
                              <content styleCode="bold">Drugs within class that are contraindicated with Atazanavir capsules</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Alpha 1-adrenoreceptor antagonist 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Alfuzosin 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Antiarrhythmics 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Amiodarone (with ritonavir), quinidine (with ritonavir) 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top"> Anticonvulsants        </td>
                           <td styleCode="Rrule" valign="top"> Carbamazepine, phenobarbital, phenytoin</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Antimycobacterials 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Rifampin 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Antineoplastics 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Apalutamide, encorafenib, irinotecan, ivosidenib 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Antipsychotics 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Lurasidone (with ritonavir), pimozide 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Benzodiazepines 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Orally administered midazolam
    
     <sup>a</sup>, triazolam 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Ergot Derivatives 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Dihydroergotamine, ergonovine, ergotamine,  methylergonovine 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">GI Motility Agent 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Cisapride 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Hepatitis C Direct-Acting Antivirals 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Elbasvir/grazoprevir; glecaprevir/pibrentasvir 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Herbal Products 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">St. John’s wort (
    
     <content styleCode="italics">Hypericum perforatum</content>) 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Lipid-Modifying Agents: 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Lomitapide, lovastatin, simvastatin 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Phosphodiesterase-5 (PDE-5) Inhibitor 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Sildenafil
    
     <sup>b</sup>when dosed as REVATIO
    
     <sup>®</sup>for the treatment of pulmonary arterial hypertension 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Protease Inhibitors  
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Indinavir 
     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="justify" styleCode="Lrule Rrule" valign="top">Non-nucleoside Reverse Transcriptase Inhibitors 
     <br/>
                           </td>
                           <td align="justify" styleCode="Rrule" valign="top">Nevirapine 
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>a </sup>See
 
  <content styleCode="italics">Drug Interactions, Table 16 (
  
   <linkHtml href="#Section_7">7</linkHtml>)
 
  </content>for parenterally administered midazolam. 
  <br/>
                     <sup>b</sup>  See
 
  <content styleCode="italics">Drug Interactions, Table 16 (
  
   <linkHtml href="#Section_7">7</linkHtml>)
 
  </content>for sildenafil when dosed as VIAGRA
 
  <sup>®</sup>for erectile dysfunction.

 </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>•  In patients with previously demonstrated hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components atazanavir capsules.  (
 
    <linkHtml href="#Section_4">4</linkHtml>) 
    <br/>  • Coadministration with drugs that are strong inducers of CYP3A, due to the potential for loss of therapeutic effect and development of resistance. (4) 

   </paragraph>
                        <paragraph>• Coadministration with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening events. (4)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="30891c38-5d72-7df7-e063-6394a90ae762"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">• Cardiac conduction abnormalities:</content>PR interval prolongation may occur in some patients.  ECG  monitoring  should  be  considered  in  patients  with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. (
 
    <linkHtml href="#Section_5.1">5.1</linkHtml>,
 
    <linkHtml href="#Section_7.3">7.3</linkHtml>,
 
    <linkHtml href="#Section_12.2">12.2</linkHtml>,
 
    <linkHtml href="#Section_16">17</linkHtml>) 
    <br/>
                           <br/>
                           <content styleCode="italics">• Severe Skin Reactions:</content>Discontinue if severe rash develops. (
 
    <linkHtml href="#Section_5.2">5.2</linkHtml>,
 
    <linkHtml href="#Section_16">17</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Hyperbilirubinemia</content>: Most patients experience asymptomatic increases in indirect bilirubin, which is reversible upon discontinuation. Do not dose reduce. If a concomitant transaminase increase occurs, evaluate for alternative etiologies. (
 
    <linkHtml href="#Section_5.8">5.8</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Hepatotoxicity:</content>Patients with hepatitis B or C virus are at risk of increased transaminases or hepatic decompensation. Monitor hepatic laboratory tests prior to therapy and during treatment. (
 
    <linkHtml href="#Section_2.7">2.8</linkHtml>,
 
    <linkHtml href="#Section_5.3">5.4</linkHtml>,
 
    <linkHtml href="#Section_8.8">8.8</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Chronic kidney disease</content>has been reported during postmarketing surveillance in patients with HIV-1 treated with atazanavir, with or without ritonavir. Consider alternatives in patients at high risk for renal disease or with preexisting renal disease. Monitor renal laboratory tests prior to therapy and during treatment. Consider discontinuation of atazanavir in patients with progressive renal disease. (
 
    <linkHtml href="#Section_5.5">5.5</linkHtml>) 
    <br/>
                           <content styleCode="italics">• Nephrolithiasis and cholelithiasis</content>have been reported. Consider temporary interruption or discontinuation. (
 
    <linkHtml href="#Section_5.6">5.6</linkHtml>) 
    <br/>  • The concomitant use of atazanavir with ritonavir and certain other medications may result in known or potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions. (
 
    <linkHtml href="#Section_5.7">5.7</linkHtml>,
 
    <linkHtml href="#Section_7.3">7.3</linkHtml>) 
    <br/>  • Patients receiving atazanavir may develop new onset or exacerbations of diabetes mellitus/hyperglycemia (
 
    <linkHtml href="#Section_5.9">5.9</linkHtml>), immune reconstitution syndrome (5.10), and redistribution/accumulation of body fat. (
 
    <linkHtml href="#Section_5.11">5.11</linkHtml>) 
    <br/>
                           <br/>  • 
 
    <content styleCode="italics">Hemophilia:</content>Spontaneous bleeding may occur, and additional factor VIII may be required. (
 
    <linkHtml href="#Section_5.12">5.12</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="30891c38-5d73-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cardiac Conduction Abnormalities</title>
                     <text>
                        <br/>
                        <paragraph>Atazanavir has been shown to prolong the PR interval of the electrocardiogram in some study participants. In healthy participants and in participants with HIV-1 treated with atazanavir, abnormalities in atrioventricular (AV) conduction were asymptomatic and generally limited to first-degree AV block. There have been reports of second-degree AV block and other conduction abnormalities
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Section_6.2">6.2</linkHtml>) and Overdosage (
  
   <linkHtml href="#Section_10">10</linkHtml>)]
 
  </content>. In clinical trials that included electrocardiograms, asymptomatic first-degree AV   block   was   observed   in 5.9% of atazanavir-treated participants (n=920), 5.2% of lopinavir/ritonavir-treated participants (n=252), 10.4% of nelfinavir-treated participants (n=48), and 3.0% of efavirenz-treated participants (n=329). In Study AI424-045, asymptomatic first-degree AV block was observed in 5% (6/118) of atazanavir with ritonavir-treated participants and 5% (6/116) of lopinavir/ritonavir-treated participants who had on-study electrocardiogram measurements. Because of limited clinical experience in those with preexisting conduction system disease (eg, marked first-degree AV block or second- or third-degree AV block), ECG monitoring should be considered in these patients
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#Section_12.2">12.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="30891c38-5d74-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Severe Skin Reactions</title>
                     <text>
                        <br/>
                        <paragraph>In controlled clinical trials, rash (all grades, regardless of causality) occurred in approximately 20% of participants with HIV-1 treated with atazanavir. The median time to onset of rash in clinical studies was 7.3 weeks and the median duration of rash was 1.4 weeks. Rashes were generally mild-to-moderate maculopapular skin eruptions. Treatment-emergent adverse reactions of moderate or severe rash (occurring at a rate of ≥2%) are presented for the individual clinical studies
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Section_6.1">6.1</linkHtml>)]
 
  </content>. Dosing with atazanavir was often continued without interruption in patients who developed rash. The discontinuation rate for rash in clinical trials was &lt;1%. Cases of Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions, including drug rash, eosinophilia, and systemic symptoms (DRESS) syndrome, have been reported in patients receiving atazanavir
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#Section_4">4</linkHtml>) and Adverse Reactions (
  
   <linkHtml href="#Section_6.1">6.1</linkHtml>)]
 
  </content>. Atazanavir should be discontinued if severe rash develops.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="30891c38-5d75-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hepatotoxicity</title>
                     <text>
                        <br/>
                        <paragraph>Patients with underlying hepatitis B or C virus or marked elevations in transaminases before treatment may be at increased risk for developing further transaminase elevations or hepatic decompensation. In these patients, hepatic laboratory testing should be conducted prior to initiating therapy with atazanavir and during treatment
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#Section_2.2">2.2</linkHtml>), Adverse Reactions (
  
   <linkHtml href="#Section_6.1">6.1</linkHtml>), and Use in Specific Populations (
  
   <linkHtml href="#Section_8.8">8.8</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="30891c38-5d76-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Chronic Kidney Disease</title>
                     <text>
                        <br/>
                        <paragraph>Chronic kidney disease in patients with HIV-1 treated with atazanavir, with or without ritonavir, has been reported during postmarketing surveillance. Reports included biopsy-proven cases of granulomatous interstitial nephritis associated with the deposition of atazanavir drug crystals in the renal parenchyma. Consider alternatives to atazanavir in patients at high risk for renal disease or with preexisting renal disease. Renal laboratory testing (including serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination) should be conducted in all patients prior to initiating therapy with atazanavir and continued during treatment with atazanavir. Expert consultation is advised for patients who have confirmed renal laboratory abnormalities while taking atazanavir. In patients with progressive kidney disease, discontinuation of atazanavir may be considered
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#Section_2.2">2.2</linkHtml>and
  
   <linkHtml href="#Section_2.6">2.7</linkHtml>) and Adverse Reactions (
  
   <linkHtml href="#Section_6.2">6.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="30891c38-5d77-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Nephrolithiasis and Cholelithiasis</title>
                     <text>
                        <br/>
                        <paragraph>Cases of nephrolithiasis and/or cholelithiasis have been reported during postmarketing surveillance in patients with HIV-1 receiving atazanavir therapy. Some patients required hospitalization for additional management, and some had complications. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made. If signs or symptoms of nephrolithiasis and/or cholelithiasis occur, temporary interruption or discontinuation of therapy may be considered
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Section_6.2">6.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="30891c38-5d78-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Risk of Serious Adverse Reactions Due to Drug Interactions</title>
                     <text>
                        <br/>
                        <paragraph>Initiation of atazanavir with ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving atazanavir with ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of atazanavir with ritonavir, respectively. These interactions may lead to: 
  <br/>  •  clinically significant adverse reactions potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications. 
  <br/>  •  clinically significant adverse reactions from greater exposures of atazanavir with ritonavir. 
  <br/>  •  loss of therapeutic effect (virologic response) of atazanavir with ritonavir and possible development of resistance. 
  <br/>  See Table 16 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#Section_7">7</linkHtml>)]
 
  </content>. Consider the potential for drug interactions prior to and during therapy containing atazanavir with ritonavir; and monitor for the adverse reactions associated with concomitant medications
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#Section_4">4</linkHtml>) and Drug Interactions (
  
   <linkHtml href="#Section_7">7</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="30891c38-5d79-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Hyperbilirubinemia</title>
                     <text>
                        <br/>
                        <paragraph>Most patients taking atazanavir experience asymptomatic elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT). This hyperbilirubinemia is reversible upon discontinuation of atazanavir. Hepatic transaminase elevations that occur with hyperbilirubinemia should be evaluated for alternative etiologies. No long-term safety data are available for patients experiencing persistent elevations in total bilirubin &gt;5 times the upper limit of normal (ULN). Alternative antiretroviral therapy to atazanavir may be considered if jaundice or scleral icterus associated with bilirubin elevations presents cosmetic concerns for patients. Dose reduction of atazanavir is not recommended since long-term efficacy of reduced doses has not been established
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Section_6.1">6.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="30891c38-5d7a-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Diabetes Mellitus/Hyperglycemia</title>
                     <text>
                        <br/>
                        <paragraph>New-onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, and hyperglycemia have been reported during postmarketing surveillance in patients with HIV-1 receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Section_6.2">6.2</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="30891c38-5d7b-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Immune Reconstitution Syndrome</title>
                     <text>
                        <br/>
                        <paragraph>Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including atazanavir. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as
 
  <content styleCode="italics">Mycobacterium avium</content>, cytomegalovirus,
 
  <content styleCode="italics">Pneumocystis jirovecii</content>pneumonia, or tuberculosis), which may necessitate further evaluation and treatment. 
  <br/>  Autoimmune disorders (such as Graves’ disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.11">
                     <id root="30891c38-5d7c-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Fat Redistribution</title>
                     <text>
                        <br/>
                        <paragraph>Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.12">
                     <id root="30891c38-5d7d-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Hemophilia</title>
                     <text>
                        <br/>
                        <paragraph>There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in patients with hemophilia type A and B treated with protease inhibitors. In some patients, additional factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced. A causal relationship between protease inhibitor therapy and these events has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.13">
                     <id root="30891c38-5d7e-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Resistance/Cross-Resistance</title>
                     <text>
                        <br/>
                        <paragraph>Various degrees of cross-resistance among protease inhibitors have been observed. Resistance to atazanavir may not preclude the subsequent use of other protease inhibitors
 
  <content styleCode="italics">[see Microbiology (
  
   <linkHtml href="#Section_12.4">12.4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="30891c38-5d7f-7df7-e063-6394a90ae762"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <br/>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling: 
  <br/>  • cardiac conduction abnormalities
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>)]
 
  </content>
                     <br/>  • rash
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.2">5.2</linkHtml>)]
 
  </content>
                     <br/>  • hyperbilirubinemia
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.8">5.8</linkHtml>)]
 
  </content>
                     <br/>  • chronic kidney disease
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.5">5.5</linkHtml>)]
 
  </content>
                     <br/>  • nephrolithiasis and cholelithiasis
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.6</linkHtml>)]
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥2%) are nausea, jaundice/scleral icterus, rash, headache, abdominal pain, vomiting, insomnia, peripheral neurologic 
    <br/>  symptoms, dizziness, myalgia, diarrhea, depression, and fever. (
 
    <linkHtml href="#Section_6.1">6.1</linkHtml>) 
    <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="308958fb-8141-a841-e063-6394a90a39b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Adverse Reactions in Treatment-Naive Adult Participants 
  <br/>
The safety profile of atazanavir in treatment-naive adults is based on 1625 participants with HIV-1 in clinical trials. 536 participants received atazanavir 300 mg with ritonavir 100 mg and 1089 participants received atazanavir 400 mg or higher (without ritonavir).
  <br/>
The most common adverse reactions were nausea, jaundice/scleral icterus, and rash.
  <br/>
Selected clinical adverse reactions of moderate or severe intensity reported in 
  <content styleCode="underline">&gt; </content>2% of treatment- naive participants receiving combination therapy including atazanavir 300 mg with ritonavir 100 mg and atazanavir 400 mg (without ritonavir) are presented in Tables 7 and 8, respectively.
  <br/>
                           <content styleCode="bold">Table 7: Selected Adverse Reactions 
   <sup>a</sup>of Moderate or Severe Intensity Reported in &gt;2% of Adult Treatment-Naive Participants with HIV-1, 
   <sup>b</sup>Study AI424-138 
  </content>
                        </paragraph>
                        <paragraph/>
                        <table border="0" cellpadding="0" cellspacing="0" width="100%">
                           <colgroup>
                              <col width="39%"/>
                              <col width="33%"/>
                              <col width="27%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">96 weeks 
      <sup>c</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">96 weeks 
      <sup>c</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold"> Atazanavir capsules 300 mg with ritonavir 100 mg (once daily) and tenofovir DF/emtricitabine 
      <sup>d</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">lopinavir/ritonavir 
      <sup>d</sup>
                                       <br/>
			400 mg/100 mg (twice daily) and tenofovir DF/emtricitabine 
      <sup>e</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">(n=441)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">(n=437)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Digestive System</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top"/>
                                 <td styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Nausea</td>
                                 <td align="center" styleCode="Rrule" valign="top">4%</td>
                                 <td align="center" styleCode="Rrule" valign="top">8%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Jaundice/scleral icterus</td>
                                 <td align="center" styleCode="Rrule" valign="top">5%</td>
                                 <td align="center" styleCode="Rrule" valign="top">*</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Diarrhea</td>
                                 <td align="center" styleCode="Rrule" valign="top">2%</td>
                                 <td align="center" styleCode="Rrule" valign="top">12%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Skin and Appendages</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Rash</td>
                                 <td align="center" styleCode="Rrule" valign="top">3%</td>
                                 <td align="center" styleCode="Rrule" valign="top">2%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* None reported in this treatment arm.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <sup>a</sup> Includes events of possible, probable, certain, or unknown relationship to treatment regimen.
  <br/>
                           <sup>b</sup> Based on the regimen containing atazanavir.
  <br/>
                           <sup>c</sup> Median time on therapy.
  <br/>
                           <sup>d</sup> Administered as a fixed-dose.
  <br/>
                           <sup>e</sup> As a fixed-dose product: 300 mg tenofovir DF, 200 mg emtricitabine once daily.
  <br/>
                           <content styleCode="bold">Table 8:  Selected Adverse Reactions 
   <sup>a</sup>of Moderate or Severe Intensity Reported in ≥2% of Adult Treatment-Naive 
   <content styleCode="bold">Participants</content> with HIV-1, 
   <sup>b</sup>  Studies AI424-034, AI424-007, and AI424-008 
  </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph/>
                        <table border="0" cellpadding="0" cellspacing="0" width="804.65">
                           <colgroup>
                              <col width="29.7520661157025%"/>
                              <col width="16.198347107438%"/>
                              <col width="16.5289256198347%"/>
                              <col width="19.3388429752066%"/>
                              <col width="18.1818181818182%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" colspan="3" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Study AI424-034</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Studies AI424-007, -008</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" colspan="2" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">64 weeks 
      <sup>c</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">64 weeks 
      <sup>c</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">120 weeks 
      <sup>c,d</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">73 weeks 
      <sup>c,d</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" colspan="2" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir capsules</content>
                                    <content styleCode="bold">400 mg (once daily) with lamivudine/</content>
                                    <br/>
                                    <content styleCode="bold">Zidovudine 
      <sup>e</sup>
                                    </content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">(n=404)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">efavirenz</content>
                                    <br/>
                                    <content styleCode="bold">600 mg (once daily) with lamivudine/</content>
                                    <br/>
                                    <content styleCode="bold">zidovudine 
      <sup>e</sup>
                                    </content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">(n=401)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir capsules 400 mg (once daily) with stavudine and lamivudine or didanosine (n=279)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">nelfinavir 750 mg TID or 1250 mg BID with stavudine and lamivudine or didanosine (n=191)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Body as a Whole</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Headache</td>
                                 <td align="center" styleCode="Rrule" valign="middle">6%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">6%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">1%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">2%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Digestive System</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="justify" styleCode="Rrule" valign="top"/>
                                 <td align="justify" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Nausea</td>
                                 <td align="center" styleCode="Rrule" valign="top">14%</td>
                                 <td align="center" styleCode="Rrule" valign="top">12%</td>
                                 <td align="center" styleCode="Rrule" valign="top">6%</td>
                                 <td align="center" styleCode="Rrule" valign="top">4%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Jaundice/scleral icterus</td>
                                 <td align="center" styleCode="Rrule" valign="top">7%</td>
                                 <td align="center" styleCode="Rrule" valign="top">*</td>
                                 <td align="center" styleCode="Rrule" valign="top">7%</td>
                                 <td align="center" styleCode="Rrule" valign="top">*</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Vomiting</td>
                                 <td align="center" styleCode="Rrule" valign="top">4%</td>
                                 <td align="center" styleCode="Rrule" valign="top">7%</td>
                                 <td align="center" styleCode="Rrule" valign="top">3%</td>
                                 <td align="center" styleCode="Rrule" valign="top">3</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Abdominal pain</td>
                                 <td align="center" styleCode="Rrule" valign="middle">4%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">4%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">4%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">2%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Diarrhea</td>
                                 <td align="center" styleCode="Rrule" valign="middle">1%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">2%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">3%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">16%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Nervous System</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="justify" styleCode="Rrule" valign="top"/>
                                 <td align="justify" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Insomnia</td>
                                 <td align="center" styleCode="Rrule" valign="middle">3%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">3%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">&lt;1%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">*</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Dizziness</td>
                                 <td align="center" styleCode="Rrule" valign="middle">2%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">7%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">&lt;1%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">*</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Peripheral neurologic symptoms</td>
                                 <td align="center" styleCode="Rrule" valign="middle">&lt;1%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">1%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">4%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">3%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Skin and Appendages</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="justify" styleCode="Rrule" valign="top"/>
                                 <td align="justify" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" colspan="2" styleCode="Lrule Rrule" valign="top">Rash</td>
                                 <td align="center" styleCode="Rrule" valign="middle">7%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">10%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">5%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">1%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* 
  <sup/> None reported in this treatment arm. 
  <br/>
                           <sup>a</sup> Includes events of possible, probable, certain, or unknown relationship to treatment regimen.
  <br/>
                           <sup>b</sup> Based on regimens containing atazanavir. 
  <br/>
                           <sup>c</sup> Median time on therapy.
  <br/>
                           <sup>d</sup> Includes long-term follow-up.
  <br/>
                           <sup>e</sup> As a fixed-dose product: 150 mg lamivudine/300 mg zidovudine twice daily.
  <br/>
Adverse Reactions in Treatment-Experienced Adult Participants
  <br/>
The safety profile of atazanavir in treatment-experienced adults with HIV-1 is based on 119 participants with HIV-1 in clinical trials.
  <br/>
The most common adverse reactions are jaundice/scleral icterus and myalgia.
  <br/>
Selected clinical adverse reactions of moderate or severe intensity reported in ≥2% of treatment- experienced participants receiving atazanavir with ritonavir are presented in Table 9.
  <br/>
                           <content styleCode="bold">Table 9:  Selected Adverse Reactions 
   <sup>a</sup>of Moderate or Severe Intensity Reported in ≥2% of  Adult Treatment-Experienced 
   <content styleCode="bold">Participants</content> with HIV-1, 
   <sup>b</sup>Study AI424-045 
  </content>
                        </paragraph>
                        <paragraph/>
                        <table border="0" cellpadding="0" cellspacing="0" width="778.05">
                           <colgroup>
                              <col width="37.0940170940171%"/>
                              <col width="33.8461538461538%"/>
                              <col width="29.0598290598291%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">48 weeks 
      <sup>c</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">48 weeks 
      <sup>c</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir capsules with ritonavir 300/100 mg (once daily) and tenofovir DF and NRTI</content>
                                    <br/>
                                    <content styleCode="bold">(n=119)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">lopinavir/ritonavir 400/100 mg (twice daily</content>
                                    <content styleCode="bold">
                                       <sup>d</sup>
                                    </content>
                                    <content styleCode="bold">) and tenofovir DF and NRTI</content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">(n=118)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Body as a Whole</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Fever</td>
                                 <td align="center" styleCode="Rrule" valign="middle">2%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">*</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Digestive System</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Jaundice/scleral icterus</td>
                                 <td align="center" styleCode="Rrule" valign="middle">9%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">*</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Diarrhea</td>
                                 <td align="center" styleCode="Rrule" valign="middle">3%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">11%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Nausea</td>
                                 <td align="center" styleCode="Rrule" valign="middle">3%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">2%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Nervous System</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Depression</td>
                                 <td align="center" styleCode="Rrule" valign="middle">2%</td>
                                 <td align="center" styleCode="Rrule" valign="middle">&lt;1%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Musculoskeletal System</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="bottom">Myalgia</td>
                                 <td align="center" styleCode="Rrule" valign="bottom">4%</td>
                                 <td align="center" styleCode="Rrule" valign="bottom">*</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*   None reported in this treatment arm.
  <br/>
                           <sup>a</sup> Includes events of possible, probable, certain, or unknown relationship to treatment regimen.
  <br/>
                           <sup>b</sup> Based on the regimen containing atazanavir.
  <br/>
                           <sup>c</sup> Median time on therapy.
  <br/>
                           <sup>d</sup> As a fixed-dose product.
 </paragraph>
                        <paragraph/>
                        <paragraph>Laboratory Abnormalities in Treatment-Naive Participants
  <br/>
The percentages of adult treatment-naive participants with HIV-1 treated with combination therapy, including atazanavir 300 mg with ritonavir 100 mg or atazanavir 400 mg (without ritonavir) with Grade 3 to 4 laboratory abnormalities, are presented in Tables 10 and 11, respectively.
 </paragraph>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250206"/>
                     <component>
                        <section ID="Section_6.1.1">
                           <id root="30891c38-5d81-7df7-e063-6394a90ae762"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">Table 10: Grade 3 to 4 Laboratory Abnormalities Reported in ≥2% of Adult Treatment-Naive
  
   <content styleCode="bold">Participants</content> with HIV-1,a Study AI424-138
 
  </content>
                              </paragraph>
                              <br/>
                              <table cellspacing="0" cellpadding="0" border="0" width="805.98">
                                 <col width="32.3432343234323%"/>
                                 <col width="24.0924092409241%"/>
                                 <col width="23.5973597359736%"/>
                                 <col width="19.96699669967%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">96 weeks
     
      <sup>b</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">96 weeks
     
      <sup>b</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Atazanavir capsules 300 mg with ritonavir 100 mg (once daily) and tenofovir DF/emtricitabine
     
      <sup>c</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">lopinavir/ritonavir</content>
                                          <br/>
                                          <content styleCode="bold">400 mg/100 mgc (twice daily) and tenofovir DF/emtricitabine
     
      <sup>d</sup>
                                          </content>
                                          <br/>    
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Variable</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Limit
     
      <sup>e</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">(n=441)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=437)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Chemistry 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="underline">High</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  SGOT/AST
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  1%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  SGPT/ALT
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Total Bilirubin
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥2.6 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  44%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;1%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Lipase
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥2.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Creatine Kinase
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  8%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  7%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Total Cholesterol
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥240 mg/dL
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  11%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  25%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Hematology
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>
                                          <content styleCode="underline">L</content>
                                          <content styleCode="underline">o</content>
                                          <content styleCode="underline">w</content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Neutrophils
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;750 cells/mm
    
     <sup>3</sup>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  5%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>
                              <paragraph>
                                 <sup>a</sup> Based on the regimen containing atazanavir. 
  <br/>
                                 <sup>b</sup> Median time on therapy. 
  <br/>
                                 <sup>c</sup> Administered as a fixed-dose product 
  <br/>
                                 <sup>d</sup> As a fixed-dose product: 300 mg tenofovir DF, 200 mg emtricitabine once daily. 
  <br/>
                                 <sup>e</sup> ULN=upper limit of normal. 
  <br/>
                                 <br/>
                                 <content styleCode="bold">Table 11: Grade 3 to 4 Laboratory Abnormalities Reported in ≥2% of Adult Treatment-Naive
  
   <content styleCode="bold">Participants</content> with HIV-1,
  
   <sup>a</sup> Studies AI424-034, AI424-007, and AI424-008
 
  </content>
                              </paragraph>
                              <br/>
                              <table cellspacing="0" cellpadding="0" border="0" width="633">
                                 <col width="17.219589257504%"/>
                                 <col width="18.4834123222749%"/>
                                 <col width="13.4281200631912%"/>
                                 <col width="17.0616113744076%"/>
                                 <col width="19.2733017377567%"/>
                                 <col width="14.5339652448657%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Study AI424-034</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Studies AI424-007, -008</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">64 weeks
     
      <sup>b</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">64 weeks
     
      <sup>b</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">120 weeks
     
      <sup>b</sup>,
     
      <sup>c</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">73 weeks
     
      <sup>bc</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Atazanavir capsules </content>
                                          <content styleCode="bold">400 mg once daily and lamivudine/</content>
                                          <br/>
                                          <content styleCode="bold">Zidovudine
     
      <sup>e</sup>
                                          </content>
                                          <br/>    
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">efavirenz</content>
                                          <br/>
                                          <content styleCode="bold">600 mg once daily and lamivudine/</content>
                                          <br/>
                                          <content styleCode="bold">zidovudine
     
      <sup>e</sup>
                                          </content>
                                          <br/>    
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Atazanavir capsules 400 mg once daily with stavudine and lamivudine or with stavudine and didanosine</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">nelfinavir 750 mg TID or 1250 mg BID with stavudine and lamivudine or with stavudine and didanosine</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Variable</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Limit
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=404)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=401)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=279)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=191)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Chemistry 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="underline">High</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  SGOT/AST
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  7%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  5%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  SGPT/ALT
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  4%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  9%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  7%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Total
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥2.6 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  35%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;1%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  47%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Bilirubin
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Amylase
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥2.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  *
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  *
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  14%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  10%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Lipase
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥2.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;1%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  1%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  4%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  5%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Creatine
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  6%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  6%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  11%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  9%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Kinase
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Total
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥240 mg/dL
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  6%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  24%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  19%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  48%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Cholesterol
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="middle">
                                          <br/>   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Triglycerides
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥751 mg/dL
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;1%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  4%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Hematology
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>
                                          <content styleCode="underline">L</content>
                                          <content styleCode="underline">o</content>
                                          <content styleCode="underline">w</content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Hemoglobin
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;8.0 g/dL
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  5%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;1%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  4%
    </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Neutrophils
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;750 cells/mm
    
     <sup>3</sup>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  7%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  9%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  7%
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>
                              <paragraph>
                                 <sup>*</sup>None reported in this treatment arm. 
  <br/>
                                 <sup>a</sup> Based on regimen(s) containing atazanavir. 
  <br/>
                                 <sup>b</sup> Median time on therapy. 
  <br/>
                                 <sup>c</sup> Includes long-term follow-up. 
  <br/>
                                 <sup>d</sup> ULN = upper limit of normal. 
  <br/>
                                 <sup>e</sup> As a fixed-dose product: 150 mg lamivudine, 300 mg zidovudine twice daily. 
  <br/>
                                 <content styleCode="italics">Change in Lipids from Baseline in Treatment-Naive Participants with HIV-1</content>
                                 <br/>  For Study AI424-138 and Study AI424-034, changes from baseline in LDL-cholesterol, HDL- cholesterol, total cholesterol, and triglycerides are shown in Tables 12 and 13, respectively. 
  <br/>
                                 <content styleCode="bold">Table 12: Lipid Values, Mean Change from Baseline, Study AI424-138</content>
                              </paragraph>
                              <br/>
                              <table cellspacing="0" cellpadding="0" border="0" width="690">
                                 <col width="13.768115942029%"/>
                                 <col width="6.81159420289855%"/>
                                 <col width="9.56521739130435%"/>
                                 <col width="9.1304347826087%"/>
                                 <col width="8.98550724637681%"/>
                                 <col width="9.1304347826087%"/>
                                 <col width="2.31884057971015%"/>
                                 <col width="8.98550724637681%"/>
                                 <col width="8.98550724637681%"/>
                                 <col width="7.2463768115942%"/>
                                 <col width="8.26086956521739%"/>
                                 <col width="6.81159420289855%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td colspan="5" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Atazanavir capsules with ritonavir
     
      <sup>a,b</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td colspan="6" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">lopinavir/ritonavir
     
      <sup>b,c</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Baseline</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 96</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Baseline</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 96</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=428
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=372
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=372
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=342
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=342
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=424
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=335
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=335
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=291
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=291
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">LDL- 
     <br/>  Cholesterol
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">92 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">105 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+14% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">105 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+14% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">93 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">111 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+19% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">110 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+17% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">HDL- 
     <br/>  Cholesterol
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">37 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">46 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+29% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">44 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+21% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">36 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">48 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+37% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">46 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+29% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Total Cholesterol
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">149 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">169 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+13% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">169 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+13% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">150 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">187 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+25% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">186 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+25% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" valign="top">Triglycerides
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">126 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">145 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+15% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">140 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+13% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">129 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">194 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+52% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">184 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">+50% 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>
                              <br/>
                              <paragraph>
                                 <sup>a</sup> Atazanavir 300 mg with ritonavir 100 mg once daily with the fixed-dose product: 300 mg tenofovir DF/200 mg emtricitabine once daily. 
  <br/>
                                 <sup>b</sup> Values obtained after initiation of serum lipid-reducing agents were not included in these analyses. At baseline, serum lipid-reducing agents were used in 1% in the lopinavir/ritonavir treatment arm and 1% in the atazanavir with ritonavir arm. Through Week  48,  serum  lipid-reducing  agents  were  used  in  8%  in  the  lopinavir/ritonavir  treatment  arm  and  2%  in  the atazanavir with ritonavir arm. 
  <br/>  Through Week 96, serum lipid-reducing agents were used in 10% in the lopinavir/ritonavir treatment arm and 3% in the atazanavir with ritonavir arm. 
  <br/>
                                 <sup>c</sup> Lopinavir/ritonavir (400 mg/100 mg) twice daily with the fixed-dose product 300 mg tenofovir DF/200 mg emtricitabine once daily. 
  <br/>
                                 <sup>d</sup> The change from baseline is the mean of within-participant changes from baseline for participants with both baseline and Week 48 or Week 96 values and is not a simple difference of the baseline and Week 48 or Week 96 mean values, respectively. 
  <br/>
                                 <sup>e</sup> Number of participants with LDL-cholesterol measured. 
  <br/>
                                 <br/>
                                 <sup>f</sup> Fasting. 
  <br/>
                                 <content styleCode="bold">Table 13: Lipid Values, Mean Change from Baseline, Study AI424-034</content>
                              </paragraph>
                              <br/>
                              <br/>
                              <table cellspacing="0" cellpadding="0" border="0" width="576">
                                 <col width="16.4359861591695%"/>
                                 <col width="14.7058823529412%"/>
                                 <col width="13.1487889273356%"/>
                                 <col width="14.7058823529412%"/>
                                 <col width="13.1487889273356%"/>
                                 <col width="13.1487889273356%"/>
                                 <col width="14.7058823529412%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td colspan="3" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Atazanavir capsules
     
      <sup>a,b</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td colspan="3" align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">efavirenz
     
      <sup>b,c</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Baseline</content>
                                          <br/>
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48</content>
                                          <br/>
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 96</content>
                                          <br/>
                                          <content styleCode="bold">Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Baseline</content>
                                          <br/>
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48</content>
                                          <br/>
                                          <content styleCode="bold">mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 96</content>
                                          <br/>
                                          <content styleCode="bold">Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=383
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=283
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=272
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=378
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=264
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=253
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">LDL- 
     <br/>  Cholesterol
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">98 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">98 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">+1% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">98 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">114 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">+18% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">HDL- 
     <br/>  Cholesterol 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">39 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">43 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">+13% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">38 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">46 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">+24% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Total Cholesterol 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">164 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">168 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">+2% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">162 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">195 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="middle">+21% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" valign="top">Triglycerides
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">138 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">124 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">−9% 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">129 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">168 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="bottom">+23% 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>
                              <br/>
                              <paragraph>
                                 <sup>a</sup> Atazanavir 400 mg once daily with the fixed-dose product: 150 mg lamivudine, 300 mg zidovudine twice daily. 
  <br/>
                                 <sup>b</sup> Values obtained after initiation of serum lipid-reducing agents were not included in these analyses. At baseline, serum lipid-reducing agents were used in 0% in the efavirenz treatment arm and &lt;1% in the atazanavir arm. 
  <br/>  Through Week 48, serum lipid-reducing agents were used in 3% in the efavirenz treatment arm and 1% in the atazanavir arm. 
  <br/>
                                 <sup>c</sup> Efavirenz 600 mg once daily with the fixed-dose product: 150 mg lamivudine/300 mg zidovudine twice daily. 
  <br/>
                                 <sup>d</sup> The change from baseline is the mean of within-participant changes from baseline for participants with both baseline and Week 48 values and is not a simple difference of the baseline and Week 48 mean values. 
  <br/>
                                 <sup>e</sup> Number of participants with LDL-cholesterol measured. 
  <br/>
                                 <sup>f</sup> Fasting. 
  <br/>  Laboratory Abnormalities in Treatment-Experienced Participants with HIV-1 
  <br/>  The  percentages  of  adult  treatment-experienced  participants  with HIV-1 treated  with  combination  therapy, including atazanavir with ritonavir having  Grade 3 to 4 laboratory abnormalities, are presented in Table 14. 
  <br/>
                                 <content styleCode="bold">Table 14: Grade 3 to 4 Laboratory Abnormalities Reported in ≥2% of Adult   Treatment-Experienced
  
   <content styleCode="bold">Participants</content> with HIV-1, Study AI424-045
  
   <sup>a</sup>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </content>
                              </paragraph>
                              <table cellspacing="0" cellpadding="0" border="0" width="574">
                                 <col width="27.1777003484321%"/>
                                 <col width="24.5644599303136%"/>
                                 <col width="23.8675958188153%"/>
                                 <col width="24.390243902439%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                          <content styleCode="bold">Variable</content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">  
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                          <content styleCode="bold">Limit
     
      <sup>c</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">48 weeks
     
      <sup>b</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">Atazanavir </content>
                                          <content styleCode="bold">with ritonavir</content>  
     <br/>
                                          <content styleCode="bold">300/100 mg (once daily) and</content>
                                          <br/>
                                          <content styleCode="bold">tenofovir DF and NRTI</content>
                                          <br/>
                                          <content styleCode="bold">(n=119)</content>
                                          <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">48 weeks
     
      <sup>b</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">lopinavir/ritonavir</content>
                                          <br/>
                                          <content styleCode="bold">400/100 mg (twice daily
     
      <sup>d</sup>) and
    
     </content>
                                          <br/>
                                          <content styleCode="bold">tenofovir DF and NRTI</content>
                                          <br/>    
     <br/>
                                          <content styleCode="bold">(n=118)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">Chemistry 
     <br/>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="underline">High</content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">  
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  SGOT/AST
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  SGPT/ALT
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  4%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Total Bilirubin
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥2.6 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  49%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;1%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Lipase
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥2.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  5%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  6%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Creatine Kinase
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥5.1 x ULN
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  8%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  8%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Total Cholesterol
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥240 mg/dL
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  25%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  26%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Triglycerides
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥751 mg/dL
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  8%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  12%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Glucose
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  ≥251 mg/dL
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  5%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;1%
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Hematology
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>
                                          <content styleCode="underline">Low</content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Platelets
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;50,000 cells/mm
    
     <sup>3</sup>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  2%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  3%
    </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <br/>  Neutrophils
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  &lt;750 cells/mm
    
     <sup>3</sup>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  7%
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <br/>  8%
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>
                              <br/>
                              <br/>
                              <paragraph>
                                 <sup>a</sup>  Based on regimen(s) containing atazanavir. 
  <br/>
                                 <sup>b</sup>  Median time on therapy. 
  <br/>
                                 <sup>c</sup>  ULN = upper limit of normal. 
  <br/>
                                 <sup>d</sup>  As a fixed-dose product. 
  <br/>
                                 <content styleCode="italics">Change in Lipids from Baseline in Treatment-Experienced Participants with HIV-1 
   <br/>
                                 </content>For Study AI424-045, changes from baseline in LDL-cholesterol, HDL-cholesterol, total cholesterol, and triglycerides are shown in Table 15. The observed magnitude of dyslipidemia was less with atazanavir with ritonavir than with lopinavir/ritonavir. However, the clinical impact of such findings has not been demonstrated.

 </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Table 15: Lipid Values, Mean Change from Baseline, Study AI424-045</content>
                              </paragraph>
                              <br/>
                              <table cellspacing="0" cellpadding="0" border="0" width="586">
                                 <col width="19.2504258943782%"/>
                                 <col width="14.4804088586031%"/>
                                 <col width="12.9471890971039%"/>
                                 <col width="14.4804088586031%"/>
                                 <col width="12.9471890971039%"/>
                                 <col width="12.9471890971039%"/>
                                 <col width="12.9471890971039%"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top"> </td>
                                       <td colspan="3" align="center" styleCode="Rrule" valign="top">
                                          <br/>
                                          <content styleCode="bold">Atazanavir with ritonavir
     
      <sup>a,b</sup>
                                          </content>
                                       </td>
                                       <td colspan="3" align="center" styleCode="Rrule" valign="top">
                                          <br/>
                                          <content styleCode="bold"> Lopinavir/ritonavir
     
      <sup>b,c</sup>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td rowspan="2" align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Baseline</content>
                                          <content styleCode="bold"> </content>
                                          <content styleCode="bold">m</content>
                                          <content styleCode="bold">g</content>
                                          <content styleCode="bold">/</content>
                                          <content styleCode="bold">dL</content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48 mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48 Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Baseline</content>
                                          <content styleCode="bold"> </content>
                                          <content styleCode="bold">m</content>
                                          <content styleCode="bold">g</content>
                                          <content styleCode="bold">/</content>
                                          <content styleCode="bold">dL</content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48 mg/dL</content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">Week 48 Change
     
      <sup>d</sup>
                                          </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">(n=111
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=75
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=74
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=108
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=76
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">(n=73
     
      <sup>e</sup>)
    
     </content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">LDL-Cholesterol
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">108 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">98 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">−10% 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">104 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">103 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">+1% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">HDL-Cholesterol 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">40 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">39 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">−7% 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">39 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">41 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">+2% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">Total Cholesterol 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">188 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">170 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">−8% 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">181 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">187 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">+6% 
     <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="justify" styleCode="Lrule Rrule" valign="top">Triglycerides
    
     <sup>f</sup>
                                          <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">215 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">161 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">−4% 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">196 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">224 
     <br/>
                                       </td>
                                       <td align="justify" styleCode="Rrule" valign="top">+30% 
     <br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>
                              <paragraph>
                                 <sup>a</sup> Atazanavir 300 mg once daily with ritonavir and tenofovir DF, and 1 NRTI.  
  <br/>
                                 <sup>b</sup> Values obtained after initiation of serum lipid-reducing agents were not included in these analyses. At baseline, serum  lipid-reducing  agents  were  used  in  4%  in  the  lopinavir/ritonavir  treatment arm  and  4%  in  the atazanavir  with ritonavir  arm.  Through  Week  48,  serum  lipid-reducing  agents  were  used  in  19%  in  the lopinavir/ritonavir treatment arm and 8% in the atazanavir with ritonavir arm. 
  <br/>
                                 <sup>c</sup> Lopinavir/ritonavir (400/100 mg), as a fixed dose regimen, BID with tenofovir DF and 1 NRTI. 
  <br/>
                                 <sup>d</sup> The change from baseline is the mean of within-participant changes from baseline for participants with both baseline and Week 48 values and is not a simple difference of the baseline and Week 48 mean values. 
  <br/>
                                 <sup>e</sup> Number of participants with LDL-cholesterol measured. 
  <br/>  f Fasting. 
  <br/>  Adverse Reactions in Pediatric Participants with HIV-1: Atazanavir Capsules 
  <br/>  The safety and tolerability of atazanavir capsules with and without ritonavir have been established in pediatric participants with HIV-1, at least 6 years of age from the open-label, multicenter clinical trial PACTG 1020A. 
  <br/>  The safety profile of atazanavir in pediatric participants with HIV-1 (6 to less than 18 years of age) taking the capsule formulation was generally similar to that observed in clinical studies of atazanavir in adults. The most common Grade 2 to 4 adverse events (≥5%, regardless of causality) reported in pediatric participants were cough (21%), fever (18%), jaundice/scleral icterus (15%), rash (14%), vomiting (12%), diarrhea (9%), headache (8%), peripheral edema (7%), extremity pain (6%), nasal congestion (6%), oropharyngeal pain (6%), wheezing (6%), and rhinorrhea (6%). Asymptomatic second-degree atrioventricular block was reported in &lt;2% of participants. The most common Grade 3 to 4 laboratory abnormalities occurring in pediatric subjects taking the capsule formulation were elevation of total bilirubin (≥3.2 mg/dL, 58%),  neutropenia (9%), and hypoglycemia (4%). All other Grade 3 to 4 laboratory abnormalities occurred with a frequency of less than 3%. 
  <br/>  Adverse Reactions in Participants with HIV-1, Co-Infected with Hepatitis B and/or Hepatitis C Virus 
  <br/>  In Study AI424-138, 60 participants administered atazanavir 300 mg with ritonavir 100 mg once daily, and 51 participants treated with lopinavir/ritonavir 400 mg/100 mg (as fixed-dose product) twice daily, each with fixed-dose tenofovir DF/emtricitabine, were seropositive for hepatitis B and/or C at study entry. ALT levels &gt;5 times ULN developed in 10% (6/60) of the participants administered atazanavir with ritonavir and 8% (4/50) of the participants treated with lopinavir/ritonavir. AST levels &gt;5 times ULN developed in 10% (6/60) of the participants administered atazanavir with ritonavir and none (0/50) of the participants treated with lopinavir/ritonavir.  
  <br/>  In Study AI424-045, 20 participants administered atazanavir 300 mg with ritonavir 100 mg once daily, and 18 participants treated with lopinavir/ritonavir 400 mg/100 mg twice daily (as fixed-dose product), were seropositive for hepatitis B and/or C at study entry. ALT levels &gt;5 times ULN developed in 25% (5/20) of the participants administered atazanavir with ritonavir and 6% (1/18) of the participants treated with lopinavir/ritonavir treated. AST levels &gt;5 times ULN developed in 10% (2/20) of the participants administered atazanavir with ritonavir and 6% (1/18) of the participants treated with lopinavir/ritonavir. 
  <br/>  In Studies AI424-008 and AI424-034, 74 participants treated with atazanavir 400 mg once daily, 58 who received efavirenz, and 12 who received nelfinavir were seropositive for hepatitis B and/or C at study entry. ALT levels &gt;5 times ULN developed in 15% of the participants treated with atazanavir, 14% of the participants treated with efavirenz, and 17% of the participants treated with nelfinavir. AST levels &gt;5 times ULN developed in 9% of the participants treated with atazanavir, 5% of the participants treated with efavirenz, and 17% of the participants treated with nelfinavir. Within atazanavir and control regimens, no difference in frequency of bilirubin elevations was noted between seropositive and seronegative participants
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.8">5.8</linkHtml>)]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250206"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="30891c38-5d82-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <br/>
                        <paragraph>The following events have been identified during postmarketing use of atazanavir. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 
  <br/>
                           <br/>
                           <content styleCode="italics">Body as a Whole:</content>edema 
  <br/>
                           <br/>
                           <content styleCode="italics">Cardiovascular System</content>: second-degree AV block, third-degree AV block, left bundle branch block, QTc prolongation
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>)]
 
  </content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Gastrointestinal System:</content>pancreatitis 
  <br/>
                           <br/>
                           <content styleCode="italics">Hepatic System:</content>hepatic function abnormalities 
  <br/>
                           <br/>
                           <content styleCode="italics">Hepatobiliary Disorders:</content>cholelithiasis
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.6</linkHtml>)]
 
  </content>, cholecystitis, cholestasis 
  <br/>
                           <br/>
                           <content styleCode="italics">Metabolic System and Nutrition Disorders:</content>diabetes mellitus, hyperglycemia
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.9">5.9</linkHtml>)]
 
  </content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Musculoskeletal System:</content>arthralgia 
  <br/>
                           <br/>
                           <content styleCode="italics">Renal System:</content>nephrolithiasis
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.6</linkHtml>)]
 
  </content>, interstitial nephritis, granulomatous interstitial nephritis, chronic kidney disease
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.5">5.5</linkHtml>)]
 
  </content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Skin and Appendages:</content>alopecia, maculopapular rash
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#Section_4">4</linkHtml>) and Warnings and Precautions (
  
   <linkHtml href="#Section_5.2">5.2</linkHtml>)]
 
  </content>, pruritus, angioedema

 </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="30891c38-5d83-7df7-e063-6394a90ae762"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Coadministration of atazanavir can alter the concentration of other drugs and other drugs may alter the concentration of atazanavir. The potential drug-drug interactions must be considered prior to and during therapy. (
 
    <linkHtml href="http://pharmaready.heterousa.local/PR/SPLLabelManager.aspx?LabelID=1962#Section_4">4</linkHtml>, 
 
    <linkHtml href="http://pharmaready.heterousa.local/PR/SPLLabelManager.aspx?LabelID=1962#Section_7">7</linkHtml>, 
 
    <linkHtml href="http://pharmaready.heterousa.local/PR/SPLLabelManager.aspx?LabelID=1962#Section_12.3">12.3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="30891c38-5d84-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Potential for Atazanavir to Affect Other Drugs</title>
                     <text>
                        <br/>
                        <paragraph>Atazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of atazanavir and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects. 
  <br/>  Atazanavir is a weak inhibitor of CYP2C8. Use of atazanavir without ritonavir is not recommended when coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide). When atazanavir with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected
 
  <content styleCode="italics">[see Clinical Pharmacology, Table 22 (
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)].
 
  </content>
                           <br/>  The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when atazanavir is coadministered with ritonavir. See the complete prescribing information for ritonavir for information on drug interactions with ritonavir.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="30891c38-5d85-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Potential for Other Drugs to Affect Atazanavir</title>
                     <text>
                        <br/>
                        <paragraph>Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce atazanavir therapeutic effect 
 
  <content styleCode="italics">(see Table 16).</content>
                           <br/>  Atazanavir solubility decreases as pH increases. Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H
 
  <sub>2</sub>-receptor antagonists are administered with atazanavir
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#Section_2.3">2.3</linkHtml>,
  
   <linkHtml href="#Section_2.4">2.4</linkHtml>, and
  
   <linkHtml href="#Section_2.5">2.6</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="30891c38-5d86-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Established and Other Potentially Significant Drug Interactions</title>
                     <text>
                        <br/>
                        <paragraph>Table 16 provides dosing recommendations in adults as a result of drug interactions with atazanavir. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. 
  <br/>
                           <content styleCode="bold">Table 16: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies
  
   <sup>a</sup>or Predicted Interactions (Information in the table applies to atazanavir with or without ritonavir, unless otherwise indicated) 
   <br/>
                           </content>
                        </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="26.08%"/>
                           <col width="23.32%"/>
                           <col width="50.6%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Concomitant Drug Class:</content>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">Specific Drugs</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Effect on Concentration of Atazanavir or Concomitant Drug</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>
                                    <content styleCode="bold">Clinical Comment</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">HIV Antiviral Agents</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Nucleoside Reverse Transcriptase Inhibitors (NRTIs):</content>
                                    <br/>  didanosine buffered formulations enteric coated (EC) capsules 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>  ↓ didanosine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">It is recommended that atazanavir be given (with food) 2 h before or 1 h after didanosine buffered formulations. Simultaneous administration of didanosine EC and atazanavir with food results in a decrease in didanosine exposure. Thus, atazanavir and didanosine EC should be administered at different times. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Nucleotide Reverse Transcriptase Inhibitors:</content>tenofovir disoproxil fumarate (DF) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓atazanavir 
     <br/>  ↑tenofovir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">When coadministered with tenofovir DF in adults, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg and tenofovir DF 300 mg (all as a single daily dose with food). The mechanism of this interaction is unknown. Higher tenofovir concentrations could potentiate tenofovir-associated adverse reactions, including renal disorders. Patients receiving atazanavir and tenofovir DF should be monitored for tenofovir-associated adverse reactions. For pregnant patients taking atazanavir with ritonavir
    
     <content styleCode="italics">and</content>tenofovir DF, see
    
     <content styleCode="italics">Dosage and Administration (2.6)</content>. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Non-nucleoside Reverse</content>
                                    <br/>
                                    <content styleCode="italics">Transcriptase Inhibitors</content>
                                    <br/>
                                    <content styleCode="italics">(NNRTIs):</content>efavirenz 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓atazanavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">In HIV-treatment-naive adult patients:</content>
                                    </content>
                                    <br/>  If atazanavir is combined with efavirenz, atazanavir 400 mg (two 200-mg capsules) should be administered with ritonavir 100 mg simultaneously once daily with food, and efavirenz 600 mg should be administered once daily on an empty stomach, preferably at bedtime. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">In HIV-treatment-experienced adult patients:</content>
                                    </content>
                                    <br/>  Coadministration of atazanavir with efavirenz is not recommended. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">nevirapine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>  ↑ nevirapine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with nevirapine is contraindicated due to the potential loss of virologic response and development of resistance, as well as the potential risk for nevirapine-associated adverse reactions
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Protease Inhibitors:</content>
                                    <br/>  saquinavir (soft gelatin capsules) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ saquinavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Appropriate dosing recommendations for this combination, with or without ritonavir, with respect to efficacy and safety have not been established. In a clinical study, saquinavir 1200 mg coadministered with atazanavir 400 mg and tenofovir DF 300 mg (all given once daily), and nucleoside analogue reverse transcriptase inhibitors did not provide adequate efficacy
    
     <content styleCode="italics">[see Clinical Studies (14.2)]</content>. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">indinavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with indinavir is contraindicated. Both atazanavir and indinavir are associated with indirect (unconjugated) hyperbilirubinemia
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">ritonavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ atazanavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">If atazanavir is coadministered with ritonavir, it is recommended that atazanavir 300 mg once daily be given with ritonavir 100 mg once daily with food in adults. See the complete prescribing information for ritonavir for information on drug interactions with ritonavir. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Others 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ other protease inhibitor 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration with other protease inhibitors is not recommended. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Hepatitis C Antiviral Agents</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">elbasvir/grazoprevir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ grazoprevir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with grazoprevir is contraindicated due to the potential for increased risk of ALT elevations
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">glecaprevir/pibrentasvir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ glecaprevir 
     <br/>  ↑ pibrentasvir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with glecaprevir/pibrentasvir is contraindicated due to the potential for increased the risk of ALT elevations
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">voxilaprevir/sofosbuvir/ velpatasvir 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ voxilaprevir 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration with atazanavir is not recommended. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">
                                       <content styleCode="bold">Other Agents</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Alpha 1-Adrenoreceptor Antagonist:</content>alfuzosin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ alfuzosin 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">Coadministration of atazanavir with alfuzosin is contraindicated due to risk for hypotension
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antacids and buffered medications:</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓atazanavir 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Atazanavir should be administered 2 hours before or 1 hour after antacids and buffered medications. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antiarrhythmics:</content>amiodarone, quinidine 
     <br/>    
     <br/>    
     <br/>    
     <br/>  amiodarone, bepridil, lidocaine (systemic), quinidine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>    
     <br/>    
     <br/>  ↑amiodarone, bepridil, lidocaine (systemic), quinidine 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Concomitant use of atazanavir with ritonavir and either quinidine or amiodarone is contraindicated due to the potential for serious or life-threatening reactions such as cardiac arrhythmias
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>    
     <br/>  Coadministration with atazanavir without ritonavir has the potential to produce serious and/or life-threatening adverse events but has not been studied. Caution is warranted and therapeutic concentration monitoring of these drugs is recommended if they are used concomitantly with atazanavir, without ritonavir. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Anticoagulants:</content>
                                    <br/>  warfarin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ warfarin 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration with atazanavir has the potential to produce serious and/or life-threatening bleeding and has not been studied. It is recommended that International Normalized Ratio (INR) be monitored. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Direct-Acting Oral</content>
                                    <br/>
                                    <content styleCode="italics">Anticoagulants:</content>betrixaban, 
     <br/>  dabigatran, edoxaban 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ betrixaban 
     <br/>  ↑ dabigatran 
     <br/>  ↑ edoxaban 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Concomitant use of atazanavir with ritonavir, a strong CYP3A4/P-gp inhibitor, may result in an increased risk of bleeding. Refer to the respective DOAC prescribing information regarding dosing instructions for coadministration with P-gp inhibitors. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">rivaroxaban 
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>  apixaban 
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir with ritonavir</content>
                                    </content>
                                    <br/>  ↑ rivaroxaban 
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <br/>  ↑ rivaroxaban 
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir with ritonavir</content>
                                    </content>
                                    <br/>  ↑ apixaban 
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <br/>  ↑ apixaban 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with ritonavir, a strong CYP3A4/P-gp inhibitor, and rivaroxaban is not recommended, as it may result in an increased risk of bleeding. 
     <br/>  Coadministration of atazanavir, a CYP3A4 inhibitor, and rivaroxaban may result in an increased risk of bleeding. Close monitoring is recommended when atazanavir is coadministered with rivaroxaban. 
     <br/>  Concomitant use of atazanavir with ritonavir, a strong CYP3A4/P-gp inhibitor, may result in an increased risk of bleeding. Refer to apixaban dosing instructions for coadministration with strong CYP3A4 and P-gp inhibitors in the apixaban prescribing information. 
     <br/>    
     <br/>  Concomitant use of atazanavir, a CYP3A4 inhibitor, and apixaban may result in an increased risk of bleeding. Close monitoring is recommended when apixaban is coadministered with atazanavir. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antidepressants:</content>tricyclic antidepressants 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ tricyclic antidepressants 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration with atazanavir has the potential to produce serious and/or life-threatening adverse events and has not been studied. Concentration monitoring of these drugs is recommended if they are used concomitantly with atazanavir. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">trazodone 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ trazodone 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Nausea, dizziness, hypotension, and syncope have been observed following coadministration of trazodone with ritonavir. If trazodone is used with a CYP3A4 inhibitor such as atazanavir, the combination should be used with caution and a lower dose of trazodone should be considered. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antiepileptics:</content>carbamazepine 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>    
     <br/>  ↑ carbamazepine 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir (with or without ritonavir) with carbamazepine is contraindicated due to the risk for loss of virologic response and development of resistance
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">phenytoin, phenobarbital 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>    
     <br/>  ↓ phenytoin 
     <br/>  ↓ phenobarbital 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir (with or without ritonavir) with phenytoin or phenobarbital is contraindicated due to the risk for loss of virologic response and development of resistance
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">lamotrigine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓lamotrigine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of lamotrigine and atazanavir
    
     <content styleCode="bold">
                                       <content styleCode="italics">with</content>
                                    </content>ritonavir may require dosage adjustment of lamotrigine. 
     <br/>    
     <br/>  No dose adjustment of lamotrigine is required when coadministered with atazanavir without ritonavir. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antifungals:</content>
                                    <br/>  ketoconazole, itraconazole 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir with ritonavir:</content>
                                    </content>
                                    <br/>  ↑ ketoconazole 
     <br/>  ↑ itraconazole 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of ketoconazole has only been studied with atazanavir without ritonavir (negligible increase in atazanavir AUC and C
    
     <sub>max</sub>). Due to the effect of ritonavir on ketoconazole, high doses of ketoconazole and itraconazole (&gt;200 mg/day) should be used cautiously when administering atazanavir with ritonavir. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">voriconazole 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">with ritonavir in participants with a functional CYP2C19 allele:</content>
                                    </content>
                                    <br/>  ↓voriconazole 
     <br/>  ↓atazanavir 
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">with ritonavir in participants without a functional CYP2C19 allele:</content>
                                    </content>
                                    <br/>  ↑voriconazole 
     <br/>  ↓atazanavir 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">The use of voriconazole in patients receiving atazanavir with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Patients should be carefully monitored for voriconazole-associated adverse reactions and loss of either voriconazole or atazanavir efficacy during the coadministration of voriconazole and atazanavir with ritonavir. Coadministration of voriconazole with atazanavir (without ritonavir) may affect atazanavir concentrations; however, no data are available. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antigout:</content>colchicine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑colchicine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">The coadministration of atazanavir with colchicine in patients with renal or hepatic impairment is not recommended. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Recommended adult dosage of colchicine when administered with atazanavir:</content>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Treatment of gout flares:</content>
                                    </content>
                                    <br/>  0.6 mg (1 tablet) for 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Not to be repeated before 3 days. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Prophylaxis of gout flares:</content>
                                    </content>
                                    <br/>  If the original regimen was 0.6 mg
    
     <content styleCode="italics">twice</content>a day, the regimen should be adjusted to 0.3 mg
    
     <content styleCode="italics">once a day</content>. 
     <br/>    
     <br/>  If the original regimen was 0.6 mg
    
     <content styleCode="italics">once</content>a day, the regimen should be adjusted to 0.3 mg
    
     <content styleCode="italics">once every other day</content>. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Treatment of familial Mediterranean fever (FMF):</content>
                                    </content>
                                    <br/>  Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day). 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antimycobacterials:</content>rifampin 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">Coadministration of atazanavir with rifampin is contraindicated due to the risk for loss of virologic response and development of resistance
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">rifabutin 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ rifabutin 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">A rifabutin dose reduction of up to 75% (eg, 150 mg every other day or 3 times per week) is recommended. Increased monitoring for rifabutin-associated adverse reactions including neutropenia is warranted. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antineoplastics:</content>
                                    <br/>  irinotecan 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ irinotecan 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with irinotecan is contraindicated. Atazanavir inhibits UGT1A1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">apalutamide 
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>  ivosidenib 
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>  encorafenib 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>  ↓ atazanavir 
     <br/>  ↑ ivosidenib 
     <br/>    
     <br/>    
     <br/>    
     <br/>  ↓ atazanavir 
     <br/>  ↑ encorafenib 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir (with or without ritonavir) and apalutamide is contraindicated due to the potential for subsequent loss of virologic response and possible resistance to the class of protease inhibitors
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>    
     <br/>  Coadministration of ivosidenib with atazanavir (with or without ritonavir) is contraindicated due to the potential for loss of virologic response and risk of serious adverse events such as QT interval prolongation. 
     <br/>    
     <br/>  Coadministration of encorafenib with atazanavir (with or without ritonavir) is contraindicated due to the potential for the loss of virologic response and risk of serious adverse events such as QT interval prolongation. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antiplatelets</content>
                                    <br/>  ticagrelor 
     <br/>    
     <br/>    
     <br/>    
     <br/>  clopidogrel 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  ↑ ticagrelor 
     <br/>    
     <br/>    
     <br/>    
     <br/>  ↓ clopidogrel active 
     <br/>  metabolite 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">  
     <br/>  Coadministration with ticagrelor is not recommended due to potential increase in the risk of dyspnea, bleeding and other adverse events associated with ticagrelor. 
     <br/>    
     <br/>  Coadministration of atazanavir (with or without ritonavir) and clopidogrel is not recommended. This is due to the potential reduction of the antiplatelet activity of clopidogrel. 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Antipsychotics:</content>
                                    <br/>  pimozide 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ pimozide 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with pimozide is contraindicated. This is due to the potential for serious and/or life-threatening reactions such as cardiac arrhythmias
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">lurasidone 
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>  quetiapine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir with ritonavir</content>
                                    </content>
                                    <br/>    
     <br/>  ↑ lurasidone 
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <br/>  ↑ lurasidone 
     <br/>    
     <br/>    
     <br/>    
     <br/>  ↑ quetiapine 
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir with ritonavir</content>
                                    </content>
                                    <br/>  Coadministration of lurasidone with atazanavir with ritonavir is contraindicated. This is due to the potential for serious and/or life-threatening reactions
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir without ritonavir</content>
                                    </content>
                                    <br/>  If coadministration is necessary, reduce the lurasidone dose. Refer to the lurasidone prescribing information for concomitant use with moderate CYP3A4 inhibitors. 
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Initiation of</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">atazanavir with ritonavir in patients taking quetiapine:</content>
                                    </content>
                                    <br/>  Consider alternative antiretroviral therapy to avoid increases in quetiapine exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring. 
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Initiation of quetiapine in patients taking</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">atazanavir with ritonavir:</content>
                                    </content>
                                    <br/>  Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Benzodiazepines:</content>
                                    <br/>  midazolam (oral) 
     <br/>  triazolam 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ midazolam 
     <br/>  ↑ triazolam 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with either orally administered midazolam or triazolam is contraindicated. Triazolam and orally administered midazolam are extensively metabolized by CYP3A4, and coadministration with atazanavir can lead to the potential for serious and/or life-threatening events such as prolonged or increased sedation or respiratory depression
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">parenterally administered 
     <br/>  midazolam
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ midazolam 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration with parenteral midazolam should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Calcium channel blockers:</content>diltiazem 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ diltiazem and desacetyl-diltiazem 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Caution is warranted. A dose reduction of diltiazem by 50% should be considered. ECG monitoring is recommended. Coadministration of diltiazem and atazanavir with ritonavir has not been studied. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">felodipine, nifedipine, nicardipine, and verapamil 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ calcium channel blocker 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Caution is warranted. Dose titration of the calcium channel blocker should be considered. ECG monitoring is recommended. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Corticosteroids:</content>
                                    <br/>  dexamethasone and other corticosteroids
    
     <content styleCode="italics">(all routes of administration)</content>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>  ↑ corticosteroids 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration with dexamethasone or other corticosteroids that induce CYP3A may result in loss of therapeutic effect of atazanavir and development of resistance to atazanavir and/or ritonavir. Alternative corticosteroids should be considered. Coadministration with corticosteroids (all routes of administration) that are metabolized by CYP3A, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression. Consider the potential benefit of treatment versus the risk of systemic corticosteroid effects. For coadministration of cutaneously administered corticosteroids sensitive to CYP3A inhibition, refer to the prescribing information of the corticosteroid for additional information. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Endothelin receptor</content>
                                    <br/>
                                    <content styleCode="italics">antagonists:</content>
                                    <br/>  bosentan 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓
    
     <content styleCode="bold">atazanavir</content>
                                    <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">with ritonavir</content>
                                    </content>
                                    <br/>  ↑ bosentan 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of bosentan and atazanavir without ritonavir is not recommended. 
     <br/>  For adult patients who have been receiving atazanavir with ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based on individual tolerability. 
     <br/>  For adult patients who have been receiving bosentan, discontinue bosentan at least 36 hours before starting atazanavir with ritonavir. At least 10 days after starting atazanavir with ritonavir, resume bosentan at 62.5 mg once daily or every other day based on individual tolerability. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Ergot derivatives:</content>dihydroergotamine, ergotamine, ergonovine, methylergonovine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ ergot derivatives 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with ergot derivatives is contraindicated. This is due to the potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">GI Motility Agents:</content>
                                    <br/>  cisapride 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ cisapride 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with cisapride is contraindicated. This is due to the potential for serious and/or life-threatening reactions such as cardiac arrhythmias
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Gonadotropin-releasing</content>
                                    <br/>
                                    <content styleCode="italics">hormone Receptor (GnRH)</content>
                                    <br/>
                                    <content styleCode="italics">Antagonists:</content>
                                    <br/>  elagolix 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>  ↑ elagolix 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of elagolix and atazanavir with or without ritonavir is not recommended due to the potential of loss of virologic response and the potential risk of adverse events such as bone loss and hepatic transaminase elevations associated with elagolix. 
     <br/>    
     <br/>  In the event coadministration is necessary, limit concomitant use of elagolix 200mg twice daily with atazanavir with or without ritonavir for up to 1 month or limit concomitant use of elagolix 150 mg once daily with atazanavir (with or without ritonavir) for up to 6 months and monitor virologic response. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Herbal Products:</content>
                                    <br/>  St. John’s wort
    
     <content styleCode="italics">(Hypericum perforatum)</content>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of products containing St. John’s wort with atazanavir is contraindicated. This may result in loss of therapeutic effect of atazanavir and the development of resistance
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Kinase inhibitors:</content>
                                    <br/>  fostamatinib 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ R406 (active metabolite of fostamatinib) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">When coadministering fostamatinib with atazanavir (with or without ritonavir), monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Lipid-modifying agents</content>
                                    <br/>    
     <br/>
                                    <content styleCode="italics">HMG-CoA reductase</content>
                                    <br/>
                                    <content styleCode="italics">inhibitors:</content>lovastatin, 
     <br/>  simvastatin 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ lovastatin 
     <br/>    
     <br/>  ↑ simvastatin 
     <br/>    
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with lovastatin or simvastatin is contraindicated. This is due to the potential for serious reactions such as myopathy, including rhabdomyolysis
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">atorvastatin, rosuvastatin 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ atorvastatin 
     <br/>  ↑ rosuvastatin 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Titrate atorvastatin dose carefully and use the lowest necessary dose. Rosuvastatin dose should not exceed 10 mg/day. The risk of myopathy, including rhabdomyolysis, may be increased when HIV protease inhibitors, including atazanavir, are used in combination with these drugs. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Other Lipid Modifying Agents:</content>lomitapide 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ lomitapide 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with lomitapide is contraindicated. This is due to the potential for risk of markedly increased transaminase levels and hepatotoxicity associated with increased plasma concentrations of lomitapide. The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or ritonavir
    
     <content styleCode="italics">[see Contraindications (4)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">H
     
      <sub>2</sub>-Receptor antagonists
    
     </content>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ atazanavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration may result in loss of virologic response and development of resistance. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">In HIV-treatment-naive adult patients:</content>
                                    </content>
                                    <br/>  Atazanavir 300 mg with ritonavir 100 mg once daily with food should be administered simultaneously with, and/or at least 10 hours after, a dose of the H
    
     <sub>2</sub>-receptor antagonist (H2RA). An H2RA dose comparable to famotidine 20 mg once daily up to a dose comparable to famotidine 40 mg twice daily can be used with atazanavir 300 mg with ritonavir 100 mg in treatment-naive patients. 
     <br/>  OR 
     <br/>  For patients unable to tolerate ritonavir, atazanavir 400 mg once daily with food should be administered at least 2 hours before and at least 10 hours after a dose of the H2RA. No single dose of the H2RA should exceed a dose comparable to famotidine 20 mg, and the total daily dose should not exceed a dose comparable to famotidine 40 mg. The use of atazanavir without ritonavir in pregnant patients is not recommended. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">In treatment-experienced adult patients:</content>
                                    </content>
                                    <br/>  Whenever an H2RA is given to a patient receiving atazanavir with ritonavir, the H2RA dose should not exceed a dose comparable to famotidine 20 mg twice daily, and the atazanavir with ritonavir doses should be administered simultaneously with, and/or at least 10 hours after, the dose of the H2RA. 
     <br/>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Atazanavir 300 mg with ritonavir 100 mg once daily (all as a single dose with food) if taken with an H2RA.</item>
                                       <item>Atazanavir 400 mg with ritonavir 100 mg once daily (all as a single dose with food) if taken with both tenofovir DF and an H2RA.</item>
                                       <item>Atazanavir 400 mg with ritonavir 100 mg once daily (all as a single dose with food) if taken with either tenofovir DF or an H2RA for pregnant patients during the second and third trimester. Atazanavir is not recommended for pregnant patients during the second and third trimester taking atazanavir with both tenofovir DF and an H2RA.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Hormonal contraceptives:</content>
                                    <br/>  ethinyl estradiol and 
     <br/>  norgestimate or norethindrone 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓ ethinyl estradiol 
     <br/>  ↑ norgestimate
    
     <sup>c</sup>
                                    <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>  ↑ ethinyl estradiol 
     <br/>  ↑ norethindrone
    
     <sup>d</sup>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Use caution if considering coadministration of oral contraceptives with atazanavir or atazanavir with ritonavir. 
     <br/>    
     <br/>  If atazanavir with ritonavir is coadministered with an oral contraceptive, it is recommended that the oral contraceptive contain at least 35 mcg of ethinyl estradiol. 
     <br/>    
     <br/>  If atazanavir is administered without ritonavir, the oral contraceptive should contain no more than 30 mcg of ethinyl estradiol. 
     <br/>    
     <br/>  Potential safety risks include substantial increases in progesterone exposure. The long-term effects of increases in concentration of the progestational agent are unknown and could increase the risk of insulin resistance, dyslipidemia, and acne. 
     <br/>    
     <br/>  Coadministration of atazanavir or atazanavir with ritonavir and other hormonal contraceptives (eg, contraceptive patch, contraceptive vaginal ring, or injectable contraceptives) or oral contraceptives containing progestogens other than norethindrone or norgestimate, or less than 25 mcg of ethinyl estradiol, has not been studied; therefore, alternative methods of contraception are recommended. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Immunosuppressants:</content>cyclosporine, sirolimus, tacrolimus 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ immunosuppressants 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with atazanavir. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Inhaled beta agonist:</content>
                                    <br/>  salmeterol 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ salmeterol 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of salmeterol with atazanavir is not recommended. Concomitant use of salmeterol and atazanavir may result in increased risk of cardiovascular adverse reactions associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Inhaled/nasal steroid:</content>
                                    <br/>  fluticasone 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <br/>  ↑ fluticasone 
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir with ritonavir</content>
                                    </content>
                                    <br/>  ↑ fluticasone 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Concomitant use of fluticasone propionate and atazanavir without ritonavir should be used with caution. Consider alternatives to fluticasone propionate, particularly for long-term use. 
     <br/>    
     <br/>  With concomitant use of fluticasone propionate and atazanavir with ritonavir systemic corticosteroid effects, including Cushing’s syndrome and adrenal suppression, have been reported during postmarketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate. Coadministration of fluticasone propionate and atazanavir with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects
    
     <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Macrolide antibiotics:</content>
                                    <br/>  clarithromycin 
     <br/>    
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ clarithromycin 
     <br/>  ↓ 14-OH clarithromycin 
     <br/>  ↑ atazanavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Increased concentrations of clarithromycin may cause QTc prolongations; therefore, a dose reduction of clarithromycin by 50% should be considered when it is coadministered with atazanavir. In addition, concentrations of the active metabolite 14-OH clarithromycin are significantly reduced; consider alternative therapy for indications other than infections due to
    
     <content styleCode="italics">Mycobacterium avium</content>complex. Coadministration of atazanavir with ritonavir and clarithromycin has not been studied. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Opioids:</content>buprenorphine 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">or</content>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">with ritonavir</content>
                                    </content>
                                    <br/>  ↑ buprenorphine 
     <br/>  ↑ norbuprenorphine 
     <br/>    
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <br/>  ↓atazanavir 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with ritonavir and buprenorphine warrants clinical monitoring for sedation and cognitive effects. A dose reduction of buprenorphine may be considered. 
     <br/>    
     <br/>  The coadministration of atazanavir and buprenorphine without ritonavir is not recommended. 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">PDE5 inhibitors:</content>sildenafil, tadalafil, vardenafil 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑ sildenafil 
     <br/>  ↑ tadalafil 
     <br/>  ↑ vardenafil 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration with atazanavir has not been studied but may result in an increase in PDE5 inhibitor-associated adverse reactions, including hypotension, syncope, visual disturbances, and priapism. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Use of PDE5 inhibitors for pulmonary arterial hypertension (PAH):</content>
                                    </content>
                                    <br/>  Coadministration of atazanavir with REVATIO
    
     <sup>®</sup>(sildenafil) for the treatment of pulmonary hypertension (PAH) is contraindicated
    
     <content styleCode="italics">[see Contraindications (4)]</content>. 
     <br/>  The following dose adjustments are recommended for the use of ADCIRCA
    
     <sup>®</sup>(tadalafil) with atazanavir: 
     <br/>  Coadministration of ADCIRCA
    
     <sup>®</sup>in patients on atazanavir (with or without ritonavir): 
     <br/>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>For patients receiving atazanavir (with or without ritonavir) for at least one week, start ADCIRCA
      
       <sup>®</sup>at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.                                                                                                       Coadministration of atazanavir (with or without ritonavir) in patients on ADCIRCA
      
       <sup>®</sup>: 
       <br/>
                                       </item>
                                       <item>Avoid the use of ADCIRCA
      
       <sup>®</sup>when starting atazanavir (with or without ritonavir). Stop ADCIRCA
      
       <sup>®</sup>at least 24 hours before starting atazanavir (with or without ritonavir). At least one week after starting atazanavir (with or without ritonavir), resume ADCIRCA
      
       <sup>®</sup>at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.
     
      </item>
                                    </list>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Use of PDE5 inhibitors for erectile dysfunction:</content>
                                    </content>
                                    <br/>  Use VIAGRA
    
     <sup>®</sup>(sildenafil) with caution at reduced doses of 25 mg every 48 hours with increased monitoring for adverse events. 
     <br/>  Use CIALIS
    
     <sup>®</sup>(tadalafil) with caution at reduced doses of 10 mg every 72 hours with increased monitoring for adverse events. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir</content>
                                    </content>
                                    <content styleCode="bold">
                                       <content styleCode="italics">with ritonavir:</content>
                                    </content>Use vardenafil with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring for adverse reactions. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">Atazanavir:</content>
                                    </content>Use vardenafil with caution at reduced doses of no more than 2.5 mg every 24 hours with increased monitoring for adverse reactions. 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="italics">Proton-pump inhibitors:</content>omeprazole 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↓atazanavir 
     <br/>    
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">Coadministration of atazanavir with or without ritonavir and omeprazole may result in loss of virologic response and development of resistance. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">In HIV-treatment-naive adult patients:</content>
                                    </content>
                                    <br/>  The proton-pump inhibitor (PPI) dose should not exceed a dose comparable to omeprazole 20 mg and must be taken approximately 12 hours prior to the atazanavir 300 mg with ritonavir 100 mg dose. 
     <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">In HIV-treatment-experienced adult patients:</content>
                                    </content>Coadministration of atazanavir with PPIs
    
     <content styleCode="bold">
                                       <content styleCode="italics"/>
                                    </content>is not recommended. 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a </sup> For magnitude of interactions

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>see
 
  <content styleCode="italics">Clinical Pharmacology, Tables 21</content>and
 
  <content styleCode="italics">22 (
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)
 
  </content>. 
  <br/>
                           <sup>b</sup>   See
 
  <content styleCode="italics">
                              <linkHtml href="#Section_4">Contraindications (4)</linkHtml>
                           </content>,
 
  <content styleCode="italics">Table 6</content>for orally administered midazolam. 
  <br/>
                           <sup>c</sup>  In combination with atazanavir 300 mg with ritonavir 100 mg once daily. 
  <br/>
                           <sup>d</sup>  In combination with atazanavir 400 mg once daily.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="30891c38-5d87-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs with No Observed Interactions with Atazanavir</title>
                     <text>
                        <br/>
                        <paragraph>No clinically significant drug interactions were observed when atazanavir was coadministered with methadone, fluconazole, acetaminophen, atenolol, or the nucleoside reverse transcriptase inhibitors lamivudine or zidovudine
 
  <content styleCode="italics">[see Clinical Pharmacology, Tables 21 and 22 (
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="30891c38-5d88-7df7-e063-6394a90ae762"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <paragraph>• 
 
    <content styleCode="italics">Pregnancy:</content>Available human and animal data suggest that atazanavir does not  increase  the  risk  of  major  birth  defects  overall  compared  to  the background rate. (
 
    <linkHtml href="#Section_8.1">8.1</linkHtml>) 
    <br/>  • 
 
    <content styleCode="italics">Hepatitis B or C co-infection:</content>Monitor liver enzymes. (
 
    <linkHtml href="#Section_5.3">5.4</linkHtml>,
 
    <linkHtml href="#Section_6.1">6.1</linkHtml>) 
    <br/>  • 
 
    <content styleCode="italics">Renal impairment:</content>Atazanavir is not recommended for use in treatment- experienced patients with end-stage renal disease managed with hemodialysis. (
 
    <linkHtml href="#Section_2.6">2.7</linkHtml>,
 
    <linkHtml href="#Section_8.7">8.7</linkHtml>) 
    <br/>  • 
 
    <content styleCode="italics">Hepatic impairment:</content>Atazanavir is not recommended in patients with severe hepatic impairment. Atazanavir with ritonavir is not recommended in patients with any degree of hepatic impairment. (
 
    <linkHtml href="#Section_2.7">2.8</linkHtml>,
 
    <linkHtml href="#Section_8.8">8.8</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="30891c38-5d89-7df7-e063-6394a90ae762"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to atazanavir during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>  Atazanavir has been evaluated in a limited number of women during pregnancy. Available human and animal data suggest that atazanavir does not increase the risk of major birth defects overall compared to the background rate
 
  <content styleCode="italics">[see Data].</content>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. No treatment-related malformations were observed in rats and rabbits, for which the atazanavir exposures were 0.7 to 1.2 times of those at the human clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir). When atazanavir was administered to rats during  pregnancy  and  throughout  lactation,  reversible  neonatal  growth  retardation  was observed
 
  <content styleCode="italics">[see Data].</content>
                           <br/>
                           <content styleCode="underline">Clinical Considerations</content>
                           <br/>
                           <content styleCode="italics">Dose Adjustments during Pregnancy and the Postpartum Period</content>
                           <br/>  •  Atazanavir must be administered with ritonavir in pregnant patients. 
  <br/>  •  For pregnant patients, no dosage adjustment is required for atazanavir with the following exceptions: 
  <br/>  •  For treatment-experienced pregnant women during the second or third trimester, when atazanavir is coadministered with either an H
 
  <sub>2</sub>-receptor antagonist
 
  <content styleCode="bold">or</content>tenofovir DF, atazanavir 400 mg with ritonavir 100 mg once daily is recommended. There are insufficient data to recommend a atazanavir dose for use with both an H
 
  <sub>2</sub>-receptor antagonist
 
  <content styleCode="italics">and</content>tenofovir DF in treatment-experienced pregnant patients. 
  <br/>  •  No dosage adjustment is required for postpartum patients. However, patients should be closely monitored for adverse events because atazanavir exposures could be higher during the first 2 months after delivery
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#Section_2.5">2.6</linkHtml>) and Clinical Pharmacology (
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)].
 
  </content>
                           <br/>
                           <content styleCode="italics">Maternal Adverse Reactions</content>
                           <br/>  Cases of lactic acidosis syndrome, sometimes fatal, and symptomatic hyperlactatemia have occurred in pregnant women using atazanavir in combination with nucleoside analogues, which are associated with an increased risk of lactic acidosis syndrome. 
  <br/>  Hyperbilirubinemia occurs frequently in patients who take  atazanavir
 
  <content styleCode="italics">[see  Warnings  and Precautions (
  
   <linkHtml href="#Section_5.8">5.8</linkHtml>)]
 
  </content>, including those who are pregnant
 
  <content styleCode="italics">[see Data].</content>
                           <br/>  Advise pregnant women of the potential risks of lactic acidosis syndrome and hyperbilirubinemia. 
  <br/>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                           <br/>  All infants, including neonates exposed to atazanavir
 
  <content styleCode="italics">in utero</content>, should be monitored for the development of severe hyperbilirubinemia during the first few days of life
 
  <content styleCode="italics">[see Data].</content>
                           <br/>  Data 
  <br/>
                           <content styleCode="italics">Human Data</content>
                           <br/>  In Study AI424-182, atazanavir with ritonavir (300/100 mg or 400/100 mg) coadministered with lamivudine/zidovudine (150 mg/ 300 mg, as fixed-dose product) was administered to 41 pregnant women with HIV-1, during the second or third trimester. Among the 39 women who completed the study, 38 women achieved an HIV-1 RNA less than 50 copies/mL at time of delivery. Six of 20 (30%) women on atazanavir with ritonavir 300/100 mg and 13 of 21 (62%) women on atazanavir with ritonavir 400/100 mg experienced hyperbilirubinemia (total bilirubin greater than or equal to 2.6 times ULN). There were no cases of lactic acidosis observed in clinical trial AI424-182. 
  <br/>  Atazanavir drug concentrations in fetal umbilical cord blood were approximately 12% to 19% of maternal concentrations. Among the 40 infants born to 40 pregnant women with HIV-1, all had test results that were negative for HIV-1 DNA at the time of delivery and/or during the first 6 months postpartum. All 40 infants received antiretroviral prophylactic treatment containing zidovudine. No evidence of severe hyperbilirubinemia (total bilirubin levels greater than 20 mg/dL) or acute or chronic bilirubin encephalopathy was observed among neonates in this study. However, 10/36 (28%) infants (6 greater than or equal to 38 weeks gestation and 4 less than 38 weeks gestation) had bilirubin levels of 4 mg/dL or greater within the first day of life. 
  <br/>  Lack of ethnic diversity was a study limitation. In the study population, 33/40 (83%) infants were Black/African American, who have a lower incidence of neonatal hyperbilirubinemia than Caucasians and Asians. In addition, women with Rh incompatibility were excluded, as well as women who had a previous infant who developed hemolytic disease and/or had neonatal pathologic jaundice (requiring phototherapy). 
  <br/>  Additionally, of the 38 infants who had glucose samples collected in the first day of life, 3 had adequately collected serum glucose samples with values of less than 40 mg/dL that could not be attributed to maternal glucose intolerance, difficult delivery, or sepsis. 
  <br/>  Based on prospective reports from the APR of approximately 1600 live births following exposure to atazanavir-containing regimens (including 1037 live births in infants exposed in the first trimester and 569 exposed in second/third trimesters), there was no difference between atazanavir, and overall birth defects compared with the background birth defect rate. In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4%. 
  <br/>
                           <content styleCode="italics">Animal Data</content>
                           <br/>  In animal reproduction studies, there was no evidence of mortality or teratogenicity in offspring 
  <br/>  born to animals at systemic drug exposure levels (AUC) 0.7 (in rabbits) to 1.2 (in rats) times those observed at the human clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir). In pre- and postnatal development studies in the rat, atazanavir caused neonatal growth retardation during lactation that reversed after weaning. Maternal drug exposure at this dose was 1.3 times the human exposure at the recommended clinical exposure. Minimal maternal toxicity occurred at this exposure level.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="30891c38-5d8a-7df7-e063-6394a90ae762"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <br/>
                        <paragraph>Risk Summary 
  <br/>  Atazanavir has been detected in human milk. No data are available regarding atazanavir effects on milk production. Atazanavir was present in the milk of lactating rats and was associated with neonatal growth retardation that reversed after weaning. 
  <br/>  Potential risks of breastfeeding include: (1) HIV-1 transmission (in infants without HIV-1), (2) developing viral resistance (in infants with HIV-1), and (3) adverse reactions in a breastfed infant similar to those seen in adults.
 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="30891c38-5d8b-7df7-e063-6394a90ae762"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <br/>
                        <paragraph>Atazanavir is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1, 6 years of age and older weighing at least 15 kg. Atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus
 
  <content styleCode="italics">[see Indications and Usage (
  
   <linkHtml href="#Section_1">1</linkHtml>)].
 
  </content>All atazanavir contraindications, warnings, and precautions apply to pediatric patients
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#Section_4">4</linkHtml>) and Warnings and Precautions (
  
   <linkHtml href="#Section_5">5</linkHtml>)]. 
   <br/>
                           </content>The safety, pharmacokinetic profile, and virologic response of atazanavir in pediatric patients at least 6 years of age and older weighing at least 15 kg were established in three open-label, multicenter clinical trial: PACTG 1020A, AI424-451, and AI424-397 
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>) and Clinical Studies (
  
   <linkHtml href="#Section_14.3">14.3</linkHtml>)].
 
  </content>The safety profile in pediatric patients was generally similar to that observed in adults
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#Section_6.1">6.1</linkHtml>)]
 
  </content>. See
 
  <content styleCode="italics">Dosage and Administration (
  
   <linkHtml href="#Section_2.4">2.4</linkHtml>)
 
  </content>for dosing recommendations for the use of atazanavir capsules.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="30891c38-5d8c-7df7-e063-6394a90ae762"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <br/>
                        <paragraph>Clinical studies of atazanavir did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Based on a comparison of mean single-dose pharmacokinetic values for C
 
  <sub>max</sub>and AUC, a dose adjustment based upon age is not recommended. In general, appropriate caution should be exercised in the administration and monitoring of atazanavir in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="30891c38-5d8d-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Age/Gender</title>
                     <text>
                        <br/>
                        <paragraph>A study of the pharmacokinetics of atazanavir was performed in young (n=29; 18 to 40 years) and elderly (n=30;
 
  <content styleCode="underline">&gt;</content>65 years) healthy participants.  There were no clinically significant pharmacokinetic differences observed due to age or gender.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="30891c38-5d8e-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Impaired Renal Function</title>
                     <text>
                        <br/>
                        <paragraph>Atazanavir is not recommended for use in treatment-experienced patients with HIV-1, who have end-stage renal disease managed with hemodialysis
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#Section_2.6">2.7</linkHtml>) and Clinical Pharmacology (
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.8">
                     <id root="30891c38-5d8f-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.8 Impaired Hepatic Function</title>
                     <text>
                        <br/>
                        <paragraph>Atazanavir is not recommended for use in patients with severe hepatic impairment. Atazanavir with ritonavir is not recommended in patients with any degree of hepatic impairment
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#Section_2.7">2.8</linkHtml>) and Clinical Pharmacology (
  
   <linkHtml href="#Section_12.3">12.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="30891c38-5d90-7df7-e063-6394a90ae762"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <effectiveTime value="20250206"/>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="30891c38-5d91-7df7-e063-6394a90ae762"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <br/>
                  <paragraph>Human experience of acute overdose with atazanavir is limited. Single doses up to 1200 mg (three times the 400 mg maximum recommended dose) have been taken by healthy participants without symptomatic untoward effects. A single self-administered overdose of 29.2 g of atazanavir in a patient with HIV-1 (73 times the 400-mg recommended dose) was associated with asymptomatic bifascicular block and PR interval prolongation. These events resolved spontaneously. At atazanavir doses resulting in high atazanavir exposures, jaundice due to indirect (unconjugated) hyperbilirubinemia (without associated liver function test changes) or PR interval prolongation may be observed
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>,
  
   <linkHtml href="#Section_5.8">5.8</linkHtml>) and Clinical Pharmacology (
  
   <linkHtml href="#Section_12.2">12.2</linkHtml>)].
 
  </content>
                     <br/>  Treatment of overdosage with atazanavir should consist of general supportive measures, including monitoring of vital signs and ECG, and observations of the patient’s clinical status. If indicated, elimination of unabsorbed atazanavir should be achieved by emesis or gastric lavage. Administration of activated charcoal may also be used to aid removal of unabsorbed drug. There is no specific antidote for overdose with atazanavir. Since atazanavir is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicine.

 </paragraph>
               </text>
               <effectiveTime value="20250206"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="30891c38-5d92-7df7-e063-6394a90ae762"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <br/>
                  <paragraph>The active ingredient in atazanavir capsules is atazanavir sulfate, which is an HIV-1 protease inhibitor.  
  <br/>  The  chemical  name  for  atazanavir  sulfate  is  ((3
 
  <content styleCode="italics">S</content>,8
 
  <content styleCode="italics">S</content>,9
 
  <content styleCode="italics">S</content>,12
 
  <content styleCode="italics">S</content>)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl] 2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester, sulfate. Its molecular formula is C
 
  <sub>38</sub>H
 
  <sub>52</sub>N
 
  <sub>6</sub>O
 
  <sub>7</sub>.H
 
  <sub>2</sub>SO
 
  <sub>4</sub>which corresponds to a molecular weight of 802.9 (sulphuric acid salt). The free base molecular weight is 704.9. Atazanavir sulfate has the following structural formula:

 </paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>  
  <br/>  Atazanavir sulfate is an off white to pale yellow coloured crystalline powder. It is slightly soluble in water at acidic pH, freely soluble in methanol, soluble in dimethylformamide and dimethylsulfoxide.  
  <br/>  Atazanavir capsules are available for oral administration in strengths of 150 mg, 200 mg, or 300 mg of atazanavir, which are equivalent to 170.854 mg, 227.805 mg, or 341.708 mg of atazanavir sulfate, respectively. The capsules also contain the following inactive ingredients: crospovidone, lactose monohydrate, and magnesium stearate. The capsule shells contain the following inactive ingredients: gelatin, FD&amp;C Blue 1, iron oxide yellow, titanium dioxide, In addition 150 mg capsule shell contains iron oxide black, 200 mg and 300 mg contains FD&amp;C Yellow 6, 300 mg also contains FD&amp;C Red 3. The capsules are printed with black ink containing iron oxide black, potassium hydroxide, propylene glycol, shellac, strong ammonia solution.
 </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>atazanavircapsulestructure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="atazanavircapsulestructure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="30891c38-5d93-7df7-e063-6394a90ae762"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250206"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="30891c38-5d94-7df7-e063-6394a90ae762"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <br/>
                        <paragraph>Atazanavir is an HIV-1 antiretroviral drug
 
  <content styleCode="italics">[see Microbiology (
  
   <linkHtml href="#Section_12.4">12.4</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="30891c38-5d95-7df7-e063-6394a90ae762"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <br/>
                        <paragraph>Cardiac Electrophysiology 
  <br/>  Concentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy participants receiving atazanavir. In placebo-controlled Study AI424-076, the mean (±SD) maximum change in PR interval from the predose value was 24 (±15) msec following oral dosing with 400 mg of atazanavir (n=65) compared to 13 (±11) msec following dosing with placebo (n=67). The PR interval prolongations in this study were asymptomatic. There is limited information on the potential for a pharmacodynamic interaction in humans between atazanavir and other drugs that prolong the PR interval of the electrocardiogram
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>)].
 
  </content>
                           <br/>  Electrocardiographic effects of atazanavir were determined in a clinical pharmacology study of 72 healthy participants. Oral doses of 400 mg (maximum recommended dosage) and 800 mg (twice the maximum recommended dosage) were compared with placebo; there was no concentration- dependent effect of atazanavir on the QTc interval (using Fridericia’s correction). In 1793 participants with HIV-1, receiving antiretroviral regimens, QTc prolongation was comparable in the atazanavir and comparator regimens. No atazanavir-treated healthy participant or participant with HIV-1 in clinical trials had a QTc interval &gt;500 msec
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="30891c38-5d96-7df7-e063-6394a90ae762"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>The pharmacokinetics of atazanavir were evaluated in adult participants who either were healthy, or with HIV, after administration of atazanavir 400 mg once daily and after administration of atazanavir 300 mg with ritonavir 100 mg once daily (see Table 17).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 17: Steady-State Pharmacokinetics of Atazanavir in Healthy Participants or Participants  with HIV-1 in the Fed State</content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle"> </td>
                                 <td colspan="3" align="center" styleCode="Rrule" valign="middle">
                                    <br/>   
    
     <content styleCode="bold">400 mg once daily</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">300 mg with ritonavir</content>
                                    <br/>
                                    <content styleCode="bold">100 mg once daily</content> 
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle"> </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold"> H</content>
                                    <content styleCode="bold">ealthy</content>
                                    <br/>
                                    <content styleCode="bold">Participants 
      <br/>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold"> Participants with 
      <br/>  HIV-1  
      <br/>
                                       <br/>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">Healthy 
      <br/>  Participants 
      <br/>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">Participants with 
      <br/>  HIV-1
     </content>
                                    <br/>
                                    <br/>   
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Parameter </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold"> (n=14)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold"> (n=13)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold"> (n=28) </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold"> (n=10)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>   C
    
     <sub>max</sub>(ng/mL) 
     <br/>  Geometric mean 
   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  5199 (26) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>   2298 (71) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  6129 (31)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>  4422 (58)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>    (CV%)  
     <br/>  Mean (SD) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>  5358 (1371) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>  3152 (2231)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  6450 (2031) 
     <br/>   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>  5233 (3033)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>   T
    
     <sub>max </sub>(h) 
     <br/>  Median
   
    </td>
                                 <td align="left" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  2.5  
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>   2.0
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  2.7 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>   3.0
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>   AUC (ng•h/mL) 
     <br/>  Geometric mean
    </td>
                                 <td align="left" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  28132 (28)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  14874 (91)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  57039 (37)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  46073 (66)
    </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>   (CV%)  
     <br/>  Mean (SD) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  29303 (8263)  
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  22262 (20159) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  61435 (22911)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  53761 (35294)
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>  T-half (h)              
     <br/>  Mean (SD) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>                                   
     <br/>  7.9 (2.9)    
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>                           
     <br/>  6.5 (2.6)   
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>                           
     <br/>  18.1 (6.2)
    
     <sup>a </sup>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>                                  
     <br/>      8.6 (2.3)             
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>   C
    
     <sub>min</sub>(ng/mL) 
     <br/>  Geometric mean
   
    </td>
                                 <td align="left" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  159 (88)  
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  120 (109) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  1227 (53)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  636 (97)
    </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <br/>   (CV%)  
     <br/>  Mean (SD)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  218 (191) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  273 (298)
    
     <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  1441 (757)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>    
     <br/>  862 (838)
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a </sup>n=26. 
  <br/>
                           <sup>b </sup>n=12. 
  <br/>  Figure 1 displays the mean plasma concentrations of atazanavir at steady state after atazanavir 400 mg once daily (as two 200 mg capsules) with a light meal and after atazanavir 300 mg (as two 150 mg capsules) with ritonavir 100 mg once daily with a light meal in adult participants with HIV-1.  
  <br/>
                           <content styleCode="bold">Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for Adult Participants with HIV-1</content> 

 </paragraph>
                        <br/>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph>  
  <br/>  Absorption 
  <br/>  Atazanavir is rapidly absorbed with a T
 
  <sub>max</sub>of approximately 2.5 hours. Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and C
 
  <sub>max</sub>values over the dose range of 200 to 800 mg once daily. Steady state is achieved between Days 4 and 8, with an accumulation of approximately 2.3 fold. 
  <br/>  Food Effect 
  <br/>  Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Administration of a single 400 mg dose of atazanavir with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in C
 
  <sub>max</sub>relative to the fasting state. Administration of a single 400 mg dose of atazanavir with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in C
 
  <sub>max</sub>relative to the fasting state. Administration of atazanavir with either a light meal or high-fat meal decreased the coefficient of variation of AUC and C
 
  <sub>max</sub>by approximately one-half compared to the fasting state. 
  <br/>  Coadministration of a single 300 mg dose of atazanavir and a 100 mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the C
 
  <sub>max</sub>and the 24-hour concentration of atazanavir relative to the fasting state. Coadministration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the C
 
  <sub>max</sub>was within 11% of fasting values. The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median T
 
  <sub>max</sub>increased from 2.0 to 5.0 hours. Coadministration of atazanavir with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and C
 
  <sub>max</sub>by approximately 25% compared to the fasting state. 
  <br/>  Distribution 
  <br/>  Atazanavir is 86% bound to human serum proteins and protein binding is independent of concentration. Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively). In a multiple-dose study in participants with HIV-1 dosed with atazanavir 400 mg once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen. The cerebrospinal fluid/plasma ratio for atazanavir (n=4) ranged between 0.0021 and 0.0226 and seminal fluid/plasma ratio (n=5) ranged between 0.11 and 4.42. 
  <br/>  Metabolism 
  <br/>  Atazanavir is extensively metabolized in humans. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. Two minor metabolites of atazanavir in plasma have been characterized. Neither metabolite demonstrated
 
  <content styleCode="italics">in vitro</content>antiviral activity.
 
  <content styleCode="italics">In vitro</content>studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A. 
  <br/>  Elimination 
  <br/>  Following a single 400 mg dose of
 
  <sup>14</sup>C-atazanavir, 79% and 13% of the total radioactivity was recovered in the feces and urine, respectively. Unchanged drug accounted for approximately 20% and 7% of the administered dose in the feces and urine, respectively. The mean elimination half-life of atazanavir in healthy participants (n=214) and adult participants with HIV-1 (n=13) was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal. 
  <br/>  Specific Populations
 
  <content styleCode="italics">
                              <br/>  Renal Impairment
  </content>
                           <br/>  In healthy participants, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose. Atazanavir has been studied in adult participants with severe renal impairment (n=20), including those on hemodialysis, at multiple doses of 400 mg once daily. The mean atazanavir C
 
  <sub>max</sub>was 9% lower, AUC was 19% higher, and C
 
  <sub>min</sub>was 96% higher in participants with severe renal impairment not undergoing hemodialysis (n=10), than in age-, weight-, and gender-matched participants with normal renal function. In a 4-hour dialysis session, 2.1% of the administered dose was removed. When atazanavir was administered either prior to, or following hemodialysis (n=10), the geometric means for C
 
  <sub>max</sub>, AUC, and C
 
  <sub>min</sub>were approximately 25% to 43% lower compared to participants with normal renal function. The mechanism of this decrease is unknown. Atazanavir is not recommended for use in treatment-experienced patients with HIV-1 who have end-stage renal disease managed with hemodialysis [
 
  <content styleCode="italics">see Dosage and Administration (2.7)].</content>
                           <br/>
                           <content styleCode="italics">Hepatic Impairment</content>
                           <br/>  Atazanavir has been studied in adult participants with moderate-to-severe hepatic impairment (14 with Child-Pugh B and 2 with Child-Pugh C participants) after a single 400 mg dose. The mean AUC(0 to ∞ ) was 42% greater in participants with impaired hepatic function than in healthy participants. The mean half-life of atazanavir in hepatically impaired participants was 12.1 hours compared to 6.4 hours in healthy participants. A dose reduction to 300 mg is recommended for patients with moderate hepatic impairment (Child-Pugh Class B) who have not experienced prior virologic failure as increased concentrations of atazanavir are expected. Atazanavir is not recommended for use in patients with severe hepatic impairment. The pharmacokinetics of atazanavir in combination with ritonavir has not been studied in participants with hepatic impairment; thus, coadministration of atazanavir with ritonavir is not recommended for use in patients with any degree of hepatic impairment
 
  <content styleCode="italics">[see Dosage and Administration (2.8)].</content>
                           <br/>
                           <content styleCode="italics">Pediatrics </content>
                           <br/>  The pharmacokinetic parameters for atazanavir at steady state in pediatric participants taking the capsule formulation were predicted by a population pharmacokinetic model and are summarized in Table 19 by weight ranges that correspond to the recommended doses
 
  <content styleCode="italics">[see Dosage and Administration (2.4)]. </content>
                           <content styleCode="bold">
                              <br/>  Table 19: Predicted Steady-State Pharmacokinetics of Atazanavir (capsule formulation) with Ritonavir in Pediatric Participants with HIV-1
  </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">Body Weight</content>
                                    <br/>
                                    <content styleCode="bold">(range in kg) </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">Atazanavir with </content>
                                    <br/>
                                    <content styleCode="bold">ritonavir</content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">Dose (mg)</content>
                                    <br/>     
     <br/>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">C
     
      <sub>max</sub>ng/mL
    
     </content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">Geometric 
      <br/>  Mean (CV%)
     </content>
                                    <br/>     
     <br/>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">AUC ng•h/mL</content>
                                    <br/>
                                    <content styleCode="bold">Geometric</content>
                                    <br/>
                                    <content styleCode="bold">Mean (CV%)</content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>
                                    <content styleCode="bold">C
     
      <sub>min</sub>ng/mL
    
     </content>
                                    <br/>
                                    <content styleCode="bold"> Geometric  
      <br/>  Mean (CV%)
     </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">
                                    <br/>  15 to &lt;35
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>   200/100
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>   3303 (86%)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>   37235 (84%)
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>   538 (99%)
    </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">
                                    <br/>    ≥35 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>  300/100 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>   2980 (82%) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>   37643 (83%) 
    </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <br/>   653 (89%)
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Pregnancy</content>
                           <br/>  The pharmacokinetic data from pregnant women with HIV-1 receiving atazanavir capsules with ritonavir are presented in Table 20.

 </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="625">
                           <col width="23.8664248372986%"/>
                           <col width="23.8664248372986%"/>
                           <col width="23.8664248372986%"/>
                           <col width="28.4007254881041%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="4" align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Table 20: Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Pregnant Women with HIV-1 in the Fed State</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="4" align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir 300 mg with ritonavir 100 mg</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Pharmacokinetic Parameter</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">2nd Trimester</content>
                                    <br/>
                                    <content styleCode="bold">(n=5
     
      <sup>a</sup>)
    
     </content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">3rd Trimester</content>
                                    <br/>
                                    <content styleCode="bold">(n=20)</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Postpartum
     
      <sup>b</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(n=34)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">C
    
     <sub>max</sub>ng/mL 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3078.85 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3291.46 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5721.21 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Geometric mean (CV%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(50) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(48) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(31) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">AUC ng•h/mL 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">27657.1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">34251.5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">61990.4 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Geometric mean (CV%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(43) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(43) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(32) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">C
    
     <sub>min</sub>ng/mL
    
     <sup>c</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">538.70 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">668.48 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1462.59 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Geometric mean (CV%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(46) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(50) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(45) 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup> a</sup>  Available data during the 2nd trimester are limited. 
  <br/>
                           <sup>b  </sup>Atazanavir peak concentrations and AUCs were found to be approximately 28% to 43% higher during the postpartum period (4 to 12 weeks) than       those observed historically in, non-pregnant patients with HIV-1. Atazanavir plasma trough concentrations were approximately 2.2-fold higher during the postpartum period when compared to those observed historically in non-pregnant patients with HIV-1. 
  <br/>
                           <sup>c  </sup>C
 
  <sub>min</sub>is concentration 24 hours post-dose. 
  <br/>  Drug Interaction Data 
  <br/>  Atazanavir is a metabolism-dependent CYP3A inhibitor, with a K
 
  <sub>inact</sub>value of 0.05 to 0.06 min
 
  <sup>-1</sup>and K
 
  <sub>i</sub>value of 0.84 to 1.0 µM. Atazanavir is also a direct inhibitor for UGT1A1 (K
 
  <sub>i</sub>=1.9 µM) and CYP2C8 (K
 
  <sub>i</sub>=2.1 µM). 
  <br/>  Atazanavir has been shown
 
  <content styleCode="italics">in vivo</content>not to induce its own metabolism nor to increase the biotransformation of some drugs metabolized by CYP3A. In a multiple-dose study, atazanavir decreased the urinary ratio of endogenous 6β-OH cortisol to cortisol versus baseline, indicating that CYP3A production was not induced. 
  <br/>  Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8. See the complete prescribing information for ritonavir for information on other potential drug interactions with ritonavir. 
  <br/>  Based on known metabolic profiles, clinically significant drug interactions are not expected between atazanavir and dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. Atazanavir does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). 
  <br/>  Drug interaction studies were performed with atazanavir and other drugs likely to be coadministered and some drugs commonly used as probes for pharmacokinetic interactions. The effects of coadministration of atazanavir on the AUC, C
 
  <sub>max</sub>, and C
 
  <sub>min</sub>are summarized in Tables 21 and 22. Neither didanosine EC nor diltiazem had a significant effect on atazanavir exposures (see Table 22 for effect of atazanavir on didanosine EC or diltiazem exposures). Atazanavir did not have a significant effect on the exposures of didanosine (when administered as the buffered tablet), stavudine, or fluconazole. For information regarding clinical recommendations, see
 
  <content styleCode="italics">Drug Interactions (
  
   <linkHtml href="#Section_7">7</linkHtml>)
 
  </content>. 
  <br/>
                           <content styleCode="bold">Table 21: Drug Interactions: Pharmacokinetic Parameters for Atazanavir in the Presence of Coadministered Drugs
  
   <sup>a</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="631">
                           <col width="0.211037248074285%"/>
                           <col width="18.1175477471774%"/>
                           <col width="18.0436847103514%"/>
                           <col width="21.8423551756885%"/>
                           <col width="14.2450142450142%"/>
                           <col width="13.29534662868%"/>
                           <col width="14.2450142450142%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td rowspan="2" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">oadministered Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">oadministered Drug</content>
                                    <br/>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">ose/Schedule</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir</content>
                                    <br/>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">ose/Schedule</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">R</content>
                                    <content styleCode="bold">atio (90% Confidence Interval) of Atazanavir Pharmacokinetic Parameters with/without</content>
                                    <br/>
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">oadministered Drug; No Effect = 1.00</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">
                                       <sub>m</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>a</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>x</sub>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">AUC</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">
                                       <sub>m</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>in</sub>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">  
     <br/>  atenolol 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  50 mg QD, 
     <br/>  d 7–11 
     <br/>  (n=19) and 
     <br/>  d 19–23 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  400 mg QD, d 1–11 (n=19) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  1.00 
     <br/>  (0.89, 1.12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  0.93 
     <br/>  (0.85, 1.01) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  0.74 
     <br/>  (0.65, 0.86) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">clarithromycin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">500 mg BID, 
     <br/>  d 7–10 
     <br/>  (n=29) and 
     <br/>  d 18–21 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, 
     <br/>  d 1–10 
     <br/>  (n=29) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.06 
     <br/>  (0.93, 1.20) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.28 
     <br/>  (1.16, 1.43) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.91 
     <br/>  (1.66, 2.21) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td rowspan="2" styleCode="Rrule" valign="top">didanosine (ddI) 
     <br/>  (buffered tablets) and stavudine (d4T)
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">ddI: 200 mg x  
     <br/>  1 dose, 
     <br/>  d4T: 40 mg x  
     <br/>  1 dose (n=31) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg x  
     <br/>  1 dose simultaneously with 
     <br/>  ddI and d4T (n=31) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.11 
     <br/>  (0.06, 0.18) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.13 
     <br/>  (0.08, 0.21) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.16 
     <br/>  (0.10, 0.27) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">ddI: 200 mg x  
     <br/>  1 dose, 
     <br/>  d4T: 40 mg x 
     <br/>  1 dose (n=32) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg x 1 dose 1 h after ddI + d4T 
     <br/>  (n=32) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.12 
     <br/>  (0.67, 1.18) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.03 
     <br/>  (0.64, 1.67) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.03 
     <br/>  (0.61, 1.73) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td rowspan="2" styleCode="Rrule" valign="top">efavirenz 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">600 mg QD,  
     <br/>  d 7–20 (n=27) 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">400 mg QD, d 1–20 (n=27) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>  0.41 
     <br/>  (0.33, 0.51)
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.26 
     <br/>  (0.22, 0.32) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.07 
     <br/>  (0.05, 0.10) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">600 mg QD,  
     <br/>  d 7–20 
     <br/>  (n=13) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–6 (n=23) 
     <br/>  then 300 mg with ritonavir 
     <br/>  100 mg QD, 2 h before efavirenz,  
     <br/>  d 7–20 (n=13) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>  1.14 
     <br/>  (0.83, 1.58)
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.39 
     <br/>  (1.02, 1.88) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.48 
     <br/>  (1.24, 1.76) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">600 mg QD, 
     <br/>  d 11–24 (pm) 
     <br/>  (n=14) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD 
     <br/>  with ritonavir 
     <br/>  100 mg QD, 
     <br/>  d 1–10 (pm) 
     <br/>  (n=22), then 
     <br/>  400 mg QD with 
     <br/>  ritonavir 100 mg QD, 
     <br/>  d 11–24 (pm), 
     <br/>  (simultaneously with 
     <br/>  efavirenz) 
     <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>  1.1 7 
     <br/>  (1.08, 1.27)
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.00 
     <br/>  (0.91, 1.10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.58 
     <br/>  (0.49, 0.69) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" rowspan="7" styleCode="Lrule Rrule" valign="top">famotidine 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">40 mg BID, d 7–12 
     <br/>  (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–6 (n=45), 
     <br/>  d 7–12 (simultaneous 
     <br/>  administration) 
     <br/>  (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.53 
     <br/>  (0.34, 0.82) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.59 
     <br/>  (0.40, 0.87) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.58 
     <br/>  (0.37, 0.89) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">40 mg BID, 
     <br/>  d 7–12 
     <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD (pm), 
     <br/>  d 1–6 
     <br/>  (n=14), d 7–12 
     <br/>  (10 h after, 
     <br/>  2 h before famotidine) 
     <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.08 
     <br/>  (0.82, 1.41) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.95 
     <br/>  (0.74, 1.21) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.79 
     <br/>  (0.60, 1.04) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">40 mg BID, 
     <br/>  d 11–20 
     <br/>  (n=14)c 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 1–10 (n=46), 
     <br/>  d 11–20d (simultaneous 
     <br/>  administration) 
     <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.86 
     <br/>  (0.79, 0.94) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.82 
     <br/>  (0.75, 0.89) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.72 
     <br/>  (0.64, 0.81) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">20 mg BID, 
     <br/>  d 11–17 
     <br/>  (n=18) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD and tenofovir DF 300 mg QD, 
     <br/>  d 1–10 (am) 
     <br/>  (n=39), d 11–17 (am) 
     <br/>  (simultaneous 
     <br/>  administration with am famotidine) (n=18)
    
     <sup>d</sup>
                                    <sup>,e</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.91 
     <br/>  (0.84, 0.99) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.90 
     <br/>  (0.82, 0.98) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.81 
     <br/>  (0.69, 0.94) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">40 mg QD (pm), 
     <br/>  d 18–24 
     <br/>  (n=20) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD and tenofovir DF 300 mg QD, 
     <br/>  d 1–10 (am) 
     <br/>  (n=39), d 18–24 (am) (12 h after pm famotidine) 
     <br/>  (n=20)
    
     <sup>e</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.89 
     <br/>  (0.81, 0.97) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.88 
     <br/>  (0.80, 0.96) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.77 
     <br/>  (0.63, 0.93) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">40 mg BID,  
     <br/>  d 18–24 
     <br/>  (n=18) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD and tenofovir DF 300 mg QD, 
     <br/>  d 1–10 (am) 
     <br/>  (n=39), d 18–24 (am) (10 h after pm famotidine and 2 h 
     <br/>  before am famotidine) 
     <br/>  (n=18)
    
     <sup>e</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.74 
     <br/>  (0.66, 0.84) 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">0.79 
     <br/>  (0.70, 0.88) 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">0.72 
     <br/>  (0.63, 0.83) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">40 mg BID, 
     <br/>  d 11–20 
     <br/>  (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD and d 1–10 (am) (n=46), then 
     <br/>  400 mg 
     <br/>  QD with ritonavir 100 mg QD, d 11–20 (am) (n=15) 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1.02 
     <br/>  (0.87, 1.18) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.03 
     <br/>  (0.86, 1.22) 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">0.86 
     <br/>  (0.68, 1.08) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" rowspan="2" styleCode="Lrule Rrule" valign="top">grazoprevir/ elbasvir 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>  grazoprevir  
     <br/>  200 mg QD 
     <br/>  d 1 - 35 
     <br/>  (n = 11)
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir  
     <br/>  100 mg QD, d 1- 35 
     <br/>  (n = 11) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.12 
     <br/>  (1.01, 1.24) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.43 
     <br/>  (1.30, 1.57) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.23 
     <br/>  (1.13, 1.34) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">elbasvir 50 mg QD 
     <br/>  d 1 - 35 
     <br/>  (n = 8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 1 - 35 
     <br/>  (n = 8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.02 
     <br/>  (0.96, 1.08) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.07 
     <br/>  (0.98, 1.17) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.15 
     <br/>  (1.02, 1.29) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule" valign="top">ketoconazole 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 mg QD,  
     <br/>  d 7–13 
     <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–13 
     <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.99 
     <br/>  (0.77, 1.28) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.10 
     <br/>  (0.89, 1.37) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.03 
     <br/>  (0.53, 2.01) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule" valign="top">nevirapine
    
     <sub>f,g</sub>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 mg BID, 
     <br/>  d 1–23 (n=23) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 4–13, then 
     <br/>  400 mg QD with ritonavir 
     <br/>  100 mg QD, d 14–23 (n=23)h 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.72 
     <br/>  (0.60, 0.86) 
     <br/>    
     <br/>  1.02 
     <br/>  (0.85, 1.24) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.58 
     <br/>  (0.48, 0.71) 
     <br/>    
     <br/>  0.81 
     <br/>  (0.65, 1.02) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.28 
     <br/>  (0.20, 0.40) 
     <br/>    
     <br/>  0.41 
     <br/>  (0.27, 0.60) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" rowspan="4" styleCode="Lrule Rrule" valign="top">omeprazole 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">40 mg QD, d 7–12 
     <br/>  (n=16)
    
     <sub>i</sub>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–6 (n=48), 
     <br/>  d 7–12 (n=16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.04 
     <br/>  (0.04, 0.05) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.06 
     <br/>  (0.05, 0.07) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.05 
     <br/>  (0.03, 0.07) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">40 mg QD, d 11–20 
     <br/>  (n=15)
    
     <sub>i</sub>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 1–20 (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.28 
     <br/>  (0.24, 0.32) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.24 
     <br/>  (0.21, 0.27) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.22 
     <br/>  (0.19, 0.26) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">20 mg QD, d 17–23 
     <br/>  (am) 
     <br/>  (n=13) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 7–16 (pm) (n=27), d 17–23 (pm) 
     <br/>  (n=13)
    
     <sub>j,k</sub>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.61 
     <br/>  (0.46, 0.81) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.58 
     <br/>  (0.44, 0.75) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.54 
     <br/>  (0.41, 0.71) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">20 mg QD, d 17–23 
     <br/>  (am) (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 7–16 (am) 
     <br/>  (n=27), then 400 mg QD with ritonavir 100 mg QD, d 17–23 (am) (n=14)
    
     <sub>l,m</sub>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.69 
     <br/>  (0.58, 0.83) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.70 
     <br/>  (0.57, 0.86) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.69 
     <br/>  (0.54, 0.88) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule" valign="top">pitavastatin 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">4 mg QD 
     <br/>  for 5 days 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD 
     <br/>  for 5 days 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.13 
     <br/>  (0.96, 1.32) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.06 
     <br/>  (0.90, 1.26) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule" valign="top">rifabutin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">150 mg QD,  
     <br/>  d 15–28 
     <br/>  (n=7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD,  
     <br/>  d 1–28 
     <br/>  (n=7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.34 
     <br/>  (1.14, 1.59) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.15 
     <br/>  (0.98, 1.34) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.13 
     <br/>  (0.68, 1.87) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule" valign="top">rifampin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">600 mg QD,  
     <br/>  d 17–26 
     <br/>  (n=16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 7–16 (n=48), 
     <br/>  d 17–26 (n=16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.47 
     <br/>  (0.41, 0.53) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.28 
     <br/>  (0.25, 0.32) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.02 
     <br/>  (0.02, 0.03) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule" valign="top">ritonavirn 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 mg QD,  
     <br/>  d 11–20 
     <br/>  (n=28) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD,  
     <br/>  d 1–20 
     <br/>  (n=28) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.86 
     <br/>  (1.69, 2.05) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3.38 
     <br/>  (3.13, 3.63) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">11.89 
     <br/>  (10.23, 13.82) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" rowspan="2" styleCode="Lrule Rrule" valign="top">tenofovir DF
    
     <sup>o</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD,  
     <br/>  d 9–16 
     <br/>  (n=34) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD,  
     <br/>  d 2–16 
     <br/>  (n=34) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.79 
     <br/>  (0.73, 0.86) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.75 
     <br/>  (0.70, 0.81) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.60 
     <br/>  (0.52, 0.68) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">300 mg QD,  
     <br/>  d 15–42 
     <br/>  (n=10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg with ritonavir 100 mg 
     <br/>  QD,  
     <br/>  d 1–42 (n=10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.72p (0.50, 1.05) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.75p (0.58, 0.97) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.77p (0.54, 1.10) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">
                                    <br/>  voriconazole 
     <br/>  (Participants with at 
     <br/>  least one 
     <br/>  functional 
     <br/>  CYP2C19 allele)
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 mg BID, 
     <br/>  d 2–3, 22–30; 
     <br/>  400 mg BID, 
     <br/>  d 1, 21 
     <br/>  (n=20) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg with ritonavir 
     <br/>  100 mg QD, d 11–30 
     <br/>  (n=20) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.87 
     <br/>  (0.80, 0.96) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.88 
     <br/>  (0.82, 0.95) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.80 
     <br/>  (0.72, 0.90) 
     <br/>    
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                    <br/>  voriconazole 
     <br/>  (Participants without 
     <br/>  a functional 
     <br/>  CYP2C19 allele)
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  50 mg BID, 
     <br/>  d 2–3, 22–30; 
     <br/>  100 mg BID, d  
     <br/>  1, 21 
     <br/>  (n=8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  300 mg with ritonavir 
     <br/>  100 mg 
     <br/>  QD, d 11–30 
     <br/>  (n=8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  0.81 
     <br/>  (0.66, 1.00) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  0.80 
     <br/>  (0.65, 0.97) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  0.69 
     <br/>  (0.54, 0.87) 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup> a</sup> Data provided are under fed conditions unless otherwise noted. 
  <br/>
                           <sup>b </sup>All drugs were given under fasted conditions. 
  <br/>
                           <sup>c  </sup>Atazanavir 300 mg with ritonavir 100 mg once daily coadministered with famotidine 40 mg twice daily resulted in atazanavir geometric mean               C
 
  <sub>max</sub>that was similar and AUC and C
 
  <sub>min</sub>values that were 1.79- ­and 4.46-fold higher relative to atazanavir 400 mg once daily alone. 
  <br/>
                           <sup>d  </sup>Similar results were noted when famotidine 20 mg BID was administered 2 hours after and 10 hours before atazanavir 300 mg and ritonavir               100 mg and tenofovir DF 300 mg. 
  <br/>
                           <sup>e  </sup>Coadministration of atazanavir with ritonavir and tenofovir DF was administered after a light meal. 
  <br/>  f  Study was conducted in participants with HIV-1. 
  <br/>
                           <sup>g  </sup>Compared with atazanavir 400 mg historical data without nevirapine (n=13), the ratio of geometric means (90% confidence intervals)  for                     C
 
  <sub>max</sub>, AUC, and C
 
  <sub>min</sub> were 1.42  (0.98, 2.05), 1.64 (1.11, 2.42), and  1.25 (0.66, 2.36), respectively, for atazanavir with ritonavir 300/100 mg;               and 2.02 (1.42, 2.87), 2.28 (1.54, 3.38), and 1.80 (0.94, 3.45), respectively, for atazanavir with ritonavir 400/100 mg. 
  <br/>
                           <sup>h  </sup>Parallel group design; n=23 for atazanavir with ritonavir and nevirapine, n=22 for atazanavir 300 mg/ritonavir 100 mg without nevirapine.                     Participants were treated with nevirapine prior to study entry. 
  <br/>
                           <sup>i  </sup>Omeprazole 40 mg was administered on an empty stomach 2 hours before atazanavir. 
  <br/>
                           <sup>j  </sup>Omeprazole 20 mg was administered 30 minutes prior to a light meal in the morning and atazanavir 300 mg with ritonavir 100 mg in the                       evening after a light meal, separated by 12 hours from omeprazole. 
  <br/>
                           <sup>k  </sup>Atazanavir 300 mg with ritonavir 100 mg once daily separated by 12 hours from omeprazole 20 mg daily resulted in increases in atazanavir                 geometric mean AUC (10%) and C
 
  <sub>min</sub>(2.4-fold), with a decrease in C
 
  <sub>max</sub>(29%) relative to atazanavir 400 mg once daily in the absence of                   omeprazole (study days 1 to 6). 
  <br/>
                           <sup>l  </sup>Omeprazole 20 mg was given 30 minutes prior to a light meal in the morning and atazanavir 400 mg with ritonavir 100 mg once daily after a                 light meal, 1 hour after omeprazole. Effects on atazanavir concentrations were similar when atazanavir 400 mg with ritonavir 100 mg was                   separated from omeprazole 20 mg by 12 hours. 
  <br/>
                           <sup>m  </sup>Atazanavir 400 mg with ritonavir 100 mg once daily administered with omeprazole 20 mg once daily resulted in increases in atazanavir geometric     mean AUC (32%) and C
 
  <sub>min</sub>(3.3-fold), with a decrease in C
 
  <sub>max</sub>(26%) relative to atazanavir 400 mg once daily in the absence of omeprazole                (study days 1–6). 
  <br/>
                           <sup>n  </sup>Compared with atazanavir 400 mg QD historical data, administration of atazanavir with ritonavir 300/100 mg QD increased the atazanavir                    geometric mean values of C
 
  <sub>max</sub>, AUC, and C
 
  <sub>min</sub>by 18%, 103%, and 671%, respectively. 
  <br/>
                           <sup>o  </sup>Note that similar results were observed in studies where administration of tenofovir DF and atazanavir was   separated by 12 hours. 
  <br/>
                           <sup>p  </sup>Ratio of atazanavir with ritonavir with tenofovir DF to atazanavir with ritonavir. Atazanavir 300 mg with ritonavir 100 mg results in higher atazanavir     exposure than atazanavir 400 mg (see footnote
 
  <sup>o</sup>). The geometric mean values of atazanavir pharmacokinetic parameters when coadministered         with ritonavir and tenofovir DF were: C
 
  <sub>max</sub>= 3190 ng/mL, AUC = 34459 ng•h/mL, and Cmin = 491 ng/mL. Study was conducted in participants with       HIV-1. 
  <br/>   NA = not available. 
  <br/>
                           <br/>
                           <content styleCode="bold">Table 22: Drug Interactions: Pharmacokinetic Parameters for Coadministered Drugs in the Presence of Atazanavir
  
   <sup>a</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="633">
                           <col width="16.3334034940013%"/>
                           <col width="17.9962113239318%"/>
                           <col width="19.8905493580299%"/>
                           <col width="14.2075352557356%"/>
                           <col width="16.6596505998737%"/>
                           <col width="14.9126499684277%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">oadministered Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">oadministered Drug Dose/Schedule</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir</content>
                                    <br/>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">ose/Schedule</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">R</content>
                                    <content styleCode="bold">atio (90% Confidence Interval) of </content>
                                    <br/>
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">o</content>
                                    <content styleCode="bold">administered Drug Pharmacokinetic Parameters with/without atazanavir;</content>
                                    <br/>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">o Effect = 1.00</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">m</content>
                                    <content styleCode="bold">a</content>
                                    <content styleCode="bold">x</content>
                                    <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">AUC</content>
                                    <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">m</content>
                                    <content styleCode="bold">in</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>  acetaminophen 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">  
     <br/>  1 g BID, d 1–20 
     <br/>  (n=10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, d 11–20 
     <br/>  (n=10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  0.87 
     <br/>  (0.77, 0.99) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  0.97 
     <br/>  (0.91, 1.03) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  1.26 
     <br/>  (1.08, 1.46) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">atenolol 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">50 mg QD, d 7–11 
     <br/>  (n=19) and d 19–23 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–11 
     <br/>  (n=19) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.34 
     <br/>  (1.26, 1.42) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.25 
     <br/>  (1.16, 1.34) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.02 
     <br/>  (0.88, 1.19) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">clarithromycin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">500 mg BID, 
     <br/>  d 7–10 (n=21) and 
     <br/>  d 18–21 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–10 
     <br/>  (n=21) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.50 
     <br/>  (1.32, 1.71) 
     <br/>  OH- 
     <br/>  clarithromycin: 
     <br/>  0.28 
     <br/>  (0.24, 0.33) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.94 
     <br/>  (1.75, 2.16) 
     <br/>  OH-clarithromycin: 
     <br/>  0.30 
     <br/>  (0.26, 0.34) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2.60 (2.35, 2.88) OH-clarithromycin: 0.38 (0.34, 0.42) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" align="center" styleCode="Lrule Rrule" valign="top">ddI (entericcoated [EC] capsules)
    
     <sup>b</sup>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg d 1 (fasted), d 8 (fed) (n=34) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, 
     <br/>  d 2–8 (n=34) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.64 
     <br/>  (0.55, 0.74) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.66 
     <br/>  (0.60, 0.74) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.13 
     <br/>  (0.91, 1.41) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">400 mg d 1 (fasted), d 19 (fed) (n=31) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 100 mg QD, d 9–19 (n=31) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.62 
     <br/>  (0.52, 0.74) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.66 
     <br/>  (0.59, 0.73) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.25 
     <br/>  (0.92, 1.69) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">diltiazem 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">180 mg QD, d 7–11 (n=28) and d 19–23 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–11 (n=28) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.98 (1.78, 2.19) desacetyl-diltiazem: 2.72 (2.44, 3.03) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2.25 (2.09, 2.16) desacetyl-diltiazem: 2.65 (2.45, 2.87) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2.42 (2.14, 2.73) desacetyl-diltiazem: 2.21 (2.02, 2.42) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">ethinyl estradiol 
     <br/>  &amp; norethindronec 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">Ortho-Novum
    
     <sup>®</sup>
                                    <br/>  7/7/7 QD, 
     <br/>  d 1–29 
     <br/>  (n=19) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, 
     <br/>  d 16–29 (n=19) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">ethinyl estradiol: 1.15 
     <br/>  (0.99, 1.32) 
     <br/>  norethindrone: 1.67 
     <br/>  (1.42, 1.96) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">ethinyl estradiol: 1.48 
     <br/>  (1.31, 1.68) 
     <br/>  norethindrone: 2.10 
     <br/>  (1.68, 2.62) 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">ethinyl estradiol: 1.91 (1.57, 2.33) norethindrone: 3.62 (2.57, 5.09) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">ethinyl estradiol 
     <br/>  &amp; norgestimate
    
     <sub>d</sub>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">Ortho 
     <br/>  Tri-Cyclen
    
     <sup>®</sup>
                                    <br/>  QD, d 1–28 (n=18), 
     <br/>  then 
     <br/>  Ortho Tri­ 
     <br/>  Cyclen
    
     <sup>®</sup>
                                    <br/>  LO QD, 
     <br/>  d 29–42
    
     <sup>e</sup>
                                    <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD, 
     <br/>  d 29–42 
     <br/>  (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">ethinyl estradiol: 
     <br/>  0.84 
     <br/>  (0.74, 0.95) 
     <br/>  17-deacetyl norgestimate:
    
     <sub>f</sub>
                                    <br/>  1.68 
     <br/>  (1.51, 1.88) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">ethinyl estradiol: 
     <br/>  0.81 
     <br/>  (0.75, 0.87) 
     <br/>  17-deacetyl norgestimate:
    
     <sub>f</sub>
                                    <br/>  1.85 
     <br/>  (1.67, 2.05) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">ethinyl estradiol: 0.63 (0.55, 0.71) 17-deacetyl norgestimate
    
     <sup>:f</sup>2.02 (1.77, 2.31) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">glecaprevir/ 
     <br/>  pibrentasvir 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg glecaprevir 
     <br/>  (n=12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD (n=12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">≥4.06g(3.15, 5.23) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">≥6.53g(5.24, 8.14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">≥14.3
    
     <sup>g</sup>(9.85, 20.7) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">120 mg pibrentasvir 
     <br/>  (n=12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD (n=12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">≥1.29g (1.15, 1.45) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">≥1.64g (1.48, 1.82) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">≥2.29
    
     <sup>g</sup>(1.95, 2.68) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" align="justify" styleCode="Lrule Rrule" valign="top">grazoprevir/ 
     <br/>  elbasvir 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">grazoprevir 200 mg 
     <br/>  QD 
     <br/>  d 1 - 35 (n=12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD 
     <br/>  d 1 - 35 (n=12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">6.24 
     <br/>  (4.42, 8.81) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10.58 
     <br/>  (7.78, 14.39) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">11.64 (7.96, 17.02) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">elbasvir 50 mg QD 
     <br/>  d 1 - 35 (n=10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with ritonavir 
     <br/>  100 mg QD 
     <br/>  d 1 - 35 (n=10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4.15 
     <br/>  (3.46, 4.97) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4.76 
     <br/>  (4.07, 5.56) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">6.45 (5.51, 7.54) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">methadone 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">Stable maintenance 
     <br/>  dose, d 1–15 (n=16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 2–15 
     <br/>  (n=16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(R)-methadone
    
     <sub>h</sub>
                                    <br/>  0.91 
     <br/>  (0.84, 1.0) 
     <br/>  total: 0.85 
     <br/>  (0.78, 0.93) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(R)-methadone
    
     <sub>h</sub>1.03 
     <br/>  (0.95, 1.10) 
     <br/>  total: 0.94 
     <br/>  (0.87, 1.02) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">(R)-methadone
    
     <sup>h</sup>1.11 (1.02, 1.20) total: 1.02 (0.93, 1.12) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">nevirapine
    
     <sub>i,j</sub>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 mg BID, 
     <br/>  d 1–23 (n=23) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with 
     <br/>  ritonavir 100 mg QD,  
     <br/>  d 4–13, then 
     <br/>  400 mg QDwith 
     <br/>  ritonavir 100 mg 
     <br/>  QD, d 14–23 (n=23) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.17 
     <br/>  (1.09, 1.25) 
     <br/>    
     <br/>  1.21 
     <br/>  (1.11, 1.32) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.25 
     <br/>  (1.17, 1.34) 
     <br/>    
     <br/>  1.26 
     <br/>  (1.17, 1.36) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.32 (1.22, 1.43) 1.35 (1.25, 1.47) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">omeprazole
    
     <sup>k</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">40 mg single dose, 
     <br/>  d 7 and d 20 (n=16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 1–12 
     <br/>  (n=16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.24 
     <br/>  (1.04, 1.47) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.45 
     <br/>  (1.20, 1.76) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" align="justify" styleCode="Lrule Rrule" valign="top">rifabutin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD, d 1–10 
     <br/>  then 150 mg QD, 
     <br/>  d 11–20 (n=3) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">600 mg QD,
    
     <sub>l</sub>
                                    <br/>  d 11–20 (n=3) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.18 
     <br/>  (0.94, 1.48) 
     <br/>  25-O-desacetyl­ rifabutin: 
     <br/>  8.20 
     <br/>  (5.90, 11.40) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2.10 
     <br/>  (1.57, 2.79) 
     <br/>  25-O-desacetyl­ rifabutin: 22.01 
     <br/>  (15.97, 30.34) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3.43 
     <br/>  (1.98, 5.96) 
     <br/>  25-O-desacetyl­ rifabutin: 75.6 
     <br/>  (30.1, 190.0) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">150 mg twice 
     <br/>  weekly, 
     <br/>  d 1–15 (n=7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QDwith 
     <br/>  ritonavir 100 mg QD,  
     <br/>  d 1–17 (n=7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2.49m (2.03, 3.06) 
     <br/>  25-O-desacetyl­ 
     <br/>  rifabutin: 7.77 
     <br/>  (6.13, 9.83) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.48m (1.19, 1.84) 
     <br/>  25-O-desacetyl­ 
     <br/>  rifabutin: 
     <br/>  10.90 
     <br/>  (8.14, 14.61) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.40m (1.05, 1.87) 
     <br/>  25-O-desacetyl­ 
     <br/>  rifabutin: 11.45 
     <br/>  (8.15, 16.10) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">pitavastatin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4 mg QD 
     <br/>  for 5 days 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD 
     <br/>  for 5 days 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.60 
     <br/>  (1.39, 1.85) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.31 
     <br/>  (1.23, 1.39) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">rosiglitazone
    
     <sup>n</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4 mg single dose, 
     <br/>  d 1, 7, 17 (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, 
     <br/>  d 2–7, then 
     <br/>  300 mg QD with 
     <br/>  ritonavir 100 mg 
     <br/>  QD, d 8–17 (n=14) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.08 
     <br/>  (1.03, 1.13) 
     <br/>  0.97 
     <br/>  (0.91, 1.04) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.35 
     <br/>  (1.26, 1.44) 
     <br/>  0.83 
     <br/>  (0.77, 0.89) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>    
     <br/>  NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">rosuvastatin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10 mg 
     <br/>  single dose 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD with 
     <br/>  ritonavir 100 mg QD for 7 days 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑7-foldo 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">↑3-foldo 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">saquinavir
    
     <sup>p</sup>(soft gelatin capsules) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1200 mg QD, 
     <br/>  d 1–13 (n=7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 7–13 
     <br/>  (n=7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4.39 
     <br/>  (3.24, 5.95) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5.49 
     <br/>  (4.04, 7.47) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">6.86 
     <br/>  (5.29, 8.91) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="3" align="justify" styleCode="Lrule Rrule" valign="top">sofosbuvir/ 
     <br/>  velpatasvir/ 
     <br/>  voxilaprevir 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg sofosbuvir 
     <br/>  single dose 
     <br/>  (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mgwith 100 mg 
     <br/>  ritonavir single dose 
     <br/>  (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.29 
     <br/>  (1.09, 1.52) 
     <br/>  sofosbuvir metabolite GS-331007 
     <br/>  1.05 
     <br/>  (0.99, 1.12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.40 
     <br/>  (1.25, 1.57) 
     <br/>  sofosbuvir metabolite GS-331007 
     <br/>  1.25 
     <br/>  (1.16, 1.36) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">100 mg velpatasvir 
     <br/>  single dose (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg with 100 mg 
     <br/>  ritonavir single dose (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.29 
     <br/>  (1.07, 1.56) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.93 
     <br/>  (1.58, 2.36) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">100 mg 
     <br/>  voxilaprevir single dose 
     <br/>  (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mgwith 100 mg 
     <br/>  ritonavir single dose (n=15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4.42 
     <br/>  (3.65, 5.35) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4.31 
     <br/>  (3.76, 4.93) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">NA 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" align="justify" styleCode="Lrule Rrule" valign="top">tenofovir DFq 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QD, d 9–16 
     <br/>  (n=33) and 
     <br/>  d 24–30 
     <br/>  (n=33) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d2–16 (n=33) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.14 
     <br/>  (1.08, 1.20) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.24 
     <br/>  (1.21, 1.28) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.22 
     <br/>  (1.15, 1.30) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">300 mg QD, d 1–7 
     <br/>  (pm) (n=14) d 25–34 (pm) (n=12) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mg QDwith ritonavir 
     <br/>  100 mg QD, d 25–34 
     <br/>  (am) (n=12)r 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.34 
     <br/>  (1.20, 1.51) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.37 
     <br/>  (1.30, 1.45) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.29 
     <br/>  (1.21, 1.36) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">voriconazole 
     <br/>  (Participants 
     <br/>  with at least one 
     <br/>  functional 
     <br/>  CYP2C19 allele) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 mg BID, 
     <br/>  d 2–3, 22–30; 
     <br/>  400 mg BID, 
     <br/>  d 1, 21 (n=20) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">300 mgwith ritonavir 
     <br/>  100 mg QD, d 11–30 (n=20) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.90 
     <br/>  (0.78, 1.04) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.67 
     <br/>  (0.58, 0.78) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.61 
     <br/>  (0.51, 0.72) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">voriconazole (Participantswithout a functional CYP2C19 allele) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">50 mg BID, 
     <br/>  d 2–3, 22–30; 
     <br/>  100 mg BID, 
     <br/>  d 1, 21 (n=8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  300 mg with ritonavir 
     <br/>  100 mg QD, d 11–30 (n=8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  4.38 
     <br/>  (3.55, 5.39) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  5.61 
     <br/>  (4.51, 6.99) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">  
     <br/>  7.65 
     <br/>  (5.71, 10.2) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">lamivudine and 
     <br/>  zidovudine 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">150 mg lamivudine 
     <br/>  and 300 mg zidovudine BID, 
     <br/>
                                    <br/>  d 1–12 (n=19)
    </td>
                                 <td align="center" styleCode="Rrule" valign="top">400 mg QD, d 7–12 
     <br/>  (n=19) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">lamivudine: 1.04 (0.92, 1.16) zidovudine: 1.05 (0.88, 1.24) zidovudine glucuronide: 0.95 (0.88, 1.02) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">lamivudine: 1.03 (0.98, 1.08) zidovudine: 1.05 (0.96, 1.14) zidovudine glucuronide: 1.00 (0.97, 1.03) 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">lamivudine: 1.12 (1.04, 1.21) zidovudine: 0.69 (0.57, 0.84) zidovudine glucuronide: 0.82 (0.62, 1.08) 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a</sup> Data provided are under fed conditions unless otherwise noted. 
  <br/>
                           <sup>b</sup> 400 mg ddI EC and atazanavir were administered together with food on Days 8 and 19. 
  <br/>
                           <sup>c</sup> Upon further dose normalization of ethinyl estradiol 25 mcg with atazanavir relative to ethinyl estradiol 35 mcg without atazanavir, the ratio of geometric means (90% confidence intervals) for C
 
  <sub>max</sub>, AUC, and C
 
  <sub>min</sub>were 0.82 (0.73, 0.92), 1.06 (0.95, 1.17), and 1.35 (1.11, 1.63), respectively. 
  <br/>
                           <sup>d</sup> Upon further dose normalization of ethinyl estradiol 35 mcg with atazanavir with ritonavir relative to ethinyl estradiol 25 mcg without atazanavir with ritonavir, the ratio of geometric means (90% confidence intervals) for C
 
  <sub>max</sub>, AUC, and C
 
  <sub>min</sub>were 1.17 (1.03, 1.34), 1.13 (1.05, 1.22), and 0.88 (0.77, 1.00), respectively. 
  <br/>
                           <sup>e</sup> All participants were on a 28-day lead-in period; one full cycle of Ortho Tri-Cyclen
 
  <sup>®</sup>. Ortho Tri-Cyclen
 
  <sup>®</sup>contains 35 mcg of ethinyl estradiol. Ortho Tri-Cyclen
 
  <sup>®</sup>LO contains 25 mcg of ethinyl estradiol. Results were dose normalized to an ethinyl estradiol dose of 35 mcg. 
  <br/>
                           <sup>f</sup> 17-deacetyl norgestimate is the active component of norgestimate. 
  <br/>
                           <sup>g</sup> Effect of atazanavir with ritonavir on the first dose of glecaprevir and pibrentasvir is reported. 
  <br/>
                           <sup>h</sup> (R)-methadone is the active isomer of methadone. 
  <br/>
                           <sup>i</sup> Study was conducted in participants with HIV-1. 
  <br/>
                           <sup>j</sup> Participants were treated with nevirapine prior to study entry. 
  <br/>
                           <sup>k</sup> Omeprazole was used as a metabolic probe for CYP2C19. Omeprazole was given 2 hours after atazanavir on Day 7; and was given alone 2 hours after a light meal on Day 20. 
  <br/>
                           <sup>l </sup>Not the recommended therapeutic dose of atazanavir. 
  <br/>
                           <sup>m</sup> When compared to rifabutin 150 mg QD alone d1–10 (n=14). Total of rifabutin + 25-O-desacetyl-rifabutin: AUC 2.19 (1.78, 2.69). 
  <br/>
                           <sup>n</sup> Rosiglitazone used as a probe substrate for CYP2C8. 
  <br/>
                           <sup>o</sup> Mean ratio (with/without coadministered drug). ↑ indicates an increase in rosuvastatin exposure. 
  <br/>
                           <sup>p</sup> The combination of atazanavir and saquinavir 1200 mg QD produced daily saquinavir exposures similar to the values produced by the standard therapeutic dosing of saquinavir at 1200 mg TID. However, the C
 
  <sub>max</sub>is about 79% higher than that for the standard dosing of saquinavir (soft gelatin capsules) alone at 1200 mg TID. 
  <br/>
                           <sup>q</sup> Note that similar results were observed in a study where administration of tenofovir DF and atazanavir was separated by 12 hours. 
  <br/>
                           <sup>r</sup> Administration of tenofovir DF and atazanavir was temporally separated by 12 hours.

 </paragraph>
                        <paragraph>NA = not available.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>atazanavircapsulecamberfigure1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="atazanavircapsulecamberfigure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.4">
                     <id root="30891c38-5d97-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <br/>
                        <paragraph>Mechanism of Action 
  <br/>  Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1-infected cells, thus preventing formation of mature virions. 
  <br/>  Antiviral Activity in Cell Culture 
  <br/>  Atazanavir exhibits anti-HIV-1 activity with a mean 50% effective concentration (EC
 
  <sub>50</sub>) in the absence of human serum of 2 to 5 nM against a variety of laboratory and clinical HIV-1 isolates grown in peripheral blood mononuclear cells, macrophages, CEM-SS cells, and MT-2 cells. Atazanavir has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture. Atazanavir has variable activity against HIV-2 isolates (1.9-32 nM), with EC
 
  <sub>50</sub>values above the EC
 
  <sub>50</sub>values of failure isolates. Two-drug combination antiviral activity studies with atazanavir showed no antagonism in cell culture with PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), NNRTIs (delavirdine, efavirenz, and nevirapine), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir DF, and zidovudine), the HIV-1 fusion inhibitor enfuvirtide, and two compounds used in the treatment of viral hepatitis, adefovir and ribavirin, without enhanced cytotoxicity. 
  <br/>  Resistance 
  <br/>
                           <content styleCode="italics">In Cell Culture:</content>HIV-1 isolates with a decreased susceptibility to atazanavir have been selected in cell culture and obtained from patients treated with atazanavir or atazanavir with ritonavir. HIV-1 isolates with 93- to 183-fold reduced susceptibility to atazanavir from three different viral strains were selected in cell culture by 5 months. The substitutions in these HIV-1 viruses that contributed to atazanavir resistance include I50L, N88S, I84V, A71V, and M46I. Changes were also observed at the protease cleavage sites following drug selection. Recombinant viruses containing the I50L substitution without other major PI substitutions were growth impaired and displayed increased susceptibility in cell culture to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir). The I50L and I50V substitutions yielded selective resistance to atazanavir and amprenavir, respectively, and did not appear to be cross-resistant. 
  <br/>
                           <content styleCode="italics">Clinical Studies of Treatment-Naïve Participants: Comparison of Ritonavir-Boosted Atazanavir vs Unboosted Atazanavir:</content>Study AI424-089 compared atazanavir 300 mg once daily with ritonavir 100 mg vs atazanavir 400 mg once daily when administered with lamivudine and extended- release stavudine in treatment-naive participants with HIV-1. A summary of the number of virologic failures and virologic failure isolates with atazanavir resistance in each arm is shown in Table 23. 
  <br/>
                           <content styleCode="bold"> Table 23:   Summary of Virologic Failures
  
   <sup>a</sup>at Week 96 in Study AI424-089: Comparison of Ritonavir Boosted Atazanavir vs Unboosted Atazanavir: Randomized Participants
 
  </content>
                        </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="644.784">
                           <col width="33.3539603960396%"/>
                           <col width="33.3230198019802%"/>
                           <col width="33.3230198019802%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir 300 mg</content>
                                    <br/>
                                    <content styleCode="bold">with</content>
                                    <br/>
                                    <content styleCode="bold">ritonavir 100 mg</content>
                                    <br/>
                                    <content styleCode="bold">(n=95)</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir 400 mg</content>
                                    <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">(n=105)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Virologic Failure (³50 copies/mL) at Week 96 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">15 (16%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">34 (32%) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Virologic Failure with Genotypes and Phenotypes Data 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">17 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Virologic Failure Isolates with 
     <br/>  atazanavir - resistance at 
     <br/>  Week 96 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0/5 (0%)
    
     <sup>b</sup>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4/17 (24%)
    
     <sup>b</sup>
                                    <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Virologic Failure Isolates with I50L Emergence at Week 96
    
     <sup>c</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0/5 (0%)
    
     <sup>b</sup>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2/17 (12%)
    
     <sup>b</sup>
                                    <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Virologic Failure Isolates with Lamivudine Resistance at Week 96 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2/5 (40%)
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">11/17 (65%)
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a </sup>Virologic failure includes participants who were never suppressed through Week 96 and on study at Week 96, had virologic rebound or discontinued due to insufficient viral load response. 
  <br/>
                           <sup>b </sup>Percentage of Virologic Failure Isolates with genotypic and phenotypic data. 
  <br/>
                           <sup>c</sup>Mixture of I50I/L emerged in 2 other atazanavir 400 mg-treated participants. Neither isolate was phenotypically resistant to atazanavir. 
  <br/>
                           <br/>
                           <content styleCode="italics">Clinical Studies of Treatment-Naive Participants Receiving Atazanavir 300 mg with Ritonavir 100 mg</content>: In Phase 3 Study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from participants who experienced virologic failure (HIV-1 RNA
 
  <content styleCode="underline">&gt;</content>400 copies/mL) or discontinued before achieving suppression on atazanavir with ritonavir (n=39; 9%) and lopinavir/ritonavir (n=39; 9%) through 96 weeks of treatment. In the atazanavir with ritonavir arm, one of the virologic failure isolates had a 56-fold decrease in atazanavir susceptibility emerge on therapy with the development of PI resistance-associated substitutions L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M. The NRTI resistance-associated substitution M184V also emerged on treatment in this isolate conferring emtricitabine resistance. Two atazanavir with ritonavir-virologic failure isolates had baseline phenotypic atazanavir resistance and IAS-defined major PI resistance-associated substitutions at baseline. The I50L substitution emerged on study in one of these failure isolates and was associated with a 17-fold decrease in atazanavir susceptibility from baseline and the other failure isolate with baseline atazanavir resistance and PI substitutions (M46M/I and I84I/V) had additional IAS-defined major PI substitutions (V32I, M46I, and I84V) emerge on atazanavir treatment associated with a 3-fold decrease in atazanavir susceptibility from baseline. Five of the treatment failure isolates in the atazanavir with ritonavir arm developed phenotypic emtricitabine resistance with the emergence of either the M184I (n=1) or the M184V (n=4) substitution on therapy and none developed phenotypic tenofovir disoproxil resistance. In the lopinavir/ritonavir arm, one of the virologic failure participant isolates had a 69-fold decrease in lopinavir susceptibility emerge on therapy with the development of PI substitutions L10V, V11I, I54V, G73S, and V82A in addition to baseline PI substitutions L10L/I, V32I, I54I/V, A71I, G73G/S, V82V/A, L89V, and L90M. Six lopinavir/ritonavir virologic failure isolates developed the M184V substitution and phenotypic emtricitabine resistance and two developed phenotypic tenofovir disoproxil resistance. 
  <br/>
                           <content styleCode="italics">Clinical Studies of Treatment-Naive Participants Receiving Atazanavir 400 mg without Ritonavir</content>: Atazanavir-resistant clinical isolates from treatment-naive participants who experienced virologic failure on atazanavir 400 mg treatment without ritonavir often developed an I50L substitution (after an average of 50 weeks of atazanavir therapy), often in combination with an A71V substitution, but also developed one or more other PI substitutions (eg, V32I, L33F, G73S, V82A, I85V, or N88S) with or without the I50L substitution. In treatment-naive participants, viral isolates that developed the I50L substitution, without other major PI substitutions, showed phenotypic resistance to atazanavir but retained in cell culture susceptibility to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir); however, there are no clinical data available to demonstrate the effect of the I50L substitution on the efficacy of subsequently administered PIs. 
  <br/>
                           <content styleCode="italics">Clinical Studies of Treatment-Experienced Participants</content>: In studies of treatment-experienced participants treated with atazanavir or atazanavir with ritonavir, most atazanavir-resistant isolates from participants who experienced virologic failure developed substitutions that were associated with resistance to multiple PIs and displayed decreased susceptibility to multiple PIs. The most common protease substitutions to develop in the viral isolates of participants who failed treatment with atazanavir 300 mg once daily and ritonavir 100 mg once daily (together with tenofovir DF and an NRTI) included V32I, L33F/V/I, E35D/G,   M46I/L,   I50L,   F53L/V,   I54V,   A71V/T/I,   G73S/T/C,   V82A/T/L,   I85V,   and L89V/Q/M/T. Other substitutions that developed on atazanavir with ritonavir treatment including E34K/A/Q, G48V, I84V, N88S/D/T, and L90M occurred in less than 10% of participant isolates. Generally, if multiple PI resistance substitutions were present in the HIV-1 virus of the participant at baseline, atazanavir resistance developed through substitutions associated with resistance to other PIs and could include the development of the I50L substitution. The I50L substitution has been detected in treatment-experienced participants experiencing virologic failure after long-term treatment. Protease cleavage site changes also emerged on atazanavir treatment, but their presence did not correlate with the level of atazanavir resistance. 
  <br/>
                           <br/>
                           <content styleCode="italics">Clinical Studies of Pediatric Participants in AI424-397 (PRINCE I) and AI424-451 (PRINCE II):</content>Treatment-emergent atazanavir with ritonavir resistance-associated amino acid substitution M36I in the protease was detected in the virus of one participant among treatment failures in AI424-397. In addition, three known resistance-associated substitutions for other PIs arose in the viruses from one participant each (L19I/R, H69K/R, and I72I/V). Reduced susceptibility to atazanavir, ritonavir, or atazanavir with ritonavir was not seen with these viruses. In AI424-451, atazanavir with ritonavir resistance-associated substitutions G16E, V82A/I/T, I84V, and/or L90M arose in the viruses of two participants. The virus population harboring the M46M/V, V82V/I, I84I/V, and L90L/M substitutions acquired phenotypic resistance to ritonavir (ritonavir phenotypic fold-change of 3.5, with a ritonavir cutoff of 2.5-fold change). However, these substitutions did not result in phenotypic resistance to atazanavir (atazanavir phenotypic fold-change of &lt;1.8, with an atazanavir cutoff of 2.2-fold change). Secondary PI resistance-associated amino acid substitutions also arose in the viruses of one participant each, including V11V/I, D30D/G, E35E/D, K45K/R, L63P/S, and I72I/T. Q61D and Q61E/G emerged in the viruses of two participants who failed treatment with atazanavir with ritonavir. Viruses from nine participants in the two studies developed NRTI resistance-associated substitutions: K65K/R (n=1), M184V (n=7), and T215I (n=1). 
  <br/>
                           <br/>  Cross-Resistance 
  <br/>
                           <br/>  Cross-resistance among PIs has been observed. Baseline phenotypic and genotypic analyses of clinical isolates from atazanavir clinical trials of PI-experienced participants showed that isolates cross- resistant to multiple PIs were cross-resistant to atazanavir. Greater than 90% of the isolates with substitutions that included I84V or G48V were resistant to atazanavir. Greater than 60% of isolates containing L90M, G73S/T/C, A71V/T, I54V, M46I/L, or a change at V82 were resistant to atazanavir, and 38% of isolates containing a D30N substitution in addition to other changes were resistant to atazanavir. Isolates resistant to atazanavir were also cross-resistant to other PIs with &gt;90% of the isolates resistant to indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, and 80% resistant to amprenavir. In treatment-experienced participants, PI-resistant viral isolates that developed the I50L substitution in addition to other PI resistance-associated substitution were also cross-resistant to other PIs. 
  <br/>
                           <br/>  Baseline Genotype/Phenotype and Virologic Outcome Analyses 
  <br/>
                           <br/>  Genotypic and/or phenotypic analysis of baseline virus may aid in determining atazanavir susceptibility before initiation of atazanavir with ritonavir therapy. An association between virologic response at 48 weeks and the number and type of primary PI resistance-associated substitutions detected in baseline HIV-1 isolates from antiretroviral-experienced participants receiving atazanavir with ritonavir once daily or lopinavir/ritonavir (fixed-dose product) twice daily in Study AI424-045 is shown in Table 24. 
  <br/>
                           <br/>  Overall, both the number and type of baseline PI substitutions affected response rates in treatment- experienced participants. In the atazanavir with ritonavir group, participants had lower response rates when 3 or more baseline PI substitutions, including a substitution at position 36, 71, 77, 82, or 90, were present compared to participants with 1 to 2 PI substitutions, including one of these substitutions. 
  <br/>
                           <br/>
                           <content styleCode="bold">Table 24: HIV-1 RNA Response by Number and Type of Baseline PI Substitution, Antiretroviral-Experienced Participants in Study AI424¬-045, As-Treated Analysis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <br/>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="527.9435">
                           <col width="37.1583322836629%"/>
                           <col width="33.2157702481421%"/>
                           <col width="29.625897468195%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Virologic Response = HIV RNA &lt;400 copies/mL
     
      <sup>b</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Number and Type of Baseline PI</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">atazanavir with ritonavir</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">lopinavir/ritonavir
     
      <sup>c</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Substitutions
     
      <sup>a</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">(n=110)</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">(n=113)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">3 or more primary PI substitutions including
     
      <sup>d</sup>:
    
     </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">D30N 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">75% (6/8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">50% (3/6) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">M36I/V 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">19% (3/16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">33% (6/18) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">M46I/L/T 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">24% (4/17) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">23% (5/22) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">I54V/L/T/M/A 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">31% (5/16) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">31% (5/16) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">A71V/T/I/G 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">34% (10/29) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">39% (12/31) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">G73S/A/C/T 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">14% (1/7) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">38% (3/8) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">V77I 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">47% (7/15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">44% (7/16) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">V82A/F/T/S/I 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">29% (6/21) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">27% (7/26) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">I84V/A 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">11% (1/9) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">33% (2/6) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">N88D 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">63% (5/8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">67% (4/6) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">L90M 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10% (2/21) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">44% (11/25) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Number of baseline primary PI substitutions</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">All patients, as-treated 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">58% (64/110) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">59% (67/113) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">0–2 PI substitutions 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">75% (50/67) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">75% (50/67) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">3–4 PI substitutions 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">41% (14/34) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">43% (12/28) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">5 or more PI substitutions 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0% (0/9) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">28% (5/18) 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a</sup> Primary substitutions include any change at D30, V32, M36, M46, I47, G48, I50, I54, A71, G73, V77, V82, I84, N88, and L90. 
  <br/>
                           <sup>b</sup> Results should be interpreted with caution because the subgroups were small. 
  <br/>
                           <sup>c</sup> Administered as a fixed-dose product. 
  <br/>
                           <sup>d</sup> There were insufficient data (n&lt;3) for PI substitutions V32I, I47V, G48V, I50V, and F53L. 
  <br/>  The response rates of antiretroviral-experienced participants in Study AI424-045 were analyzed by baseline phenotype (shift in susceptibility in cell culture relative to reference, Table 25). The analyses are based on a select population with 62% of participants receiving an NNRTI-based regimen before study entry compared to 35% receiving a PI-based regimen. Additional data are needed to determine clinically relevant break points for atazanavir. 
  <br/>
                           <content styleCode="bold">Table 25: Baseline Phenotype by Outcome, Antiretroviral-Experienced Participants in Study AI424-045, As-Treated Analysis </content>
                        </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <col width="28.5781544256121%"/>
                           <col width="38.771186440678%"/>
                           <col width="32.65065913371%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">  
     <br/>    
     <br/>
                                 </td>
                                 <td colspan="2" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Virologic Response = HIV-1 RNA&lt;400 copies/mL
     
      <sup>b</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Baseline Phenotype
     
      <sup>a</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">atazanavir with ritonavir</content>
                                    <br/>
                                    <content styleCode="bold">(n=111)</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">lopinavir/ritonavir
     
      <sup>c</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(n=111)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">0–2 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">71% (55/78) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">70% (56/80) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">&gt;2–5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">53% (8/15) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">44% (4/9) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">&gt;5–10 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">13% (1/8) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">33% (3/9) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">&gt;10 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10% (1/10) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">23% (3/13) 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <br/>
                        <paragraph>
                           <sup> </sup>
                           <br/>
                           <sup>a</sup>  Fold change susceptibility in cell culture relative to the wild-type reference. 
  <br/>
                           <br/>
                           <sup>b </sup>Results should be interpreted with caution because the subgroups were small. 
  <br/>
                           <sup>c </sup>Administered as a fixed-dose product.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="30891c38-5d98-7df7-e063-6394a90ae762"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250206"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="30891c38-5d99-7df7-e063-6394a90ae762"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <br/>
                        <paragraph>Carcinogenesis 
  <br/>  Long-term carcinogenicity studies in mice and rats were carried out with atazanavir for two years. In the mouse study, drug-related increases in hepatocellular adenomas were found in females at 360 mg/kg/day. The systemic drug exposure (AUC) at the NOAEL (no observable adverse effect level) in females, (120 mg/kg/day) was 2.8 times and in males (80 mg/kg/day) was 2.9 times higher than those in humans at the clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir, non-pregnant patients). In the rat study, no drug-related increases in tumor incidence were observed at doses up to 1200 mg/kg/day, for which AUCs were 1.1 (males) or 3.9 (females) times those measured in humans at the clinical dose. 
  <br/>  Mutagenesis  
  <br/>  Atazanavir tested positive in an
 
  <content styleCode="italics">in vitro</content>clastogenicity test using primary human lymphocytes, in the absence and presence of metabolic activation. Atazanavir tested negative in the
 
  <content styleCode="italics">in vitro</content>Ames reverse-mutation assay,
 
  <content styleCode="italics">in vivo</content>micronucleus and DNA repair tests in rats, and
 
  <content styleCode="italics">in vivo</content>DNA damage test in rat duodenum (comet assay).  
  <br/>  Impairment of Fertility  
  <br/>  At the systemic drug exposure levels (AUC) 0.9 (in male rats) or 2.3 (in female rats) times that of the human clinical dose, (300 mg/day atazanavir boosted with 100 mg/day ritonavir) significant effects on mating, fertility, or early embryonic development were not observed.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="30891c38-5d9a-7df7-e063-6394a90ae762"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250206"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="30891c38-5d9b-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Adult Participants without Prior Antiretroviral Therapy</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Study AI424-138: a 96-week study comparing the antiviral efficacy and safety of either atazanavir or lopinavir/ritonavir, each in combination with fixed-dose tenofovir DF-emtricitabine in treatment-naive participants with HIV-1.</content>Study AI424-138
 
  <content styleCode="italics">(NCT00272779)</content>was a 96-week, open-label, randomized, multicenter study, comparing atazanavir (300 mg once daily) with ritonavir (100 mg once daily) to lopinavir/ritonavir (400/100 mg twice daily as fixed-dose product), each in combination with the fixed-dose product, tenofovir DF/emtricitabine (300/200 mg once daily), in 878 antiretroviral treatment-naive participants. Participants had a mean age of 36 years (range: 19 to 72), 49% were Caucasian, 18% Black, 9% Asian, 23% Hispanic/Mestizo/mixed race, and 68% were male. The median baseline plasma CD4+ cell count was 204 cells/mm
 
  <sup>3</sup>(range: 2 to 810 cells/mm
 
  <sup>3</sup>) and the mean baseline plasma HIV-1 RNA level was 4.94 log
 
  <sub>10</sub>copies/mL (range: 2.60 to 5.88 log
 
  <sub>10</sub>copies/mL). Treatment response and outcomes through Week 96 are presented in Table 26. 
  <br/>
                           <content styleCode="bold">Table 26: Outcomes of Treatment Through Week 96 in Treatment-Naive Adults (Study AI424-138)</content>
                        </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="591">
                           <col width="42.4529365347762%"/>
                           <col width="30.3911622139556%"/>
                           <col width="27.1559012512682%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">Outcome</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir</content>
                                    <br/>
                                    <content styleCode="bold">30</content>
                                    <content styleCode="bold">0 mg </content>
                                    <content styleCode="bold">with</content>
                                    <content styleCode="bold">ritonavir 100 mg</content>
                                    <br/>
                                    <content styleCode="bold">(once daily) </content>
                                    <content styleCode="bold">and</content>
                                    <br/>
                                    <content styleCode="bold">tenofovir DF/emtricitabine</content>
                                    <br/>
                                    <content styleCode="bold">(once daily)a</content>
                                    <br/>
                                    <content styleCode="bold">(n=441)</content>
                                    <br/>    
     <br/>
                                    <content styleCode="bold">9</content>
                                    <content styleCode="bold">6 Weeks</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">lopinavir</content>
                                    <br/>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">ritonavir
     
      <sup>b</sup>400 mg/100 mg
    
     </content>
                                    <br/>
                                    <content styleCode="bold">(twice daily) with</content>
                                    <br/>
                                    <content styleCode="bold">tenofovir DF/emtricitabine</content>
                                    <br/>
                                    <content styleCode="bold">(once daily)a</content>
                                    <br/>
                                    <content styleCode="bold">(n=437)</content>
                                    <br/>    
     <br/>
                                    <content styleCode="bold">9</content>
                                    <content styleCode="bold">6 Weeks</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Responder 
    
     <sup>c</sup>
                                    <sup>,d,e</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">75% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">68% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Virologic failure
    
     <sup>f</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">17% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">19% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Rebound 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">8% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">10% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Never suppressed through Week 96 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">9% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">9% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Death 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Discontinued due to adverse event 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">5% 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Discontinued for other reasons
    
     <sup>g</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">4% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">7% 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a</sup> As a fixed-dose product: 300 mg tenofovir DF/200 mg emtricitabine once daily. 
  <br/>
                           <sup>b</sup> As a fixed-dose product: 400 mg lopinavir/100 mg ritonavir (twice daily). 
  <br/>
                           <sup>c</sup> Participants achieved HIV-1 RNA &lt;50 copies/mL at Week 96. Roche Amplicor®, v1.5 ultra-sensitive assay. 
  <br/>
                           <sup>d</sup> Pre-specified ITT analysis at Week 48 using as-randomized cohort: atazanavir with ritonavir 78% and lopinavir/ritonavir 76% (difference estimate: 1.7% [95% confidence interval: −3.8%, 7.1%]). 
  <br/>
                           <sup>e</sup> Pre-specified ITT analysis at Week 96 using as-randomized cohort: atazanavir with ritonavir 74% and lopinavir/ritonavir 68% (difference estimate: 6.1% [95% confidence interval: 0.3%, 12.0%]). 
  <br/>  f Includes viral rebound and failure to achieve confirmed HIV-1 RNA &lt;50 copies/mL through Week 96. 
  <br/>
                           <sup>g</sup> Includes lost to follow-up, participant's withdrawal, noncompliance, protocol violation, and other reasons. 
  <br/>  Through 96 weeks of therapy, the proportion of responders among participants with high viral loads (ie, baseline HIV-1 RNA
 
  <content styleCode="underline">&gt;</content>100,000 copies/mL) was comparable for the atazanavir with ritonavir (165 of 223 participants, 74%) and lopinavir/ritonavir (148 of 222 participants, 67%) arms. At 96 weeks, the median increase from baseline in CD4+ cell count was 261 cells/mm3 for the atazanavir with ritonavir arm and 273 cells/mm
 
  <sup>3</sup>for the lopinavir/ritonavir arm. 
  <br/>
                           <content styleCode="italics">Study AI424-034: Atazanavir once daily compared to efavirenz once daily, each in combination with fixed-dose lamivudine/zidovudine twice daily.</content>Study AI424-034 (NCT00013897) was a randomized, double-blind, multicenter trial comparing atazanavir (400 mg once daily) to efavirenz (600 mg once daily), each in combination with the fixed-dose product of lamivudine/zidovudine (150 mg/300 mg) given twice daily, in 810 antiretroviral treatment-naive participants. Participants had a mean age of 34 years (range: 18 to 73), 36% were Hispanic, 33% were Caucasian, and 65% were male. The mean baseline CD4+ cell count was 321 cells/mm
 
  <sup>3</sup>(range: 64 to 1424 cells/mm
 
  <sup>3</sup>) and the mean baseline plasma HIV-1 RNA level was 4.8 log
 
  <sub>10</sub>copies/mL (range: 2.2 to 5.9 log
 
  <sub>10</sub>copies/mL). Treatment response and outcomes through Week 48 are presented in Table 27. 
  <br/>
                           <content styleCode="bold">Table 27: Outcomes of Randomized Treatment Through Week 48 in Treatment-Naive Adults (Study AI424-034) </content>
                        </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="659.2145">
                           <col width="35.3475234540502%"/>
                           <col width="30.929083022294%"/>
                           <col width="33.7233935236558%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">  
     <br/>    
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">Outcome</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir</content>
                                    <br/>
                                    <content styleCode="bold">400 mg once daily and lamivudine/zidovudine
     
      <sup>d</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(n=405)</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">efavirenz</content>
                                    <br/>
                                    <content styleCode="bold">600 mg once daily and lamivudine/zidovudine
     
      <sup>d</sup>
                                    </content>
                                    <br/>    
     <br/>
                                    <content styleCode="bold">(n=405)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Responder
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">67% (32%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">62% (37%) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Virologic failure
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">20% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">21% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Rebound 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">17% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">16% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Never suppressed through Week 48 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Death 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">– 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">&lt;1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Discontinued due to adverse event 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5% 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">7% 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="top">Discontinued for other reasons
    
     <sup>c</sup>
                                    <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">8% 
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10% 
     <br/>    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>
                           <sup>a</sup> Participants achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL (&lt;50 copies/mL) through Week 48. Roche Amplicor® HIV-1 Monitor
 
  <sup>TM</sup>Assay, test version 1.0 or 1.5 as geographically appropriate.  
  <br/>
                           <sup>b</sup> Includes viral rebound and failure to achieve confirmed HIV-1 RNA &lt;400 copies/mL through Week 48. 
  <br/>
                           <sup>c</sup> Includes lost to follow-up, participants withdrawal, noncompliance, protocol violation, and other reasons. 
  <br/>
                           <sup>d</sup> As a fixed-dose product: 150 mg lamivudine/300 mg zidovudine twice daily. 
  <br/>  Through 48 weeks of therapy, the proportion of responders among participants with high viral loads (ie, baseline HIV-1 RNA ≥100,000 copies/mL) was comparable for the atazanavir and efavirenz arms. The mean increase from baseline in CD4+ cell count was 176 cells/mm
 
  <sup>3</sup>for the atazanavir arm and 160 cells/mm
 
  <sup>3</sup>for the efavirenz arm. 
  <br/>
                           <content styleCode="italics">Study AI424-008: Atazanavir 400 mg once daily compared to atazanavir 600 mg once daily, and compared to nelfinavir 1250 mg twice daily, each in combination with stavudine and lamivudine twice daily.</content>Study AI424-008 (NCT identifier not available) was a 48-week, randomized, multicenter trial, blinded to dose of atazanavir, comparing atazanavir at two dose levels (400 mg and 600 mg once daily) to nelfinavir (1250 mg twice daily), each in combination with stavudine (40 mg) and lamivudine (150 mg) given twice daily, in 467 antiretroviral treatment-naive participants. Participants had a mean age of 35 years (range: 18 to 69), 55% were Caucasian, and 63% were male. The mean baseline CD4+ cell count was 295 cells/mm
 
  <sup>3</sup>(range: 4 to 1003 cells/mm
 
  <sup>3</sup>) and the mean baseline plasma HIV-1 RNA level was 4.7 log
 
  <sub>10</sub>copies/mL (range: 1.8 to 5.9 log
 
  <sub>10</sub>copies/mL). Treatment response and outcomes through Week 48 are presented in Table 28. 
  <br/>
                           <content styleCode="bold">Table 28: Outcomes of Randomized Treatment Through Week 48 in Treatment-Naive Adults (Study AI424-008)</content>
                        </paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="555">
                           <col width="38.3783783783784%"/>
                           <col width="32.2522522522522%"/>
                           <col width="29.3693693693694%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">  
     <br/>    
     <br/>    
     <br/>
                                    <content styleCode="bold">Outcome</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir</content>
                                    <br/>
                                    <content styleCode="bold">40</content>
                                    <content styleCode="bold">0 mg once daily with lamivudine and stavudine</content>
                                    <br/>
                                    <content styleCode="bold">(n=181)</content>
                                    <br/>    
     <br/>    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">elfinavir</content>
                                    <br/>
                                    <content styleCode="bold">125</content>
                                    <content styleCode="bold">0 mg twice daily with lamivudine and stavudine</content>
                                    <br/>
                                    <content styleCode="bold">(n=91)</content>
                                    <br/>    
     <br/>    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Responder
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">67% (33%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">59% (38%) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Virologic failure
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">24% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">27% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Rebound 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">14% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">14% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Never suppressed through Week 48 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">13% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Death 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">&lt;1% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">– 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Discontinued due to adverse event 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3% 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">Discontinued for other reasons
    
     <sup>c</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">7% 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10% 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>a Participants achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL (&lt;50 copies/mL) through Week 48. Roche Amplicor
 
  <sup>®</sup>HIV-1 Monitor™ Assay, test version 1.0 or 1.5 as geographically appropriate. 
  <br/>  b Includes viral rebound and failure to achieve confirmed HIV-1 RNA &lt;400 copies/mL through Week 48. 
  <br/>  c Includes lost to follow-up, participants withdrawal, noncompliance, protocol violation, and other reasons. 
  <br/>  Through 48 weeks of therapy, the mean increase  from  baseline  in  CD4+  cell  count  was 234 cells/mm
 
  <sup>3</sup>for the atazanavir 400 mg arm and 211 cells/mm
 
  <sup>3</sup>for the nelfinavir arm.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="30895357-bd03-43d1-e063-6294a90aca2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Adult Participants with Prior Antiretroviral Therapy</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Study AI424-045: Atazanavir once daily with ritonavir once daily compared to atazanavir once daily and saquinavir (soft gelatin capsules) once daily, and compared to lopinavir/ritonavir twice daily, each in combination with tenofovir DF and one NRTI.</content>Study AI424-045 
  <content styleCode="italics">(NCT00035932):</content>was a randomized, multicenter trial comparing atazanavir (300 mg once daily) with ritonavir (100 mg once daily) to atazanavir (400 mg once daily) with saquinavir soft gelatin capsules (1200 mg once daily), and to lopinavir/ritonavir (400/100 mg twice daily as fixed-dose product), each in combination with tenofovir DF and one NRTI, in 347 (of 358 randomized) participants who experienced virologic failure on highly active antiretroviral therapy regimens containing PIs, NNRTIs, and NRTIs. The mean time of prior exposure to antiretrovirals was 139 weeks for PIs, 85 weeks for NNRTIs, and 283 weeks for NRTIs. The mean age was 41 years (range: 24 to 74); 60% were Caucasian, and 78% were male. The mean baseline CD4+ cell count was 338 cells/mm 
  <sup>3</sup>(range: 14 to 1543 cells/mm 
  <sup>3</sup>) and the mean baseline plasma HIV-1 RNA level was 4.4 log 
  <sub>10</sub>copies/mL (range: 2.6 to 5.88 log 
  <sub>10</sub>copies/mL).
 </paragraph>
                        <paragraph>Treatment outcomes through Week 48 for the atazanavir with ritonavir and lopinavir/ritonavir treatment arms are presented in Table 29. Atazanavir with ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV-1 RNA level. Study AI424-045 was not large enough to reach a definitive conclusion that atazanavir with ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV-1 RNA lower limit of quantification 
  <content styleCode="italics">[see Microbiology, Tables 24 and 25 ( 
   <linkHtml href="#Section_12.4">12.4</linkHtml>)]. 
  </content>
                           <br/>
                           <content styleCode="bold">Table 29:  Outcomes of Treatment Through Week 48 in Study AI424-045 (Participants with Prior Antiretroviral Experience)</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph/>
                        <table border="0" cellpadding="0" cellspacing="0" width="643">
                           <colgroup>
                              <col width="28.8086342880863%"/>
                              <col width="24.8650892486509%"/>
                              <col width="25.1037775010378%"/>
                              <col width="21.222498962225%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">Outcome</content>
                                 </td>
                                 <td align="justify" colspan="2" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Atazanavir 300 mg with</content>
                                    <br/>
                                    <content styleCode="bold">ritonavir 100 mg once</content>
                                    <br/>
                                    <content styleCode="bold">daily </content>
                                    <br/>
                                    <content styleCode="bold">and</content>
                                    <br/>
                                    <content styleCode="bold">tenofovir DF </content>
                                    <br/>
                                    <content styleCode="bold">and</content>
                                    <br/>
                                    <content styleCode="bold">1 NRTI</content>
                                    <br/>
                                    <content styleCode="bold">(n=119)</content>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">lopinavir/ritonavir (400/100 mg) twice daily </content>
                                    <br/>
                                    <content styleCode="bold">and</content>
                                    <br/>
                                    <content styleCode="bold">tenofovir DF +</content>
                                    <br/>
                                    <content styleCode="bold">1 NRTI</content>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">(n=118)</content>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Difference 
      <sup>a</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(Atazanavir -</content>
                                    <br/>
                                    <content styleCode="bold">lopinavir/ritonavir) 
      <sup>b</sup>
                                    </content>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">
                                       <content styleCode="bold">(CI)</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">HIV-1 RNA Change from
     <br/>
			Baseline (log 
     <sub>10</sub> copies/mL) 
     <sup>c</sup>
                                 </td>
                                 <td align="justify" colspan="2" styleCode="Rrule" valign="middle">−1.58</td>
                                 <td align="justify" styleCode="Rrule" valign="middle"> −1.70</td>
                                 <td align="justify" styleCode="Rrule" valign="middle">+0.12 
     <sup>c</sup>(−0.17, 0.41)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="2" styleCode="Lrule Rrule" valign="top">CD4+ Change from Baseline
     <br/>
			(cells/mm 
     <sup>3</sup>) 
     <sup>e</sup>
                                 </td>
                                 <td align="justify" colspan="2" styleCode="Rrule" valign="middle">116</td>
                                 <td align="justify" styleCode="Rrule" valign="middle">   123</td>
                                 <td align="justify" styleCode="Rrule" valign="middle">−7
     <br/>
			(−67, 52)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" colspan="6" styleCode="Lrule Rrule" valign="top">Percent of Participants Responding 
     <sup>e</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">HIV-1 RNA &lt;400 copies/mL 
     <sup>c</sup>
                                 </td>
                                 <td align="justify" colspan="2" styleCode="Rrule" valign="middle">55% </td>
                                 <td align="justify" colspan="2" styleCode="Rrule" valign="middle">   57%</td>
                                 <td align="justify" styleCode="Rrule" valign="middle">−2.2%
     <br/>
			(−14.8%, 10.5%)
    </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="top">HIV-1 RNA &lt;50 copies/mL 
     <sup>c</sup>
                                 </td>
                                 <td align="justify" colspan="2" styleCode="Rrule" valign="middle">
                                    <br/>
			38%   
    </td>
                                 <td align="justify" colspan="2" styleCode="Rrule" valign="middle">
                                    <br/>
			   45%
    </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">−7.1%
     <br/>
			(−19.6%, 5.4%)
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <paragraph>
                           <sup>a</sup> Time-averaged difference through Week 48 for HIV-1  RNA; Week 48 difference in HIV-1 RNA percentages and CD4+ mean changes, atazanavir with ritonavir vs lopinavir/ritonavir; CI = 97.5% confidence interval for change in HIV-1 RNA; 95% confidence interval otherwise.
 </paragraph>
                        <paragraph>
                           <sup>b</sup>  Administered as a fixed-dose product.
  <br/>
                           <sup>c</sup>  Roche Amplicor 
  <sup>®</sup>HIV-1 Monitor 
  <sup>TM</sup>Assay, test version 1.5.
  <br/>
                           <sup>d</sup>  Protocol-defined primary efficacy outcome measure.
  <br/>
                           <sup>e</sup>  Based on participants with baseline and Week 48 CD4+ cell count measurements (atazanavir with ritonavir, n=85; lopinavir/ritonavir, n=93).
  <br/>
                           <sup>f</sup>  Participants achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL (&lt;50 copies/mL) through Week 48.
  <br/>
No participants in the atazanavir with ritonavir treatment arm and three participants in the lopinavir/ritonavir treatment arm experienced a new-onset CDC Category C event during the study.
  <br/>
In Study AI424-045, the mean change from baseline in plasma HIV-1 RNA for atazanavir 400 mg with saquinavir (n=115) was −1.55 log 
  <sub>10</sub>copies/mL, and the time-averaged difference in change in HIV-1 RNA  levels  versus lopinavir/ritonavir was 0.33. The corresponding mean increase in CD4+ cell count was 72 cells/mm 
  <sup>3</sup>. Through 48 weeks of treatment, the proportion of participants in this treatment arm with plasma HIV-1 RNA &lt;400 (&lt;50) copies/mL was 38% (26%). In this study, coadministration of atazanavir and saquinavir did not provide adequate efficacy 
  <content styleCode="italics">[see Drug Interactions ( 
   <linkHtml href="#Section_7">7</linkHtml>)] 
  </content>.
  <br/>
Study AI424-045 also compared changes from baseline in lipid values. 
  <content styleCode="italics">[See Adverse Reactions ( 
   <linkHtml href="#Section_6.1">6.1</linkHtml>).] 
  </content>
                           <br/>
                           <content styleCode="italics">Study AI424-043 (NCT00028301):</content>Study AI424-043 was a randomized, open-label, multicenter trial comparing atazanavir (400 mg once daily) to lopinavir/ritonavir (400/100 mg twice daily as fixed-dose product), each in combination with two NRTIs, in 300 participants who experienced virologic failure to only one prior PI-containing regimen. Through 48 weeks, the proportion of participants with plasma HIV-1 RNA &lt;400 (&lt;50) copies/mL was 49% (35%) for participants randomized to atazanavir (n=144) and 69% (53%) for participants randomized to lopinavir/ritonavir (n=146). The mean change from baseline was −1.59 log 
  <sub>10</sub>copies/mL in the atazanavir treatment arm and −2.02 log 
  <sub>10</sub>copies/mL in the lopinavir/ritonavir arm. Based on the results of this study, atazanavir without ritonavir was inferior to lopinavir/ritonavir in PI-experienced participants with prior virologic failure and is not recommended for such patients.
 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.3">
                     <id root="30891c38-5d9d-7df7-e063-6394a90ae762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Pediatric Participants</title>
                     <text>
                        <br/>
                        <paragraph>Pediatric Trials with Atazanavir Capsules  
  <br/>
                           <content styleCode="italics">Study AI424-040; PACTG 1020A (NCT00006604):</content>Assessment of the pharmacokinetics, safety, tolerability, and virologic response of atazanvir capsules was based on data from this open-label, multicenter clinical trial which included participants from 6 years to 21 years of age. In this study, 105 participants (43 antiretroviral-naive and 62 antiretroviral-experienced) received once daily atazanvir capsule formulation, with or without ritonavir, in combination with two NRTIs.  
  <br/>  One-hundred five (105) participants (6 to less than 18 years of age) treated with the atazanvir capsule formulation, with or without ritonavir, were evaluated. Using an intent-to-treat (ITT) analysis, the overall proportions of antiretroviral-naive and -experienced participants with HIV-1 RNA &lt;400 copies/mL at Week 96 were 51% (22/43) and 34% (21/62), respectively. The overall proportions of antiretroviral-naive and -experienced participants with HIV-1 RNA &lt;50 copies/mL at Week 96 were 47% (20/43) and 24% (15/62), respectively. The median increase from baseline in absolute CD4 count at 96 weeks of therapy was 335 cells/mm
 
  <sup>3</sup>in antiretroviral-naive participants and 220 cells/mm
 
  <sup>3</sup>in antiretroviral-experienced participants.

 </paragraph>
                     </text>
                     <effectiveTime value="20250206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="30891c38-5d9e-7df7-e063-6394a90ae762"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Atazanavir Capsules 150 mg</content>are off white to pale yellow colored granular powder filled in size "1" hard gelatin capsules with green opaque cap imprinted with "H" in black color and light green opaque body imprinted with "A6" in black color. 
  <br/>  Bottles of 60 with child-resistant closure          NDC 31722-653-60 
  <br/>  Bottles of 1000 with child-resistant closure      NDC 31722-653-10 
  <br/>  Carton of 100 (10×10) unit-dose capsules       NDC 31722-653-31 
  <br/>  150 mg atazanavir equivalent to 170.854 mg atazanavir sulfate. 
  <br/>
                     <content styleCode="bold">Atazanavir Capsules 200 mg</content>are off white to pale yellow colored granular powder filled in size "0" hard gelatin capsules with green opaque cap imprinted with "H" in black color and light green opaque body imprinted with "A7'' in black color. 
  <br/>  Bottles of 60 with child-resistant closure          NDC 31722-654-60 
  <br/>  Bottles of 1000 with CT closure                       NDC 31722-654-10 
  <br/>  Carton of 100 (10×10) unit-dose capsules       NDC 31722-654-31 
  <br/>  200 mg atazanavir equivalent to 227.805 mg atazanavir sulfate. 
  <br/>
                     <content styleCode="bold">Atazanavir Capsules 300 mg</content>are off white to pale yellow colored granular powder filled in size "00" hard gelatin capsules with orange opaque cap imprinted with "H" in black color and green opaque body imprinted with "A8" in black color. 
  <br/>  Bottles of 30 with child-resistant closure            NDC 31722-655-30 
  <br/>  Bottles of 500 with child-resistant closure          NDC 31722-655-05 
  <br/>  Carton of 100 (10×10) unit-dose capsules         NDC 31722-655-31 
  <br/>  300 mg atazanavir equivalent to 341.708 mg atazanavir sulfate. 
  <br/>  Keep capsules in a tightly closed container. 
  <br/>  Store atazanavir capsules at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

 </paragraph>
               </text>
               <effectiveTime value="20250206"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="30891c38-5d9f-7df7-e063-6394a90ae762"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <br/>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling
 
  <content styleCode="italics">(Patient Information)</content>  
  <br/>  Atazanavir capsules are not a cure for HIV-1 infection. Advise patients to remain under the care of a healthcare provider while using atazanavir capsules. 
  <br/>  Cardiac Conduction Abnormalities 
  <br/>  Inform patients that atazanavir may produce changes in the electrocardiogram (eg, PR prolongation). Tell patients to consult their healthcare provider if they are experiencing symptoms such as dizziness or lightheadedness
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.1">5.1</linkHtml>)].
 
  </content>
                     <br/>  Severe Skin Reaction 
  <br/>  Inform patients that there have been reports of severe skin reactions (eg, Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions) with atazanavir capsules use. Advise patients that if signs or symptoms of severe skin reactions or hypersensitivity reactions develop, they must discontinue atazanavir capsules and seek medical evaluation immediately
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.2">5.2</linkHtml>) and Adverse Reactions (
  
   <linkHtml href="#Section_6.1">6.1</linkHtml>)].
 
  </content>
                     <br/>  Hyperbilirubinemia 
  <br/>  Inform patients that asymptomatic elevations in indirect bilirubin have occurred in patients receiving atazanavir capsules. This may be accompanied by yellowing of the skin or whites of the eyes and alternative antiretroviral therapy may be considered if the patient has cosmetic concerns
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.8">5.8</linkHtml>)].
 
  </content>
                     <br/>  Chronic Kidney Disease 
  <br/>  Inform patients that treatment with atazanavir capsules may lead to the development of chronic kidney disease, and to maintain adequate hydration while taking atazanavir capsules
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.5">5.5</linkHtml>)].
 
  </content>
                     <br/>  Nephrolithiasis and Cholelithiasis 
  <br/>  Inform patients that kidney stones and/or gallstones have been reported with atazanavir capsules use. Some patients with kidney stones and/or gallstones required hospitalization for additional management, and some had complications. Discontinuation of atazanavir capsules may be necessary as part of the medical management of these adverse events
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.6">5.6</linkHtml>)]
 
  </content>. 
  <br/>  Drug Interactions 
  <br/>  Atazanavir capsules may lead to significant interaction with some drugs; therefore, advise patients to report the use of any other prescription, nonprescription medication, or herbal products, particularly St. John’s wort, to their healthcare provider prior to use
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#Section_4">4</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#Section_5.7">5.7</linkHtml>)].
 
  </content>
                     <br/>  Immune Reconstitution Syndrome 
  <br/>  Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV-1, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV-1 treatment is started
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.10">5.10</linkHtml>)].
 
  </content>
                     <br/>  Fat Redistribution 
  <br/>  Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy including protease inhibitors and that the cause and long-term health effects of these conditions are not known at this time
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#Section_5.11">5.11</linkHtml>)].
 
  </content>
                     <br/>  Dosing Instructions 
  <br/>  Advise patients to take atazanavir capsules with food every day and take other concomitant antiretroviral therapy as prescribed. Atazanavir capsules must always be used in combination with other antiretroviral drugs. Advise patients that they should not alter the dose or discontinue therapy without consulting with their healthcare provider. Tell patients if a dose of atazanavir capsules are missed, they should take the dose as soon as possible and then return to their normal schedule; however, if a dose is skipped the patient should not double the next dose. 
  <br/>  Pregnancy 
  <br/>  Inform pregnant patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in pregnant patients exposed to atazanavir capsules during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#Section_8.1">8.1</linkHtml>)].
 
  </content>
                     <br/>  Lactation 
  <br/>  Instruct patients with HIV-1 HIV-1 transmission to infants without HIV-1, (2) developing viral resistance in infants with HIV-1, and (3) adverse reactions in a breastfed infant similar to those seen in adults
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#Section_8.2">8.2</linkHtml>)]
 
  </content>.

 </paragraph>
                  <br/>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>  </paragraph>
                  <paragraph>Camber Pharmaceuticals, Inc., 
  <br/>  Piscataway, NJ 08854 
  <br/>
                     <br/>  by: 
 
  <content styleCode="bold">HETERO
  
   <sup>TM</sup>
                     </content>
                     <br/>  Hetero Labs Limited 
  <br/>  Jeedimetla, Hyderabad - 500 055, India.

 </paragraph>
                  <br/>
                  <paragraph>Revised: 02/2025</paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>atazanavircapsulecamberlogo1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="atazanavircapsulecamberlogo1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_37">
               <id root="30891c38-5da0-7df7-e063-6394a90ae762"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0">
                     <tbody>
                        <tr styleCode="Botrule">
                           <td align="center" styleCode="Lrule Rrule" valign="middle">
                              <br/>                                                                       
    
     <content styleCode="bold">Atazanavir (A-ta-ZAN-a-vir)                                                                  </content>
                              <br/>
                              <br/>
                              <content styleCode="bold">      Capsules</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">Important: Ask your healthcare provider or pharmacist about medicines that should not be taken with atazanavir capsules. For more information, see “Do not take atazanavir capsules if you” and “Before taking atazanavir capsules”.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">What is atazanavir capsules?</content>
                              <br/>  Atazanavir capsules are a prescription medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection, in combination with other HIV-1 medicines in adults and children at least 6 years of age and older and weighing at least 15 kg. 
     <br/>  HIV-1 is the virus that causes AIDS (Acquired Immunodeficiency Syndrome). 
     <br/>  Atazanavir capsules should not be used in children younger than 3 months of age.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold"> Do not take atazanavir capsules if you:</content>
                              <br/>  • are allergic to atazanavir or any of the ingredients in atazanavir capsules. See the end of this leaflet  for a complete list of ingredients in atazanavir capsules.  
     <br/>  • are taking any of the following medicines. Taking atazanavir capsules with these medicines may affect how atazanavir capsules works. Atazanavir capsules may cause serious or life-threatening side effects, or death when used with these medicines:  
     <br/>  o alfuzosin  
     <br/>  o amiodarone (when atazanavir capsules are used with ritonavir)   
     <br/>   o lurasidone (when atazanavir is used with ritonavir) 
     <br/>  o lomitapide 
     <br/>  o apalutamide 
     <br/>  o carbamazepine 
     <br/>  o cisapride  
     <br/>   o lovastatin 
     <br/>  o midazolam, when taken by mouth for sedation 
     <br/>  o elbasvir and grazoprevir  
     <br/>  o encorafenib  
     <br/>   o nevirapine 
     <br/>  o phenobarbital 
     <br/>  o ergot medicines including:  
     <br/>   dihydroergotamine 
     <br/>   ergonovine  
     <br/>   ergonovine ergotamine  
     <br/>   methylergonovine  
     <br/>   o phenytoin 
     <br/>  o pimozide 
     <br/>  o quinidine (when atazanavir is used with ritonavir) 
     <br/>  o rifampin 
     <br/>  o glecaprevir and pibrentasvir  
     <br/>  o indinavir  
     <br/>   o sildenafil, when used for the treatment of pulmonary arterial hypertension 
     <br/>  o irinotecan   
     <br/>   o simvastatin 
     <br/>  o ivosidenib  
     <br/>   o St. John’s wort 
     <br/>  o triazolam 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">Before taking atazanavir capsules, tell your healthcare provider about all of your medical conditions, including if you: </content>
                              <br/>  • have heart problems  
     <br/>  • have liver problems, including hepatitis B or C virus  
     <br/>  • have kidney problems  
     <br/>  • are receiving dialysis treatment  
     <br/>  • have diabetes  
     <br/>  • have hemophilia  
     <br/>  • are pregnant or plan to become pregnant.  
     <br/>  o 
    
     <content styleCode="bold">Atazanavir capsules must be taken with ritonavir during pregnancy. </content>
                              <br/>  o 
    
     <content styleCode="bold">Hormonal forms of birth control, such as injections, vaginal rings or implants, contraceptive patch, and some birth control pills may not work during treatment with atazanavir capsules.</content>Talk to your healthcare provider about forms of birth control that may be used during treatment with atazanavir capsules.  
     <br/>  o 
    
     <content styleCode="bold">Pregnancy Exposure Registry.</content>There is a pregnancy exposure registry for people who take atazanavir capsules during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry. 
     <br/>  o 
    
     <content styleCode="bold">After your baby is born,</content>tell your healthcare provider if your baby’s skin or the white part of their eyes turns yellow.  
     <br/>  • are breastfeeding or plan to breastfeed. Atazanavir capsules can pass into your breast milk.  
     <br/>  o Talk to your healthcare provider about the following risks of breastfeeding during treatment with atazanavir capsules:  
     <br/>  • The HIV-1 virus may pass to your baby if your baby does not have the HIV-1 virus.  
     <br/>  • The HIV-1 virus may become harder to treat if your baby has the HIV-1 virus.  
     <br/>  • Your baby may get side effects from atazanavir capsules. 
     <br/>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.  
     <br/>  Some medicines interact with atazanavir capsules.
    
     <content styleCode="bold">Keep a list of your medicines to show your healthcare provider and pharmacist. </content>
                              <br/>  • You can ask your healthcare provider or pharmacist for a list of medicines that interact with atazanavir capsules. 
     <br/>  • 
    
     <content styleCode="bold">Do not start taking a new medicine without telling your healthcare provider.</content>Your healthcare provider can tell you if it is safe to take atazanavir capsules with other medicines. 
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">How should I take atazanavir capsules? </content>
                              <br/>  • 
    
     <content styleCode="bold">Take atazanavir capsules exactly as your healthcare provider tells you to.</content>  
     <br/>  • Do not change your dose or stop taking atazanavir capsules unless your healthcare provider tells you to.  
     <br/>  • Stay under the care of your healthcare provider during treatment with atazanavir capsules. 
     <br/>  • Atazanavir capsules must be used with other HIV-1 medicines.  
     <br/>  • Take atazanavir capsules 1 time each day.  
     <br/>  • Atazanavir capsules comes as capsules. 
     <br/>  • Take atazanavir capsules with food.  
     <br/>  • Swallow the capsules whole. Do not open the capsules. 
     <br/>  • Your child’s healthcare provider will prescribe the right dose of atazanavir based on your child’s weight. 
     <br/>  • If you miss a dose of atazanavir capsules, take it as soon as you remember. Then take the next dose at your regular time. Do not take 2 doses at the same time.  
     <br/>  • If you take too much atazanavir, call your healthcare provider or go to the nearest hospital emergency room right away.  
     <br/>
                              <content styleCode="bold">When your supply of atazanavir capsules starts to run low,</content>get more from your healthcare provider or pharmacy. It is important not to run out of atazanavir capsules. The amount of HIV-1 in your blood may increase if the medicine is stopped for even a short time. The virus may become resistant to atazanavir capsules and harder to treat.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">What are the possible side effects of atazanavir capsules?</content>
                              <br/>
                              <content styleCode="bold">Atazanavir capsules can cause serious side effects, including: </content>
                              <br/>  • 
    
     <content styleCode="bold">A change in the way your heart beats (heart rhythm change).</content>Tell your healthcare provider right away if you get dizzy or lightheaded. These could be symptoms of a heart problem.  
     <br/>  • 
    
     <content styleCode="bold">Skin rash.</content>Skin rash is common with atazanavir capsules but can sometimes be severe. Severe rash may develop with other symptoms which could be serious. If you develop a severe rash or a rash with any of the following symptoms, stop taking atazanavir capsules and call your healthcare provider or go to the nearest hospital emergency room right away:  
     <br/>  o general feeling of discomfort or “flu-like” symptoms  o blisters  
     <br/>  o fever  o mouth sores 
     <br/>  o muscle or joint aches  o swelling of your face  
     <br/>  o red or inflamed eyes, like “pink eye” (conjunctivitis)  o painful, warm, or red lump under your skin  
     <br/>  • 
    
     <content styleCode="bold">Liver problems.</content>If you have liver problems, including hepatitis B or C, your liver problems may get worse when you take atazanavir capsules. Your healthcare provider will do blood tests to check your liver before you start atazanavir capsules and during treatment. Tell your healthcare provider right away if you get any of the following symptoms: 
     <br/>  o dark “tea-colored” urine  o nausea  
     <br/>  o your skin or the white part of your eyes turns yellow  o itching  
     <br/>  o light colored stools  o stomach-area pain  
     <br/>  • 
    
     <content styleCode="bold">Chronic kidney disease.</content>Atazanavir Capsules may affect how well your kidneys work. Your healthcare provider will do blood and urine tests to check your kidneys before you start atazanavir capsules and during treatment. Drink plenty of fluids during treatment with atazanavir capsules. 
     <br/>  • 
    
     <content styleCode="bold">Kidney stones</content>have happened in some people who take atazanavir capsules, and sometimes may lead to hospitalization. Tell your healthcare provider right away if you get symptoms of kidney stones which may include pain in your low back or low stomach area, blood in your urine, or pain when you urinate. 
     <br/>  • 
    
     <content styleCode="bold">Gallbladder stones</content>have happened in some people who take atazanavir capsules, and sometimes may lead to hospitalization. Tell your healthcare provider right away if you get symptoms of a gallbladder problem which may include: 
     <br/>  o pain in the right or middle upper stomach area  o nausea and vomiting  
     <br/>  o fever  o your skin or the white part of your eyes turns yellow  
     <br/>  • 
    
     <content styleCode="bold">Yellowing of your skin or the white part of your eyes</content>is common with atazanavir capsules but may be a symptom of a serious problem. These symptoms may be due to increases in bilirubin levels in your blood (bilirubin is made by the liver). Tell your healthcare provider right away if your skin or the white part of your eyes turns yellow.  
     <br/>  • 
    
     <content styleCode="bold">New or worsening diabetes and high blood sugar (hyperglycemia)</content>have happened in some people who take protease inhibitor medicines like atazanavir capsules. Some people have had to start taking medicine to treat diabetes or have changes to their dose of their diabetes medicine. Tell your healthcare provider if you notice an increase in thirst or if you start urinating more often while taking atazanavir capsules. 
     <br/>  • 
    
     <content styleCode="bold">Changes in your immune system (Immune Reconstitution Syndrome)</content>can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider if you start having new symptoms after starting atazanavir capsules. 
     <br/>  • 
    
     <content styleCode="bold">Changes in body fat</content>can happen in people taking HIV-1 medicines. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breast, and around the main part of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The exact cause and long-term health effects of these conditions are not known.  
     <br/>  • 
    
     <content styleCode="bold">Increased bleeding problems in people with hemophilia</content>have happened when taking protease inhibitors like atazanavir capsules. 
     <br/>  The most common side effects of atazanavir capsules include:  
     <br/>  • nausea                      • dizziness  
     <br/>  • headache  • muscle pain  
     <br/>  • stomach-area pain  • diarrhea  
     <br/>  • vomiting  • depression  
     <br/>  • trouble sleeping  • fever  
     <br/>  • numbness, tingling, or burning of hands or feet   
     <br/>  Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of atazanavir capsules. For more information, ask your healthcare provider or pharmacist.  
     <br/>  Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. 
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">How should I store atazanavir capsules? </content>
                              <br/>
                              <content styleCode="bold">Atazanavir capsules:</content>  
     <br/>  • Store atazanavir capsules at room temperature, between 68°F to 77°F (20°C to 25°C). 
     <br/>  • Keep capsules in a tightly closed container. 
     <br/>
                              <content styleCode="bold">Keep atazanavir capsules and all medicines out of the reach of children. </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">General information about the safe and effective use of atazanavir capsules</content>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use atazanavir capsules for a condition for which it was not prescribed. Do not give atazanavir capsules to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about atazanavir capsules that is written for health professionals. 
     <br/>  For more information, call 1-866-495-1995.
   
    </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="middle">
                              <content styleCode="bold">What are the ingredients in atazanavir capsules? </content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content>  atazanavir sulfate  
     <br/>
                              <content styleCode="bold">Inactive ingredients:</content>crospovidone, lactose monohydrate, and magnesium stearate. The capsule shells contain the following inactive ingredients: gelatin, FD&amp;C Blue 1, iron oxide yellow, titanium dioxide, In addition 150 mg capsule shell contains iron oxide black, 200 mg and 300 mg contains FD&amp;C Yellow 6,300 mg also contains FD&amp;C Red 3. The capsules are printed with black ink containing iron oxide black, potassium hydroxide, propylene glycol, shellac, strong ammonia solution. 
     <br/>    
     <br/>
                              <renderMultiMedia referencedObject="MM4"/>
                              <br/>  Manufactured for: 
     <br/>  Camber Pharmaceuticals, Inc., 
     <br/>  Piscataway, NJ 08854 
     <br/>  by:
    
     <content styleCode="bold">HETERO
     
      <sup>TM</sup>
                              </content>
                              <br/>  Hetero Labs Limited 
     <br/>  Jeedimetla, Hyderabad - 500 055, India. 
     <br/>
                              <br/>  The brands listed are the trademarks of their respective owners and are not trademarks of Hetero Labs Limited.  
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration. 
  <br/>
                     <br/>                                                                                                                                                                                      Revised: 02/2025
 </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>atazanavircapsulecamberlogo1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="atazanavircapsulecamberlogo1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="30891c38-5da1-7df7-e063-6394a90ae762"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <br/>
                  <paragraph>atazanavir capsule 150 mg 60's count</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <br/>
                  <paragraph>atazanavir capsule 200 mg 60's count  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph>atazanavir capsule 300 mg 30's count</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM7"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250206"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>atazanavircapsule150mg60scount</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="atazanavircapsule150mg60scount.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>atazanavircapsule200mg60scount</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="atazanavircapsule200mg60scount.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>atazanavircapsule300mg30scount</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="atazanavircapsule300mg30scount.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>